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Foreword
The Alzheimer Society of Ireland (ASI), as the leading advocacy and service organisation 
for people with dementia and their families, is concerned with the lack of accurate 
and available data about dementia in Ireland. Other jurisdictions have national data 
collection and storage structures which play a vital role in the development of many 
aspects of dementia health and social care. They help to improve and shape service 
planning and patient care, also informing policy and providing a research infrastructure.
With the publication of Ireland’s first National Dementia Strategy in 2014, there was 
a governmental shift to take a strategic approach to address dementia. With this in 
mind, the ASI feels it is the right time to examine the potential for a framework to  
collect information on dementia in a reliable, accurate, valid, complete and timely 
way, specifically to explore what role a dementia registry can have in our national 
strategic approach to dementia. 
This report, commissioned under the ASI’s expert policy series, provides much needed 
information on the feasibility of developing a dementia registry within the Irish context. 
The authors proactively engaged with leading experts both in the field of dementia 
and in patient registries more generally. They also, very importantly, met and engaged 
with people living with dementia; those whose information would be collected, stored 
and used in any future registry. These expert opinions, combined with a review of 
national patient registries and a review of international dementia registries, identifies 
good practice as well as potential pitfalls in establishing and running such a registry.  
We would like to sincerely thank the authors of the report, Dr Louise Hopper, Suzanne 
Hughes, Dr Kate Irving and Professor Teresa Burke from Dublin City University and all 
those who gave up their time to contribute to its contents. It provides an excellent 
evidence-base for a national discussion on this issue and to determine action on how 
we should move forward to make it a reality.
The ASI feels strongly that we need to continue to strengthen collaboration and  
partnership across disciplines and sectors to ensure that this report does not just  
collect dust but is used to bring real change to the growing number of people living 
with dementia. 
Pat McLoughlin
CEO, The Alzheimer Society of Ireland
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Executive Summary
Purpose
Patient registries, it is argued, should be “central to 
the planning, delivery and review of health care in 
Ireland” (Medical Research Charities Group (MRCG) 
& Irish Platform for Patients’ Organisations, Science 
and Industry (IPPOSI), 2011, p. 1). The breadth, 
depth and longitudinal nature of patient registry 
data can inform clinical and policy decision making, 
support comprehensive health economic assess-
ment, and facilitate health and policy research.
Unlike other jurisdictions that have national  
structures that play a vital role in the development 
of many aspects of healthcare services, including 
the provision of accurate and comprehensive data 
on dementia to facilitate clinical and policy decision-
making, there is very poor recording and coding of 
dementia across all care settings (Cahill, O’Shea, 
& Pierce, 2012). The Alzheimer Society of Ireland 
(ASI) commissioned this study as part of their expert 
evidence-based policy series. The overall aim was to 
generate an evidence-based discussion document 
addressing the feasibility of a national dementia 
registry for Ireland. The specific objectives were to:
• Review	patient	registry	models	in	Ireland	and	
examine	their	function	and	operation.
• Review	dementia	registries	that	exist	in	other	
jurisdictions	and	examine	their	function	and	
operation.
• Undertake	a	‘landscape	analysis’	identifying	
the impact of relevant legal, ethical, clinical, 
IT	systems	and	financial	issues	crucial	to	the	
development	of	a	national	dementia	registry.
• Provide evidence-based policy 
recommendations	that	can	progress	the	issue	
of	improved	recording	structures	for	dementia	
in Ireland.
Terminology
For the purposes of this report, the term 'register' 
refers to the patient records (i.e. the patient data) 
and the patient record database. Furthermore, a 
proper register is considered to be one that exists 
at a population level and is complete. The term 
'registry' refers to the organisation and process that 
supports the register. 
Methodology
A rapid review of published and grey literature 
examining the definition, function, operation and 
evaluation of patient registries, best-practice guide-
lines for their development, and the legal, ethical, 
clinical, technical and financial issues that need to 
be considered when establishing a patient registry 
was carried out. In addition, literature pertaining 
to existing international dementia registries and to 
existing patient registries in Ireland was reviewed. 
Semi-structured expert interviews were conducted 
with national and international experts (n=21) in 
areas relevant for this project. Two focus groups 
were held with representatives of the Irish Dementia 
Working Group (IDWG; n=9)	in	order	to	gain	insight	
into the potential benefits and risks of a national  
dementia registry from the perspective of those 
with a diagnosis of dementia. 
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Findings: Literature review
Reliable, accurate, valid, comprehensive and timely 
data has a significant record of contributing to the 
effective and efficient planning, operation and 
evaluation of health and related social services. The 
breadth, depth and longitudinal nature of patient 
registry data can inform public health policy, improve 
patient care, support health research, and facilitate 
health technology assessment. Although the collection 
of these data is often expensive in terms of time and 
cost, requires ethical justification and flexibility to 
adapt to a changing legislative environment.
With the growth of patient registries worldwide, 
best practice guidelines have emerged in Australia, 
Sweden, the UK, the US and from the EU Cross- 
border Patient Registries Initiative. These guidelines  
provide guidance on registry purpose, the selection,  
collection, management and quality evaluation of 
registry data, ethics and data privacy, funding and 
resources, registry governance, registry quality and 
evaluation, registry outputs, the use of registry data 
and facilitating registry interoperability.
Several international dementia registries are currently 
operational and they provide useful epidemiological 
data for policy-making, resource planning and service 
provision. No one ideal model for a dementia registry 
has as yet been established, but the Swedish Dementia 
Registry (SveDem) is the most comprehensive and 
arguably the ‘gold standard’ of existing registries. It 
is a government funded web-based registry that  
operates with a national mandate and an opt-out 
consent process. Annual reports, registry evaluations 
and research publications illustrate how SveDem 
can contribute to the enhancement of expertise and 
how it supports the embedding of application of  
research findings in clinical practice. In contrast to 
the Swedish model, Denmark uses a continuous 
process of data collection as part of their National 
Clinical Quality Databases framework that in turn 
supports harmonisation and quality improvements 
in dementia services provided in each participating 
institution. In contrast, the Registry of Dementia of 
Griona offers a model that could be used as a starting 
point for any dementia registry that requires the 
potential to expand its scope over time. 
The feasibility of any patient registry is influenced 
by the environment in which the registry operates. 
Previous Medical Research Charities Group reports 
have reviewed the national legislation and the  
international directives, conventions and codes  
relevant to patient registries. Such registries also 
need to be cognisant of the requirements of the 
recent European Data Protection Reform 2016  
legislation, the Assisted Decision Making (Capacity) 
Act 2015, and the potential implications of the 
Health Information and Patient Safety Bill. Despite 
previous discussions regarding the strategic nature 
of patient registries and the publication of guiding 
principles for health and social care data collection, 
there is still a lack of strategic direction in Ireland. 
As a result Irish patient registries are characterised 
by significant heterogeneity with regard to size, 
function, disease, funding, cost and governance. 
Even when operating with a national mandate, the 
National Cancer Registry omits patients in private 
hospitals and still tends to be seen as external to the 
health service. That said, the review of existing Irish 
patient registries demonstrates that a lot can be 
achieved within the current limitations of the Irish 
health system.
vii
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Findings: Expert interviews 
and focus groups
A number of core themes emerged from the  
thematic analysis of the expert interviews and 
focus groups. These were: 
• Registry function – experts agreed that a 
dementia	registry	would	provide	much	needed	
data	to	enhance	policy,	enormous	potential	to	
improve care, and facilitate research within an 
Irish context. 
• Registry data – expert consensus was that 
a	formal	diagnosis	of	dementia	would	be	
required for registry inclusion, but the 
complexity of this diagnosis and the lack of 
coding	in	primary	care	would	be	problematic.	
Data requirements and format should be 
driven by the primary purpose of the registry, 
opt-in	patient	consent	is	preferred,	and	
data accuracy and completeness will be 
fundamental to registry success.
• Data collection – experts felt that data will be 
required from primary and secondary care. 
This will be challenging without electronic 
health records, but achievable with appropriate 
data	matching	processes.	Data	collection	
should not further stretch front-line resources 
and	stakeholder	buy-in	will	be	essential	to	
registry success.
• Data management – there was clear 
agreement that consumers of registry data 
should	only	have	access	to	the	data	specific	 
to their needs. Clear access rules, data privacy 
and	data	protection	plans,	and	adequate	
technical support will also be required.
• Registry governance – experts agreed that 
a	dementia	registry	should	be	independent,	
have formalised governance structures and 
undergo	regular	quality	evaluations.	They	
recognised challenges with regard to registry 
funding	and	the	lack	of	national	strategic	
planning.
• Legislation	–	privacy	and	data	protection	
concerns were most prevalent. Experts also 
discussed	the	need	for	and	the	potential	
impact	of	individual	health	identifiers	and	the	
Health	Information	and	Patient	Safety	Bill.
Three high level cross-cutting themes were also 
identified: 
• Benefits and risks – improved policy-making, 
patient	care	and	research	potential	were	
identified	as	key	benefits.	Risks	would	include	
securing funding to sustain the registry, 
privacy,	confidentiality,	data	protection	and	
data access, but experts felt each could be 
mitigated.
• Barriers and facilitators – the main barriers 
were thought to be a lack of strategic policy 
and sustainable funding, poor coding for 
dementia	in	primary	care,	consent	procedures	
and	the	complexity	of	data	collection.	The	
changing	legislative	environment	and	the	
recognised	need	for	better	dementia-related	
information	by	policy	makers	were	seen	as	key	
facilitators.
• Dementia-specific challenges – the complexity 
of	a	dementia	diagnosis,	the	degenerative	
nature	of	dementia	with	regard	to	capacity,	
and	the	stigma	associated	with	dementia	were	
considered	to	be	additional	factors	that	would	
not	be	encountered	in	other	patient	registries.
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Findings: Key considerations 
and recommendations
When taken together the findings indicate some 
clear direction for any potential registry in Ireland.
1.	 Clear	aims	and	objectives	are	needed	for	the	
registry to be successful. 
2.	 Legislative	support	is	beneficial	with	regard	
to	legitimacy	and	sustainability,	however,	the	
registry should remain independent.
3. Stable funding is crucial for the longevity of  
a registry. 
4.	 Strong	relationships	and	‘buy-in’	are	needed	
from all stakeholders.
5.	 Registry	location	can	enable	access	to	additional 
resources; independence must be preserved.
6.	 Patient	consent	needs	to	be	carefully	
considered. 
7.	 Patient	recruitment	is	essential	to	the	success	
of any registry.
8.	 Data	collection	is	a	complex	process.	
9. Data will never be truly comprehensive; this is 
a	particular	concern	in	the	Irish	health	system.
10. Clear unambiguous and tangible outcome 
measures are required.
11. Registry governance must be formalised but 
not unwieldy. 
12.	 Quality	evaluations	are	vital	in	order	to	ensure	
that	the	registry	is	fit-for-purpose.
13.	 Standardisation	of	dementia	diagnosis	is	
needed to protect the credibility of the data.
14.	 Privacy	and	confidentiality	needs	to	be	
assured for those registered.
15.	 Opportune	timing	can	be	instrumental	in	the	
setting	up	of	a	new	registry.
16. A centralised ethical approval process is highly 
recommended.
17.	 Primary	legislation	is	needed	to	establish	a	
firm	legal	basis	for	data	collection,	research	
and	data	sharing	with	regard	to	patient	
registry data.
It is also clear that there are a number of key decisions 
that need to be made in order to develop a  
comprehensive proposal for a national dementia 
registry. Firstly, clear leadership and appropriate 
funding are required. Secondly, the scope, scale and 
main function(s) of the proposed registry need to 
be established as these will drive the design of the 
processes and procedures necessary to operate  
the registry effectively, efficiently and ultimately 
successfully. Subsequently, sustainability planning, 
governance structures and registry evaluation 
processes should be put in place. Finally, the registry 
team must advocate for a suitable policy and  
legislative environment conducive to the effective 
operation of any registry. To achieve this, they will 
need to increase awareness of the value of patient 
registries and the specific benefits of having a  
National Dementia Registry for Ireland.
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Conclusions
This study assessed the feasibility of a National  
Dementia Registry for Ireland. The findings suggest 
that the benefits of developing such a registry make 
the required investment worthwhile as long as the 
registry has clear and focused aims and objectives, 
solid data management and data collection processes, 
produces credible results and is demonstrably fit-for- 
purpose. The funding for such a registry needs to 
be discussed in light of these key objectives (i.e. a 
definitive understanding of what the registry is for) 
as they will guide the identification of appropriate 
funding sources and the prioritisation of the dementia 
registry in comparison to other potential calls on this 
money. 
Clear leadership will be required to win the ‘hearts 
and minds’ of the stakeholders that will be involved 
and the people with dementia who will provide their 
data to the registry. Ireland can and should learn from 
the development of dementia registries in other 
jurisdictions and the development of other patient 
registries in Ireland. Ideally, a national strategic policy 
on patient registries, adequate funding mechanisms, 
data sharing legislation and a robust eHealth system 
that includes unique health identifiers would be 
pre-requisites to the development of the registry, 
but one of the biggest challenges in Ireland is the 
length of time policy development and legislative 
and regulatory changes take and the long-awaited 
Health Information and Patient Safety Bill (HIPS) is 
a case in point. Were we to wait for each of these 
pre-requisites to arrive, it is likely that the national 
dementia registry would never be developed. 
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1.1 Introduction
It is argued that patient registries should be “central 
to the planning, delivery and review of health care in 
Ireland” (MRCG & IPPOSI, 2011, p. 1). Such registries 
provide data: 
• that enable the trends and course of a disease 
to be observed, 
• to	identify	differences	and	inequities	in	service	
provision and service use, 
• to	assess	the	efficacy	of	clinical	outcomes,
• to explore the impact of the disease, 
treatment	and	care	plans	on	patients’	quality	
of	life	and	other	patient-reported	outcomes.	
These findings, in turn, inform clinical and policy 
decision making and support comprehensive health 
economic assessment. Although Ireland does not as 
yet have a national strategy on patient registries, a 
variety of patient registries already exist and others 
are in the process of development. 
The Alzheimer Society of Ireland (ASI), as a leading 
advocacy and service organization for people with 
dementia and their families, has concerns over the 
lack of data and information about dementia in 
Ireland. There is very poor recording and coding of 
dementia across all care settings (Cahill et al., 2012). 
This is unlike other jurisdictions that have national 
structures that play a vital role in the development 
of many aspects of healthcare services including the 
provision of accurate and comprehensive data on 
dementia to facilitate clinical and policy decision-
making. 
Given the strategic approach the Government is now 
taking to address dementia, with the publication of 
the Irish National Dementia Strategy (Department  
of Health (DoH), 2004), it is timely to examine the 
potential for a framework to collect dementia-related 
information in a reliable, accurate, valid, complete 
and timely way. 
1.2 Terms of reference
The ASI has commissioned this study as part of their 
expert evidence-based policy series. The overall aim 
was to generate an evidence-based discussion  
document addressing the feasibility of a national 
dementia registry for Ireland. The specific objectives 
of this study were to:
i Review	patient	registry	models	in	Ireland	and	
examine	their	function	and	operation.
ii Review	dementia	registries	that	exist	in	other	
jurisdictions	and	examine	their	function	and	
operation.
iii Undertake	a	‘landscape	analysis’	identifying	
the impact of relevant legal, ethical, clinical, 
information	technology	(IT)	systems	and	
financial	issues	crucial	to	the	development	 
of	a	national	dementia	registry.
iv Provide evidence-based policy 
recommendations	that	can	progress	this	 
issue of improved recording structures for 
dementia	in	Ireland.
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1.3 Definitions and 
 Terminology
Inconsistent and confusing terminology has been 
used to refer to a wide variety of disease registries 
and to clinical and research databases (Gliklich & 
Dreyer, 2014; Newton & Garner, 2002), and the 
terms ‘registry’ and ‘register’ are often used inter-
changeably. 
For the purposes of this study, Newton and Garner’s 
(2002) terminology will be used. 
• Register	refers	to	the	patient	records	(i.e.	the	
personal	health	information	of	an	individual	
kept	over	a	long	period	of	time)	and	the	
patient	record	database,	and	it	is	consistent	
with	Last’s	(2001)	description	of	a	file	of	data	
concerning	all	cases	of	a	particular	disease	or	
health	condition	in	a	defined	population	such	
that	the	cases	can	be	related	to	a	population	
base.	An	individual	person	(patient)	is	
registered	once	as	a	unique	entity	that	is	not	
duplicated.
• Registry	refers	to	the	organisation	and	
process that supports a register. One registry 
may	support	the	operation	of	a	number	of	
individual registers.
Registers are subsequently classified according to the 
way in which their populations are defined (Gliklich 
& Dreyer, 2014). Population registers, alternatively 
referred to as disease, case and patient registers,  
are the most common and they specifically refer to 
databases that strive to identify systematically all 
cases of a particular disease in a specific population 
(Gliklich & Dreyer, 2014; Newton & Garner, 2002); for 
example national cancer registers. These registers are 
used for epidemiological research (e.g. prevalence, 
incidence and mortality rates), needs assessment, 
monitoring the effectiveness and improving the quality 
of clinical care, service provision and technology 
assessment. They are usually costly and it has been 
suggested that they are prone to over-estimating 
epidemiological variables by over-rating symptoms 
(González, 2015).
Population registers are distinct from clinical registers 
that collect data from those treated in a particular 
institution or group of institutions (e.g. hospital or 
primary care practice) and are focused on patient 
care, quality improvement and health technology 
assessment (Newton & Garner, 2002). They are also 
distinct from patient databases that are a simple 
collection of patients that share some characteristics 
(e.g. a diagnosis or treatment plan) and that are 
used to support the delivery of a particular service, 
clinical trial, or research study (MRCG & IPPOSI, 2011). 
Population registers should also be differentiated 
from research registers where people register their 
interest in participating in research; for example 
Join Dementia Research in the UK enables people 
with and without dementia to volunteer to take part 
in research projects (National Institute for Health 
Research, 2016). 
Non-specific registers that identify all events of a 
particular type (e.g. GP Consultations, Hospital  
admissions, prescribed medications, population  
biomedical databases) also exist but they are not the 
focus of this study and are not included in this report.
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1.4 Methodology
Although several aspects of this research could be 
achieved through review of policy documents and 
published research, we interviewed expert stake-
holders to garner a system view of the impact of any 
proposed approach to the generation of a national 
dementia registry, and held focus groups with  
representatives of the Irish Dementia Working Group 
(IDWG) to gain insight into the potential benefits 
and risks of a national dementia registry from the 
perspective of those with a diagnosis of dementia. 
The study ran for six months from January to July 
2016. 
1.4.1 Rapid literature review
Full systematic literature reviews are time-consuming 
and often take a minimum of six months to one year 
to complete (Ganann, Ciliska, & Thomas, 2010;  
Higgins	&	Green,	2008).	Evidence	suggests	that	more 
pragmatic searches focused on providing answers to  
a specific question can produce similar information 
more quickly (from one week to several months) and 
at less cost (Parkhill et al., 2011). As a result, there is 
an increasing move towards rapid literature reviews 
in order to synthesise high quality evidence for the 
purposes of policy development and planning while 
meeting the time constraints under which policy-
makers often operate (Featherstone et al., 2015; 
Khangura, Konnyu, Cushman, Grimshaw, & Moher, 
2012;	Watt	et	al.,	2008).	The	target	audiences	for	
these reviews typically include government policy-
makers, healthcare institutions and health  
professionals, patient associations and patient 
advocacy groups (Ganann et al., 2010). A number of 
studies have examined the differences between the 
evidence produced by systematic and rapid reviews 
and generally rapid reviews that are fit-for-purpose 
are seen as positive and not inherently inferior to 
more comprehensive reviews (Khangura et al., 2012; 
Watt	et	al.,	2008).
Given the time constraints of this study and the  
specific nature of the question asked, a rapid  
review of published and grey literature was deemed 
appropriate. The review concentrated on under-
standing what patient registries and registers are; 
the functions they fulfil; how they are developed, 
maintained and evaluated; and the legal, ethical, 
clinical, technical and financial issues that need to 
be considered when establishing a patient registry. 
We also specifically examined literature pertaining 
to existing international dementia registries and to 
existing patient registries in Ireland. In accordance 
with Burls (2004) recommendations, authoritative 
guidance was provided in planning and reporting the 
rapid review by an advisory panel that included key 
stakeholders from primary care, health informatics 
and a representative from the ASI. 
1.4.2 Expert Interviews
Expert interviews are about a person’s special 
knowledge and experiences that result from the  
actions, responsibilities, or obligations of their specific 
functional status within an organisation or institution. 
They are not about the experts themselves, nor 
about the individual or single case, but about the 
expert as informant or source of information. With 
this in mind, we conducted systematising expert 
interviews with the objective of reconstructing the 
expert’s special knowledge in one or more of the  
following areas: (1) Existing patient registries in  
Ireland; (2) Dementia registries in other jurisdictions; 
(3) Health policy; (4) Health Informatics; (5) Patient 
advocacy; (6) Clinical perspectives on dementia care. 
An initial list of potential experts was purposively 
developed from our knowledge of the health and 
dementia landscape in Ireland, from discussions 
with colleagues and the advisory panel, and from 
the literature review. 
Following ethical approval from the DCU Research 
Ethics Committee, recommended experts were  
contacted and those who consented to participate 
were individually interviewed either face-to-face or  
by telephone/Skype. Interviews (n=21) were audio-
recorded, transcribed intelligent verbatim and  
anonymised. The transcripts were analysed by  
applying an inductive qualitative content analysis; 
that is using open coding and deriving categories 
directly	from	the	material	(Elo	&	Kyngäs,	2008;	
Hsieh & Shannon, 2005). Some additional experts 
were suggested during the initial interviews and 
these were also invited to participate using the 
same process as described above. We additionally 
had personal communication with other experts 
(n=13) who were unavailable for formal interview. 
Every effort was made to anonymise the interview 
transcripts, but given the particular nature of the 
expertise required by this study and the limited 
range of suitable experts, it is possible that experts 
may be identified from the nature or context of their 
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opinions. Experts were provided with a copy of the 
anonymised transcript for their review prior to data 
analysis and quotations used in this report were 
agreed with each expert prior to publication.
The semi-structured interview protocol was compiled 
following the rapid literature review and the protocol 
was reviewed by the advisory panel prior to  
commencing data collection. The interview protocol 
covered the topics presented in Table 1 above. Not 
all question areas were relevant for all experts; for 
example, a patient organisation may not have had the 
requisite knowledge to answer questions related to 
data storage costs, so a recommended interview path 
was identified for each expert prior to carrying out the 
interview. The protocol was flexible enough to allow 
for situations where additional areas of expertise 
were identified as the interview progressed.
1.4.3 Focus Groups
Two focus groups were conducted with representatives 
from the IDWG (n=9;	Male	=	5	and	Female	=	4;	
Mean age = 63.56 years; 1 person newly diagnosed, 
4 diagnosed for 1-3 years and 4 for more than 3 
years) to ascertain their opinions on the idea of a 
national dementia registry for Ireland. The focus 
groups took place after more than half of the expert 
interviews had been conducted and analysed so that 
potential registry models could be explored with the 
groups. This ensured that tangible examples could 
be used to illustrate the discussion questions. 
The focus group setting encouraged free and open 
discussion among participants who were already 
familiar with working in that way. It allowed these 
participants to discuss their perceptions, opinions, 
beliefs and attitudes towards the idea of a national 
dementia registry for Ireland, and what the suggested 
model(s) would mean for them. A semi-structured 
format, similar to the expert interviews, was used 
and a sub-set of question areas were addressed: 
i Definition	–	what	a	‘register’	means	to	you;	
ii Registry coverage; 
iii Content; 
iv Data ownership and governance; 
v Registry	function;	
vi Benefits	and	risks.	
Questions were simplified to suit the needs of these 
participants and the focus groups were carried  
out by researchers with previous experience of  
moderating discussions with people with dementia. 
The discussions were audio-recorded, transcribed 
intelligent verbatim, anonymised and analysed using 
the same procedures as detailed above for the 
expert interviews.
1.4.4 Limitations of this study
Given the scope and timeline available for this study, 
it was necessary to conduct a rapid rather than a 
systematic review of relevant literature. However, 
previous research suggests that rapid reviews are 
capable of reaching appropriate conclusions that do 
not differ extensively from those reached by a more 
systematic review (Featherstone et al., 2015; Watt 
et	al.,	2008).	They	are	also	particularly	useful	for	
contextualising the findings of previously published 
generalised findings, as was the objective here. 
The selection of appropriate experts was guided 
by the advisory group but unfortunately, due to 
demanding work commitments, the expert from 
the Swedish Dementia Registry was unavailable for 
interview. Other members of the Swedish Registry 
team provided their input and comprehensive annual 
reports and published literature was used to extract 
other relevant information about the operation of 
that registry. 
TABLE 1  Question areas included in the expert interview protocol   
Personal experience of registries Data considerations Legal aspects
Utility of patient registries Data ownership and governance Ethical considerations
Planning a registry Cost, funding and sustainability Technology requirements
Policy implications Benefits and risks
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Background and Methods 1
SUMMARY
The overall aim of this research was to generate an evidence-based discussion document  
addressing the feasibility of a national dementia registry for Ireland. 
The specific objectives were to: 
•  Review	patient	registry	models	in	Ireland	and	examine	their	function	 
and	operation.
•  Review	dementia	registries	that	exist	in	other	jurisdictions	and	examine	 
their	function	and	operation.
•  Undertake	a	‘landscape	analysis’	identifying	the	impact	of	relevant	legal,	 
ethical,	clinical,	IT	systems	and	financial	issues	crucial	to	the	development	 
of	a	national	dementia	registry.
•  Provide	evidence-based	policy	recommendations	that	can	progress	the	 
issue	of	improved	recording	structures	for	dementia	in	Ireland.
A rapid literature review, semi-structured expert interviews (n=21), and two focus groups 
with the Irish Dementia Working Group (n=9)	were	carried	out	to	analyse	the	feasibility	 
of creating a national dementia registry for Ireland.
62 Rapid Review of Patient Registries
2.1 The functions of patient 
 registries
Reliable, accurate, valid, comprehensive and timely 
information is essential to the effective and efficient 
planning, operation and evaluation of health and 
related social services (MRCG, 2015). Such data 
has a significant record of contributing to medical 
knowledge and health care in the UK (Newton & 
Garner, 2002) and it forms the backbone of current 
health (Department of Health, 2015; Department of 
Taoiseach, 2016), health information (Department 
of Health and Children, 2004) and disease-specific 
strategies in Ireland; for example the Irish National 
Dementia Strategy (Department of Health, 2014b). 
A variety of different patient registries exist today 
and new registries are increasingly being developed 
to fulfil a variety of needs within health services. The 
breadth, depth and longitudinal nature of patient 
registry data enables a range of different health 
services and research objectives to be met, although 
the collection of these data is often expensive in 
terms of time and cost, requires ethical justification 
and flexibility to adapt to a changing legislative  
environment (MRCG, 2015; Newton & Garner, 2002). 
Chapter two of the MRCG and IPPOSI (2011) report 
on considerations for a national strategy on patient 
registries provides a detailed review of the range of 
functions supported by patient registries. In summary, 
the four main aims of a patient registry are:
Inform public health policy
The dynamic, ongoing and systematic process of  
collecting, analysing, interpreting and disseminating 
registry data correlated from a wide variety of 
sources is particularly suited to supporting public 
health decision-making. It is especially suitable for  
epidemiological surveillance, the monitoring of  
public health prevention and treatment strategies, 
the identification of disease-specific risk factors and 
at-risk populations, health and social care planning 
and resource allocation within these services 
(González, 2015; Morris, Mohs, Rogers, Fillenbaum, 
&	Heyman,	1987).	Longitudinal	data	facilitate	analysis 
of disease trends and the examination of health  
service processes over time. Registry data can also be 
analysed to determine rapid responses to emerging 
research and policy questions (Gliklich & Dreyer, 2014). 
An improved understanding of disease progression, 
the monitoring of at-risk patient groups and the 
general ability to better determine the needs of  
patients and the likely burden of care, enables better 
planning and more equitable provisioning of health 
services (MRCG, 2015). As a result, patient registries 
enable public health policy makers to evaluate the 
aspects of the public health system that work well 
and those that are more problematic, and they 
provide an evidence base that can be used to drive 
continuous process quality improvements once 
there is an awareness of the data stored within the 
registry, that these data are accessible and that their 
accuracy and comprehensiveness has been evaluated 
(MRCG, 2015).
Improve patient care
Patient registries are increasingly seen as intrinsic 
components of a quality health service and important 
enablers of improvements in clinical care. The 
systematic collection of registry data can be used to 
standardise diagnostic and assessment processes, 
to manage demand and service provision and to 
monitor service access, thereby ensuring equitable 
and consistent delivery of health services that meet 
patient needs (Colias, 2005; Gliklich & Dreyer, 2014; 
Newton & Garner, 2002). When patient registries 
contain comprehensive medical records, this can  
facilitate the creation and monitoring of individualised 
care plans, the availability of co-ordinated patient data 
at the point of care and improved multidisciplinary 
collaboration. To successfully achieve care improve-
ments, registries must collect data that can be used 
to modify health-related behaviours, processes or 
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systems of care. This may necessitate integration 
with other data sources, which has ramifications for 
patient privacy and for data sharing processes and 
regulations. It may also require the use of specific 
quality improvement or benchmarking tools and the 
ability to compare quality across different aspects of 
the health service. Benchmarking has been found to 
introduce certain worries among health care providers 
and they may resist providing the necessary data 
to the registry unless they are clearly aware of the 
benefits that will accrue for themselves, their  
organisations and their patients (Trotter, 2002). 
Reporting can be blinded, but data can also be  
examined at local, regional and national levels (Gliklich 
& Dreyer, 2014); for example, patients who use a 
particular health service, or those with a specific 
disease or condition, can be tracked over time and 
across multiple health care providers. Finally, the 
registry must be able to adapt over time to new  
information, evidence and care processes that  
support the improvement of patient care. 
Support health research
Patient registries can support research across all 
forms of disease and all manner of interventions, and 
a range of different research study methodologies 
can be supported by patient registry data; descriptive 
studies, research design improvements, process 
studies, intervention studies, hypothesis testing and 
randomised control trials (Gliklich & Dreyer, 2014; 
MRCG, 2012; Newton & Garner, 2002). In situations 
where research questions cannot be answered by 
registry data alone, the availability of patient  
identifiers within the registry can enable linking with 
other data sources (Gliklich & Dreyer, 2014), although 
processes for managing consent, data sharing, data 
transfer and data issues (e.g. patient matching, data 
duplication, patients in one source but not in the 
other) will be required. Patient registry data can 
also support the prioritisation of funding allocation 
to public health and health research priorities, as 
it helps to bridge the gap between research and 
practice and provides an evidence base from which 
to drive patient care and public health initiatives 
(González, 2015). 
Facilitate health technology assessment
Health services face a growing need to be able to 
evaluate an ever-increasing range of new treatments 
and technologies. Although similar in some regards 
to research studies, these assessments typically  
precede government or health service approval for 
new treatments as they essentially use a cost-benefit 
analysis to establish the value of an intervention 
(Patrick et al., 2010). The completion of a health 
technology assessment has not as yet been carried 
out prior to the establishment of any of the existing 
Irish patient registries, although it has been  
suggested as something that should be considered 
for new registries.
While it is certainly possible to design registries  
that aim to address all of the above objectives, it is 
generally easier to establish patient registries that 
have public health needs and patient care as a primary 
objective as a registry built primarily to meet specific 
research objectives would require a substantially  
different design (Newton & Garner, 2002). In addition, 
rare disease registries are helped by clear diagnostic 
criteria and a limited number of care centres, each 
of which reduces the complexity of data collection, 
while the diagnostic criteria may be uncertain or 
more complex for other diseases or disease-specific 
outcome measures may be evolving. In these cases, 
the initial registry will need to be designed in a way 
that is more flexible and facilitates change so that it 
can adapt and grow as more information becomes 
available. 
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2.2 Review of existing 
 best-practice guidelines
As more patient registries are established, operated 
and evaluated, it is becoming easier to identify the 
characteristics that drive success, those that can lead 
to problems and to be guided by the experiences of 
existing registries and the lessons they have learned. 
As a result, best practice guidelines have begun to 
emerge, initially in the UK (Newton & Garner, 2002), 
then in Sweden (EyeNet Sweden with support from 
the Decision Body for National Quality Registries, 
2005), Australia (Australian Commission on Safety 
and	Quality	in	Health	Care,	2008)	and	most	recently	
the US (Gliklich & Dreyer, 2014; Milken Institute, 2016) 
and from the EU Cross-border Patient Registries 
Initiative (Zaletel & Kralj, 2015). A comparative  
summary of these four guideline documents is 
provided in Annex 2 of the MRCG and IPPOSI (2011) 
strategic report. A brief summary of the recommended 
guidelines from across the four documents is also 
presented here. 
2.2.1 Registry purpose
Each set of guidelines highlight the importance of 
formulating specific aims and objectives for the  
registry as these will enable the registry scope, target 
population and stakeholders to be clearly identified. 
Gliklich and Dreyer (2014) recommend designing the 
registry with respect to its primary purpose; this  
requires careful prioritisation of a range of objectives 
that are likely to be held by different stakeholders. 
Questions of clinical and epidemiological interest must 
be capable of being translated into specific, valid 
and measureable data items and clinical outcomes. 
Consideration will need to be given to where these 
data can be found, potential sources of bias and the 
feasibility of collecting these data accurately,  
comprehensively and in a timely fashion. A patient 
registry will not be successful or sustainable if it does 
not address the purpose for which it was intended.
2.2.2 Registry data
Best-practice guidelines illustrate that the core  
processes that must be supported by a patient  
registry are the selection of appropriate data and  
its collection, storage and processing. 
Data selection: Required data items should be driven 
by the purpose of the registry, the target population 
(clearly identified with appropriate inclusion and  
exclusion criteria), the intended users and the 
specific outcomes of interest, including the quality 
characteristics that need to be measured. The  
collection of data with marginal value should be 
avoided (MRCG & IPPOSI, 2011). The comprehen-
siveness and validity of the registry data will largely 
depend on how well these data variables have been 
selected. Best practice guidelines recommend that 
a registry balances importance (data integrity and 
analysis of primary outcomes) and reliability with 
the ease or complexity of data collection, cost and 
the burden placed on data providers and patients. 
A registry should also focus on consistency across 
patients and across data collection sites, which  
influences the sources of data, the measures that are 
chosen and how data are collected by the registry. 
Not only is the importance of data standards stressed 
in each of the published guidelines documents, 
funding allocations are based on evidence of meeting 
these standards in the US (Gliklich & Dreyer, 2014) 
and in Australia (Australian Commission on Safety 
and	Quality	in	Health	Care,	2008).	
Data collection: A single registry can collect data from 
a single source or it can integrate data from a variety 
of sources. An integrated system for collecting, 
cleaning, storing, monitoring, reviewing and reporting 
on registry data is recommended as this maximises 
the utility of the registry and more easily enables all 
registry goals to be met (Zurriaga et al., 2015). This 
does increase the complexity of the registry and  
sufficient personal identifiers will be required in 
order to match accurately patient data. Some see 
the use of shared patient identifiers as a tool to 
reduce administrative overheads and facilitate data 
exchange, but others see serious privacy and data 
protection concerns related to their use (MRCG, 
2012; Newton & Garner, 2002). This debate is still 
unresolved in the US (Gliklich & Dreyer, 2014), but 
unique patient identifiers are widely used in the 
Scandinavian countries. The MRCG and IPPOSI 
(2011) argue that electronic patient records are the 
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building blocks of effective and efficient registries 
and they can certainly streamline the data collection 
process, however, effective data collection procedures 
can be designed in situations where these are not 
available as long as robust data linking procedures 
ensure accuracy and effectiveness of registry data. 
The guidelines caution that data collection is costly 
and registry designers must be aware of the likely 
burden on data providers. Although it is recommended 
that data are collected as close as possible to the 
point of care, data collection during routine health-
care procedures is often perceived as extra work 
‘imposed’ on frontline healthcare professionals and 
can reduce their motivation to engage with the  
registry (EyeNet Sweden, 2005). Finally, data 
collection tools should be adequately pilot tested 
before being rolled out across the healthcare system 
to ensure ease of use, the collection of accurate and 
complete data and the robustness of the collection 
and issue resolution processes. 
Data management: The ideal registry model would 
be a computerised system that imports data directly 
from electronic medical records in various locations 
and settings, with unique patient identifiers that 
facilitate data matching (Zurriaga et al., 2015). This 
ideal remains elusive but best practice dictates that 
a national registry should strive to create secure  
encrypted web-based data entry, data feedback and 
ad hoc reporting mechanisms and an online system 
for handling participant usernames, passwords, 
consent and other administrative functions (EyeNet 
Sweden, 2005). New registries are encouraged to 
consult with, or obtain the services of, an established 
technology firm with proven success in the creation 
and secure management of patient registries (Milken 
Institute, 2016). The precise level of data security 
required will be driven by the purpose of the registry 
and the nature of the data within. Each registry must 
establish the legal requirements that are specific to 
their collection, storage, processing and reporting 
of anonymised and personally identifiable health-
care data, and the associated level of data security 
required given the available technical options, their 
cost and the likely risks to be mitigated.
Data quality: Monitoring data collection against an 
established data dictionary ensures that items are 
collected and stored in accordance with the correct 
procedures, that data meets predefined quality 
standards and that it is capable of meeting registry 
objectives. Potential missing data can be identified 
and the impact of data issues on results generation 
can be minimised. Best practice guidelines  
recommend the creation of a quality assurance plan 
that identifies and monitors the most likely and 
most critical sources of error and the issues that will 
have the greatest impact on the accuracy and the 
validity of the results. 
2.2.3 Ethics and privacy
The purpose of the registry, the type of entity that 
creates and maintains the registry, those that  
contribute the data and use the reports and the 
extent to which data are anonymised or identifiable 
will drive the ethical, privacy and legislative  
implications of the registry. Public health and quality 
improvement initiatives can be driven by results 
based on fully anonymised data, but it is difficult  
to operate a registry with this type of data alone 
(Newton & Garner, 2002). There is the basic need 
to be able to match data from different sources to 
avoid double counting and to create complete longi-
tudinal patient records as individuals move between 
different services and service providers. Registries 
may also wish to validate their data against other 
existing databases or to link with data in other 
unrelated datasets for research purposes. Although 
the consensus across best practice guidelines is the 
use of fully informed consent, it is possible to obtain 
different levels of consent for different registry  
functions, albeit that a more complex data manage- 
ment process will be required to support this. 
Where an individual is unable to give informed 
consent, proxy consent or assisted decision-making 
supports should be sought from a relevant other 
in accordance with legislative and research ethics 
requirements. If the use or availability of identifiable 
data changes, re-consent may be required. The form 
and documentation of initial and revised consent 
needs to be explicitly stated in the registry rules and 
a process put in place to manage the removal of 
data from the registry if consent is withdrawn.
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2.2.4 Funding and resources
Funding is central to the sustainability of a registry 
and the final costs are generally determined by a 
combination of registry size, function, quality and 
the complexity of data collection and reporting 
processes. There are ethical implications if data 
are gathered without having a sustainable funding 
stream identified (MRCG & IPPOSI, 2011) yet, funding 
seems to be insecure for registries that do not have 
a national mandate (Newton & Garner, 2002). It is 
also rare that a single funding stream will be sufficient 
to ensure that sustainability of a registry in the  
longer term (Milken Institute, 2016). 
Four guiding principles have been suggested to assist 
with funding allocations to patient registries: 
• the relevance of the registry in terms of 
severity, volume, costs and needs, addressed 
at	a	national	level;	
• the	potential	of	the	proposed	design	to	
provide	the	information	required;	
• the competence of the registry governance 
structure to deliver; 
• and the likely analysis and feedback that 
the registry can provide to enable clinical 
improvement (EyeNet Sweden, 2005). 
Newton and Garner (2002) suggest that health  
authorities, specialist commissioning groups, national 
bodies and primary care centres should fund registers 
that inform public health policy and patient care 
improvements. Stakeholders are also likely to incur 
some costs and these are typically not borne by the  
registry itself, so funding packages may need to be 
structured in a way that enables stakeholders to 
claim for registry-related expenses to ensure their 
support. The consensus from best-practice guide-
lines is that although contributions from industry 
can be received, these must be evaluated carefully 
and appropriate consideration given to the continued 
independence and credibility of the registry. 
2.2.5 Registry governance
Formal governance structures provide the overall 
direction for and facilitate the smooth operation 
of the registry (Wall, Irvine, & O’Brien, 2015). A 
governance plan should be prepared that clearly 
assigns responsibility for each registry function, data 
ownership and all aspects of data management. 
Swedish guidelines suggest that it can be particularly 
advantageous to invite key stakeholders essential to 
the overall success of the registry and any specialist 
associations or supporters to become members of 
the registry steering committee. This helps increase 
their motivation to support the successful operation 
of the registry (EyeNet Sweden, 2005). It also ensures 
that all stakeholders have a voice in the periodic 
evaluation of the registry and its ability to meet  
its objectives, to review potential changes to or  
expansion of any of the established registry processes 
and to plan and manage the range of issues that arise 
during the day-to-day operation of the registry. All 
guidelines also recommend the inclusion of members 
from established registries as they will be further 
along the natural lifecycle of a patient registry and 
their expertise can provide valuable guidance. 
2.2.6 Registry quality and evaluation
The characteristics that describe quality healthcare 
in the US and Swedish health systems are “knowledge 
-based, suitable, safe, patient-oriented, effective, 
and unbiased” and ‘timely’, and the objective of any 
patient registry should be to facilitate the continuous 
strengthening and improvement of these attributes 
(Brkić,	Pleše,	Pajić,	Pristaš,	et	al.,	2015;	EyeNet	 
Sweden, 2005). Regular and transparent registry 
evaluations are essential in order to provide  
confidence that the registry design is fit-for-purpose, 
that registry processes are conducted ethically, 
legally and appropriately to meet these objectives, 
that data analyses are protected against bias and 
systematic	error	(Brkić,	Pleše,	Pajić,	Pristaš,	et	al.,	
2015) and to encourage interoperability with other 
registries and research collaborations. Gliklich and 
Dreyer (2014) recommend that a registry evaluation 
differentiates between “research quality”, defined as 
the scientific process of the registry, and “evidence 
quality”, that which relates to the selection and  
collection of data items, and the analysis and  
interpretation of findings. A registry evaluation should 
also include an assessment of the cost of the resources 
needed to operate the registry, the effectiveness of 
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the registry governance structures and suggest  
improvements where appropriate. Although  
comprehensive annual evaluations are recommended, 
there is a need to balance the scope of these  
evaluations with their feasibility and affordability. 
The responsibility for registry evaluations should  
be determined during initial planning. 
2.2.7 Registry outputs and the use 
 of registry data
Best-practice guidelines suggest that the registry’s 
governing body should decide who accesses registry 
data and for what purpose, and the degree of  
transparency applied to registry findings and reports. 
The guidelines generally recommend considerable 
openness in the reporting of results, particularly 
with non-identifiable data, but they also acknowledge 
the need to balance openness and privacy require-
ments, and they caution that the registry may first 
need to reach a certain degree of maturity so that 
the validity and accuracy of reported results can be 
assured. It is likely that different levels of transparency 
will be agreed for different stakeholders so the 
guidelines recommend the development of an analysis 
and reporting framework that details the different 
types of reports that will be produced, report 
frequency, intended audience(s) and how data will 
be analysed and outcomes addressed. Frequent 
communication can be an effective tactic for keeping 
participants and stakeholders engaged (Milken  
Institute, 2016). At a minimum, the registry should 
meet with all stakeholders once a year and produce 
a publicly available annual report (see Gliklich and 
Dreyer (2014) for a detailed recommendation on the 
content of these reports). Guidelines suggest that  
local registry managers and data providers should 
also have the ability to perform ad hoc queries 
within the bounds of privacy and data access rules 
and consent limitations. At a minimum, this should 
include the ability to compare themselves to average 
data and see how all providers are distributed around 
the mean. All other requests for data access should 
be made formally to the registry and adjudicated on 
separately. Best practice guidelines also recommend 
that all publications that use registry data should be 
peer reviewed prior to publication.
2.2.8 Facilitating registry 
 interoperability
Achieving interoperability with other national and 
international registries and databases is becoming 
increasingly important (Gliklich & Dreyer, 2014).  
As a result, best practice guidelines highlight: 
• the need for open standards that facilitate 
communication	and	data	transfer	without	
specific	customisations	at	either	end	 
(syntactic	interoperability);
• shared	data	dictionaries;	
• standardised	data	definitions	and	measures	
(semantic	interoperability);	
• mutually	agreed	operating	principles	
underpinned by the appropriate legal and 
ethical frameworks to govern data sharing  
and independent governance processes.
The	PARENT	framework	(Brkić,	Pleše,	Pajić,	Kostešić,	
et al., 2015) is an example of an objective-based 
framework that provides guidelines to and a shared 
infrastructure for the development of registry  
environments that support interoperability needs.
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2.3 Review of international 
 dementia registries
Since	the	1980s,	several	dementia	registries	have	
been established internationally. No one ideal model 
for a dementia registry has as yet been established 
and it can be argued that design should be based 
on the objective of the proposed registry (González, 
2015). Population registries are most common 
among international dementia registries and they 
provide useful epidemiological data for policy-making 
and planning resources and services for people 
with dementia and their families. A summary of the 
international dementia registries that are currently 
active is provided in Table 2 and a brief overview is 
presented of each.
2.3.1 Swedish Dementia Registry 
 (SveDem)
SveDem was established in 2007 to monitor and  
improve the quality of diagnoses, treatment and 
care of patients with dementia. It is currently the 
most comprehensive dementia registry covering  
almost all of Sweden. Swedish National Guidelines 
for Care (Socialstyrelsen, 2016) identify seven  
indicators to evaluate the quality of dementia care: 
1 proportion	of	patients	diagnosed	with	
dementia	in	last	year;
2 proportion	of	patients	undergoing	basic	
dementia	work-up;	
3 proportion	of	Alzheimer	Disease	(AD)	patients	
treated with cholinesterase-inhibitors and/or 
memantine;	
4 proportion	of	patients	treated	with	anti-
psychotic	drugs	in	nursing	homes;	
5 proportion	of	patients	with	day-care	at	
diagnosis; 
6 proportion	of	patients	living	in	nursing	homes;	
7 proportion	of	patients	followed-up	at	least	
once a year. 
For each indicator, SveDem has established internal 
goals that they continually work towards achieving 
such	as	90%	of	people	receiving	basic	dementia	
work-up and reducing use of antipsychotic use in 
nursing	homes	to	10%	(Religa	et	al.,	2015).	
People with dementia and their families have the 
right to ‘Opt-Out’ or have their data removed from 
the registry if they wish (Religa et al., 2015). The 
data are collected by physicians or nurses at affiliated 
SveDem units and entered into a web-based registry. 
A local co-ordinator for each unit can manage their 
own data and they can compare this to data from 
all units in Sweden. When the registry began, the 
majority of affiliated units were specialist settings 
(memory clinics) with data from primary care units 
gradually	increasing	from	25.6%	(2007)	to	48.2%	
(2012).	By	2015,	93%	of	all	specialist	settings	and	
60%	of	all	primary	care	centres	were	covered	(Religa	
et al., 2015). Nursing homes were affiliated in 2012 
and	the	registry	continues	to	grow	with	58,823	
people registered as of 31st March 2016 (SveDem, 
2016). The availability of unique health identifiers 
facilitates the use of multiple sources and supports 
increased accuracy and completeness. Furthermore, 
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a research nurse visits all SveDem units to verify that 
the data in the registry matches the original data  
in the person’s medical records. Yet, despite the 
comprehensiveness of the registry, difficulties 
remain regarding the involvement of primary care 
centres. A significant part of the regional co-ordinators 
role relates to ongoing efforts to ensure primary 
care units are affiliated with SveDem to facilitate 
the completeness and accuracy of the data in the 
registry (Religa et al., 2015).
SveDem receives government funding (Swedish 
Association of Local Authorities and Regions) and 
funding from the Swedish Brian Power Network.  
It is governed by a steering committee made up  
of several healthcare professionals and headed by 
the registry holder who, along with the national  
co-ordinator, has responsibility for day-to-day registry 
function. There is also a full-time administrator  
employed by the registry and regional co-ordinators 
to ensure that SveDem is being implemented  
correctly in the units throughout the country.  
Uppsala Clinical Research Centre is responsible for 
developing the online database and its technical 
support and security, while Karolinska University 
Hospital has overall responsibility for the data. The 
organisational structure of SveDem, described in 
detail by Religa and colleagues (2015, p. 5), is an 
example of a comprehensive governance structure 
that can be adopted by any patient registry.
In addition to publishing an annual report of the 
quality of dementia diagnosis, treatment and care in 
Sweden, SveDem has published a variety of research 
studies using SveDem data that relate to prevalence 
(Religa et al., 2012), diagnostics (Falahati et al., 2014), 
costs (Wimo et al., 2013), medication (Fereshtehnejad, 
Johnell, & Eriksdotter, 2014), risk factors for dementia 
(Nilsson, Waldö, Nilsson, Santillo, & Vestberg, 2014) 
and clinical aspects of dementia (Eriksson et al., 2014). 
In a recent review, Religa and colleagues (2015) 
illustrate how SveDem can contribute to the enhance-
ment of expertise and how it supports the embedding 
of application of research findings in clinical practice. 
They suggest that SveDem could also address some of 
the methodological problems currently experienced 
when researching dementia (e.g. research on  
individuals that do not reflect the population at risk) 
as it could function as a tool to identify and recruit  
patients that are suitable for specific studies. Given the 
possibility to observe the clinical course and progression 
of dementia, they also suggest that SveDem could 
facilitate certain improvements in clinical trial design. 
2.3.2 Danish Dementia Registry (DCDR)
DCDR, created in 2010, gathers dementia-related 
data from six geriatric, eight psychiatric and four 
neurology clinics relating to eight quality indicators 
that were chosen on the basis of meeting agreed 
minimum standards (Johannsen et al., 2011; Phung 
et al., 2007), namely: 
1 percentage	of	patients	with	dementia	
proportional	to	number	referred;
2 proportion	of	patients	with	dementia	
(including	those	with	mild	cognitive	
impairment)	evaluated	within	90	days;	
3 proportion	of	patients	assessed	with	the	 
Mini	Mental	State	Examination	(MMSE);	
4 proportion	of	patients	assessed	using	
Functional	Activities	Questionnaire	(FAQ)	scale;	
5 proportion	of	patients	with	available	results	 
of all recommended blood tests; 
6 proportion	of	patients	with	a	CT	or	MRI	scan;	
7 proportion	of	patients	where	etiological	
diagnosis is determined; 
8 proportion	of	patients	with	Alzheimer	Disease,	
Dementia	with	Lewy	Bodies	and	Parkinson’s	
Disease	Dementia	treated	with	anti-dementia	
drugs. 
Despite the use of mutually agreed guidelines,  
diagnostic variance still occurs. 
    
The Danish Clinical Registries (RKKP) was subsequently 
established with responsibility for the infrastructure 
of all national clinical quality databases. With an  
annual budget of approximately €6.5m, RKKP  
manages	69	such	clinical	registries,	now	including	
the DCDR, which was rolled out on a national level 
in January 2016. As the purpose of clinical quality 
databases is to survey quality of health care services 
that are approved by the Danish National Board of 
Health, information can be collected without an 
individual's consent (Johannsen et al., 2011). RKKP  
consists of registry support centres, epidemiology 
and biostatistics that are affiliated with specialist 
universities and clinical quality and health informatics. 
Data are registered by clinical personnel and gathered 
through data-collection systems accessible from all 
computers within the hospital system. RKKP provides
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quality improvement feedback to clinicians and 
produces a yearly report with analysis and  
recommendations per database (Databasernes  
Faellessekretariat, 2016). Each registry has a  
professional board appointed by professional  
medical and nursing societies, representing the main 
clinical stakeholders, and each has to pass appraisal 
in the National Health Authority every three years, 
where it is assessed against national criteria for 
functionality, data safety and methodology. 
Rather than following a typical dementia registry 
model such as that used in Sweden, the DCDR  
facilitates a continuous process of data collection 
that in turn supports harmonisation and quality 
improvements in services provided in each  
participating institution (Johannsen et al., 2011). 
Despite the use of different models, comparative 
studies with SveDem data demonstrate the potential 
value of using registries for comparing patient  
demographics, diagnostic procedures, diagnostic 
accuracy and the quality of dementia care in different 
countries (Fereshtehnejad et al., 2015). 
2.3.3 The Registry of Dementia of 
 Girona, Spain (ReDeGi) 
ReDeGi is a clinical registry of newly diagnosed  
dementia cases established to gather epidemiological 
data to inform policy and planning services for 
dementia	(Garre-Olmo	et	al.,	2009)	and	to	facilitate	
research. To date, these have predominately been 
drug studies (Àvila-Castells et al., 2013; Calvó-Perxas 
et al., 2012; Turró-Garriga et al., 2015). ReDeGi 
currently	covers	70%	of	the	Girona	region	and	its	
limited scope (seven data collection sites) and size 
make it relatively easy to manage (ReDeGi, personal 
communication, April 2016). It offers an alternate 
approach to a comprehensive national registry 
model such as that implemented in SveDem and one 
that could be utilised as a starting point for any 
dementia registry that requires the potential to expand 
its scope over time. Patient consent is obtained  
following diagnosis and a registry technician reviews 
the patient’s medical records, transcribes the 
required data into a paper data collection form and 
then enters the data into the registry database. 
While ReDeGi do not receive data directly from  
primary care sources, they do not consider this  
a significant factor because suspected cases of 
dementia in primary care are referred to memory 
clinics in one of the seven hospitals in the region 
(ReDeGi, personal communication, April 2016).  
Registry data can reliably be used to ascertain the  
incidence of new cases that contact specialised health 
services but caution is needed when estimating  
diagnostic coverage as the data are not representa-
tive of the real population incidence. The diagnosed 
cases consist of people referred to a specialised 
diagnostic clinic some of whom present with  
moderate to severe severity and a mean time of two 
years from onset of symptoms to time of diagnosis 
(Garre-Olmo	et	al.,	2009).	ReDeGi	has	a	board	and	
employs a director, a researcher and a technician. 
Annual reports containing data longevity statistics 
and quality evaluations are submitted to the regional 
government, and comparisons to MMSE scores  
validate the overall quality of the data in the registry. 
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2.3.4 South Carolina Alzheimer’s 
 Disease Registry (SCADR)
SCADR is a population registry of over 230,000 
cases of Alzheimer’s disease and related disorders 
(ADRD) in South Carolina (Arnold School of Public 
Health, 2014). It aims to provide disease prevalence 
estimates to support social and medical service 
planning, identify differences in disease prevalence 
among demographic groups, improve care for those 
with ADRD and to foster research into risk factors for 
ADRD. Numerous research studies have been carried 
out using registry data; for example, behavioural  
difficulties in long-term care (Dennehy, Kahle-
Wrobleski, Sarsour, & Milton, 2013). Additionally, 
the registry facilitates many requests for information 
from grants projects with local hospitals and agencies 
(SCADR, 2016). 
The SCADR can access multiple data sources, as  
outlined in Figure 1, yet the registry acknowledges 
that coverage issues remain, in particular data  
completeness as diagnosis and/or treatment can 
take place in many different settings. Additionally, 
the registry misses data on those who do not seek 
medical treatment, a problem with all registries 
and the individuals who cross into border-states for 
diagnosis and/or treatment (SCADR, personal com-
munication, May 2016).  
In the United States, the collection of data that is 
deemed to be in the best interest of the public’s 
health and well-being, is exempt from the Health 
Insurance Portability and Accountability Act (HIPAA) 
Privacy Rule (U.S. Department of Health and Human 
Services, 2016). When a person goes to any medical 
facility they usually sign an agreement form that  
authorises the release of data for health statistics 
and health study purposes and acts as consent. As 
a result, SCADR does not need to obtain specific 
consent to collect and store registry data. Identifiable 
data are held by the registry but it can only be  
accessed by registry staff (SCADR, 2016). The registry 
itself is based in the Office of Aging in the Arnold 
School of Public Health in the University of South 
FIGURE 1  SCADR Data Sources (Arnold School of Public Health, 2014)  
Reprinted with permission from South Carolina Alzheimer’s Disease Registry Annual Report 2013-2014 (p. 4), by 
Arnold School of Public Health, 2014, Retrieved from http://www.asph.sc.edu/osa/OSA_annualreport_FINAL1.
pdf. Copyright 2014 by Arnold School of Public Health.
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will facilitate its survival (WVADR, personal  
communication, June 2016). 
2.3.5 Georgia Alzheimer’s and Related  
 Disorders Registry (GARDR) 
GARDR is a population registry located within the 
Georgia Department of Public Health (GDPH) and 
based on the SCADR and WVADR models. It aims 
to collect sufficient data to identify epidemiological 
trends, inform programs and services for the ageing 
population, increase awareness at state level to the 
issues that affect healthy ageing and to plan and 
manage future registry needs (GDPH, 2016). Currently, 
Medicare is their only source of data but they plan 
more comprehensive data collection in the future 
and the registry has created a secure portal for 
physicians to report diagnoses of ADRD. The registry 
acknowledges getting agreements in place for data 
sharing and ‘buy-in’ from clinicians is challenging 
(Georgia Department of Human Services, 2015).
2.3.5 Other dementia registries 
 and databases
Within this review, we identified a number of inter-
national dementia registries that were successfully 
implemented but have since ceased to operate.  
Additional dementia registries whose definition 
does not meet the criteria for inclusion in this study 
and some proposed dementia registries that have 
not as yet progressed beyond the proposal or pilot 
stage were also identified. The additional registries 
and databases are summarised in Table 3.
 
Carolina (USC) and USC has joint ownership of the 
registry data with the Department of Health and  
Human Services. SCADR is governed by a board  
and it employs a Registry Co-ordinator who is an  
epidemiologist and a PhD student who is a  
biostatistician, but USC is accountable for meeting  
quality standards as they are most involved with 
running the registry on a day-to-day basis. SCADR 
provides mandatory annual reports to its board, to 
legislators, to agencies they work closely with (e.g. 
The Alzheimer’s Association) and to researchers in 
the university. 
2.3.5 West Virginia Alzheimer’s 
 Disease Registry (WVADR)
WVADR is a population registry that collects data 
from healthcare providers on newly diagnosed cases 
of ADRD in West Virginia to enable policy, planning 
and research (WVADR, 2016). Patient data are similar 
to that collected by SCADR and they can be submitted 
on paper or entered by clinicians through a web-based 
registry data entry screen (Schreurs, 2010). WVADR 
acknowledges there have been obstacles in obtaining 
‘buy-in’ from healthcare providers to provide patient 
information; the 3,500 registered entries in 2013 fell 
considerably short of the estimated 36,000 people 
diagnosed with dementia in the state.  Subsequent 
access to data from the Medicare database, the  
national social insurance program and medical  
provider for all over 65s in the United States, has led 
to an increase in the number of cases registered by 
early	2015	to	almost	28,000	(Schreurs,	2010).	
Under HIPAA exemption rules, the WVADR does not 
require consent to collect data, but patients are  
assigned a unique identifying number to protect 
their privacy. Access to identifiable data is restricted 
to the Registry Director and only summary statistical 
data are used in all reports (Schreurs, 2010). The 
registry is located in West Virginia University and is 
run by a board of governors and overseen by an  
advisory board that includes representatives from 
The Blanchette Rockefeller Neurosciences Institute, 
The Institute on Aging, Marshall University, West  
Virginia Department of Health and Human Resources 
and representatives of public and private entities 
and organizations and other individuals involved 
in ADRD (WVADR, 2016). Previously funded by the 
state, recent deficit cuts have left the sustainability 
of the registry at a challenging crossroads, but  
it is hoped that the legal status of the registry  
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TABLE 3 Other dementia registries and databases identified during the literature review  
Registry Country Category Year Inclusion Funding Status and Description
CDCR  
(Camberwell  
Dementia 
Case 
Register) 
UK Case 1992– 
1997
Dementia 
diagnosis
Project  
grant and 
donations
Ceased – was specifically created to refine  
diagnostic criteria for dementia and develop  
predictive tests or risk factors for dementia sub-
types	(Cooper	&	Holmes,	1998);	examine	non-
cognitive symptoms and clinical correlations of 
different subtypes (Holmes & Lovestone, 2003); 
and act as a framework for clinico-pathological 
studies (Russ et al., 2001) by the additional  
collection of biological material, ante- and post- 
mortem,	from	registry	participants	(Holmes,	1996).
CERAD  
(Consortium 
to Establish  
a Registry for 
Alzheimer’s 
Disease)
USA Clinical- 
Epidemio-
logical
1986 Alzheimer’s 
Disease 
diagnosis
National 
Institute  
on Aging 
(NIA)
Does not meet ‘Dementia Registry’ criteria – 
CERAD	was	established	in	1986	to	standardize	
procedures for the evaluation and diagnosis of 
patients	with	AD	(Fillenbaum	et	al.,	2008).
NYSDR  
(New York 
State  
Alzheimer’s  
Disease and  
other  
Dementias 
Registry)
USA Population 1986	 Dementia 
diagnosis 
(ICD-9)
State Replaced	–	established	in	1986	as	a	surveillance	
system to collect information necessary to  
“identify, locate and investigate the occurrence, 
frequency, incidence, cause, effect and prognosis of 
Alzheimer’s Disease” and maintain this information 
for research purposes (Lillquist, 2004). The New 
York State Coordinating Council for Services 
Related to ADRD now produces reports every two 
years with general information about ADRD that 
appears to have replaced the NYDSR (New York 
State Department of Health, 2016). Prevalence 
and epidemiological data are not reported. 
ReDeCAr  
(Centralised  
Registry of 
Cases with 
Cognitive 
Impairment 
in Argentina) 
Argentina Clinical-
Epidemio-
logical
2009 Cognitive 
Impair-
ment 
diagnosis
National 
Health 
Research 
Committee
Does not meet ‘Dementia Registry’ criteria – 
Proposed development of a Cognitive Impair-
ment Centralized Case Registry in Argentina 
based on the Epidemiological Surveillance 
Model. An observational prospective study was 
conducted in different healthcare centres and 
hospitals around Argentina (Melcon et al., 2010).
ReCeDemCu 
(Cuban 
National 
Dementia  
Registry)
Cuba Clinical-
Epidemio-
logical
2015 Dementia 
diagnosis 
(DSM-IV or 
ICD-10)
State 
funding 
suggested
Does not meet ‘Dementia Registry’ criteria –  
Proposal for a centralised automated registry on 
cognitive deterioration and dementia in Cuba.  
A pilot study was scheduled to begin in 2015 
to test the operational structure of hospitals, 
specialised clinics and several primary care  
facilities where registries will be compiled and 
later extended nationally (González Cáceres, 
2013). No further information is available.
UCLA  
Alzheimer’s 
and  
Dementia 
Care Program
USA Clinical-
Epidemio-
logical
2012 Dementia 
diagnosis
Assess- 
ment 
charge and 
multiple 
grants
Does not meet ‘Dementia Registry’ criteria – 
Patients are referred from physicians, usually 
general practitioners or geriatricians for the 
medical management of dementia-related issues 
by Nurse Practitioners (Reuben et al., 2013). 
WADPR  
(Washington  
Alzheimer’s 
Disease  
Patient  
Registry)
USA Population 
(post  
January 
1987)
1987–
1997
Dementia 
diagnosis
National 
Institute 
of Aging 
grant
Ceased – gathered epidemiological and genetic 
data for research purposes in a circumscribed 
area of Seattle with approximately 23,000 
people over the age of sixty who were cared  
for by seven to nine primary care clinics (Larson 
et	al.,	1990).	The	registry	did	not	intend	to	find	
‘all’ cases of ADRD but rather to find as many 
newly diagnosed cases as possible in the  
specified area (WADPR, 2016).
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the MRCG and IPPOSI (2011), the fragmented nature 
and the absence of a strategic policy framework for 
the operation of patient registries has detrimental 
implications for future research in Ireland. For example, 
Irish institutions or researchers may be unable to 
participate in research at national or international 
levels because of a lack of accurate and comprehensive 
data or due to an inability to identify potential  
research participants, with subsequent impact  
on the profile of health research in Ireland and the 
potential to secure future international funding. 
The MRCG and IPPOSI (2011) report advocates for 
incorporating the findings from high-quality patient 
registries into mainstream health service reports 
and decision-making while still ensuring that patient 
registries remain independent and in line with inter-
national best-practice. They see the Swedish registry 
support model as good practice that can inform 
policy development in Ireland. This model provides 
centralised allocation of resources, a national body 
for co-ordinating funding and the prioritisation of 
disease areas for investment (Swedish Association  
of Local Authorities and Regions (SALAR), 2005). 
Using this model, strong patient care and business 
cases can be made to support the creation of new 
patient registries that increase the effectiveness 
and efficiency of health services in Ireland. This is 
particularly the case for patients requiring chronic 
disease management that comes at a considerable 
cost to the state. The first step towards developing  
a strategic framework and appropriate funding 
mechanisms to support patient registries in Ireland 
is to raise awareness and understanding of the value 
of registries with all key stakeholders and demonstrate 
how the information gathered in existing patient 
registries can be integrated into decision-making 
processes (MRCG & IPPOSI, 2011). A potential  
Patient Registries Framework was suggested in the 
MRCG and IPPOSI (2011) report and this is reproduced 
with permission in Table 4.
2.4 Review of existing 
 patient registries in 
 Ireland 
The feasibility of any patient registry is influenced by 
the environment in which the registry operates. This 
section provides an overview of the policy and legal 
frameworks relevant to the creation of a national 
dementia registry in Ireland. The development of  
patient registries in Ireland is recent, but they  
continue to grow in number. The section concludes 
with a more detailed review of three examples  
representing the current spectrum of Irish patient 
registries. They demonstrate that a lot can be 
achieved within the current limitations of the Irish 
health system.
2.4.1 Strategic policy framework 
Discussions regarding the strategic nature of patient 
registries have been taking place in Ireland over the 
last ten years. They have included a 2007 working 
group comprised of representatives from the HSE, 
Health Research Board (HRB), Health Information 
and Quality Authority (HIQA) and the research 
charities.	A	2008	meeting	on	patient	registries	was	
attended by experts from science, industry, patient 
groups, medical charities and other key stakeholders.  
Despite this, there is still a lack of strategic direction 
in Ireland and the recommendations that were  
included in the Health Information and Patient Safety 
Bill (HIPS) consultation documents have had little 
response from government to date and the  
momentum has gradually ‘fizzled out’ (IPPOSI, 2015; 
MRCG & IPPOSI, 2011). Although HIQA have published 
guiding principles for health and social care data 
collection in Ireland (Health Information and Quality 
Authority, 2013), these do not go as far as setting 
national standards for databases such as patient 
registries and HIQA’s remit currently only extends to 
data collection within the HSE. They have identified 
that current data collections are often paper based, 
have limited data dictionaries and limited standardi-
sation of coding, and are poorly integrated with  
other patient information systems (Donoghue, 2011). 
As a result Irish patient registries are characterised 
by significant heterogeneity with regard to size, 
function, disease, funding, cost and governance, and 
they still tend to be seen as external to the health 
service and somewhat of an ‘add-on’. According to 
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TABLE 4 Patient Registries Framework*     
Shared characteristics: The whole national population of the disease is covered. Each individual person 
(patient) is registered only once as a unique entity that is not duplicated.
Patient Registry The gold standard in the registries framework is the independent and well-resourced patient 
registry. A wide range of relevant data is collected and analysed. Compatibility with data  
collected by registries in other countries is a key concern. Registries strive to provide data and 
analysis that can shape the planning, delivery and review of services impacting on a particular 
disease, but not on the day to day treatment of individual patients. Depending on the level  
of resources, registries generally employ full and part-time staff with a range of data capture 
and analysis skills. 
Patient / Electronic 
Health Register
Patient/Electronic Health Registers are an important development. They tend to be primarily 
developed and led by clinicians as an operational tool from which to support treatment and 
provide a relatively sophisticated level of data capture and analysis. Patient/Electronic Health 
Registers are less likely to have full or part-time staff. Resource issues are also likely to restrict 
the range of data collected and analysed and, concomitantly, they may have less of an impact 
on shaping overall policy in relation to a particular disease. 
Patient Database Patient Registries at their most basic are databases of patients who share some characteristics, 
such as a certain condition or medication regimen. They can be very useful in helping to deliver 
a defined service, including services provided by national patient advocacy bodies (mainly  
charities). Also developed in some instances by the pharmaceutical industry to support research. 
Electronic Patient  
Records (hospital 
level)
Increasingly essential to the development of Patient Registries is the development of Electronic 
Patient Records (EPR). The EPR’s contain relevant information captured by a hospital on all  
patients from one disease area attending that Hospital. Electronic Patient Records are, at  
present, an optional add-on to complement mandatory paper-based patient records. They 
are primarily developed for operational use in the treatment of a particular disease, including 
analysis of the key health indicators and treatment records of individual patients over a period 
of time. They also provide the most effective way for registries operating at a national level to 
capture the data they need, once the data capture template for Electronic Patient Records is 
consistent with that of the registry and data protection is observed. 
*Reprinted with permission from South Carolina Alzheimer’s Disease Registry Annual Report 2013-2014 (p. 4), by 
Arnold School of Public Health, 2014, Retrieved from http://www.asph.sc.edu/osa/OSA_annualreport_FINAL1.pdf. Copy-
right 2014 by Arnold School of Public Health.
One of the core assumptions of this framework is 
the standardisation of patient records within the 
HSE and the use of electronic patient records (EPR). 
Although there has been some movement with 
regard to electronic health records and investment 
in eHealth in Ireland since the publication of this 
report, huge disparities still exist with regard to the 
recording of patient data and there is also huge  
variance in the quality of data recorded by different 
hospitals and GPs (IPPOSI, 2015; MRCG & IPPOSI, 
2011). This significantly compromises the current 
ability of patient registries to collect and manage 
data effectively and efficiently; the matching of  
patient data is currently tedious and labour intensive, 
although possible in the current environment.
2
2.4.2 Legal and regulatory 
 environment
There are a number of international directives, 
conventions and codes relevant to patient registries 
and these are summarised in Appendix 1 of the 
MRCG (2012) report on patient registries in Ireland. 
The Irish legislation, directives and codes relevant to 
patient registries, relevant Law Reform Commission 
reports and an overview of the proposed Health 
Information Bill are also presented in that report in 
Appendices 2, 3 and 4 respectively (MRCG, 2012). 
This section will highlight relevant legislation that 
has been introduced since 2012 (specifically the 
European Data Protection Reform 2016 legislation 
(European Council, 2016) and the Assisted Decision 
Making (Capacity) Act 2015 (House of the Oireachtas, 
2015)) and comment on the current status of the 
Health Information and Patient Safety Bill. 
Data Protection Legislation
The newly enacted EU Data Protection 2016 (EUDP) 
regulation that came into force on the 25th of May 
2016 covers the use of personal data in all sectors 
other than law enforcement. At a meeting of the 
Irish Health Research Forum (IHRF) in May 2016, Dr 
Beth Thompson (Wellcome Trust) argued that the 
EUDP essentially falls somewhere between an EU 
regulation and a directive; the guidelines are quite 
flexible and they provide individual member states 
with a lot of scope to be more flexible in their own 
legislation as a result (IHRF, 2016). It essentially  
preserves the status quo for health research in 
Europe, although there are some points that will 
require further confirmation with the EU (IHRF, 2016). 
We are now in the two-year period where each 
member state must determine how to introduce the 
changes required by EUDP and to clarify their  
position in legislative changes of their own. As 
policy, clinical care and research all depend on data 
it is incumbent on all stakeholders to engage with 
the debate to determine how best to make the 
EUDP work for them. As such, this is an opportune 
time for the Department of Health, the HSE and all 
patient registry stakeholders (including clinicians, 
policymakers, patient advocates and researchers) 
to engage in debate with the Data Protection Office 
and the Department of Justice to ensure that the 
resulting Irish legislation takes the needs of current 
and future patient registries into account.
The following are the key elements that directly 
influence the creation of patient registries:
• The	regulation	applies	to	personal	data;	it	does	
not apply to fully anonymised data, but there 
are	inconsistencies	in	how	different	member	
states	define	‘fully	anonymised’.	Dr	Thompson	
highlighted	the	fact	that	‘Pseudonymisation’	
was	defined	in	the	EUDP	but	the	definition	
differs	from	that	typically	used	in	research	
and it does not address the idea of coding 
where a key holder typically has the ability to 
identify	the	data	(a	method	used	by	a	number	
of	existing	patient	registries).	Further	direction	
will be needed from the EU in this regard. 
• The	need	to	ensure	that	confidential	
data are collected carefully, securely and 
comprehensively, and with an individual’s 
consent – once. It is no longer acceptable to 
duplicate	data	collection	in	many	sites.
• Consent	processes	should	be	specific,	explicit	
and	informed	–	careful	consideration	at	a	
national	level	is	needed	to	determine	how	best	
to implement this guideline, understanding 
that	there	will	be	times	when	obtaining	this	
type	of	informed	consent	is	difficult;	for	
example,	in	situations	where	bio-bank	data	
are being collected and we are unsure how 
it	might	be	used	in	the	future,	or	situations	
where	there	is	a	question	regarding	the	
person’s capacity to give consent. The EUDP 
board are expected to issue guidance to 
member states covering these types of 
situations.	Dr	Thompson	also	suggested	
that	‘public	interest’	is	poorly	defined	giving	
member	states	some	flexibility	in	determining	
their	own	definitions.
• Data	controllers	(e.g.	the	‘owner’	of	a	patient	
registry) are now required to demonstrate 
their	compliance	with	the	regulation.	It	is	
possible that the Privacy Impact Statements 
(PIAs) created by HIQA may play some role 
here although that has yet to be determined.
• New rules and requirements have been 
included	specifically	related	to	data	breaches.
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Assisted Decision Making (Capacity) Act 2015 
The Assisted Decision Making (Capacity) Act 2015 
is scheduled to be commenced by Ministerial Order 
during 2016 (House of the Oireachtas, 2015). It 
provides a statutory framework that enables an 
individual who lacks, or may lack capacity, to make a 
decision unaided to receive support and assistance 
when making decisions about their welfare, property, 
health care and other affairs. The Act provides for 
different levels of decision making support: Assisted 
decision-making, Co-decision making, Enduring 
Power of Attorney, Wards of Court and the  
introduction of a Decision Support Service within 
the Mental Health Commission to oversee, deliver 
and support each of these new functions. The Act 
also introduces the concept of Advanced Healthcare 
Directives into Irish law. The Act defines capacity as 
the ability to understand, at the time the decision 
is being made, the nature and consequences of the 
decision in the context of the choices that are available 
at the time (Citizens Information Bureau, 2015). A 
person lacks capacity if they are unable to under-
stand the information pertinent to the decision, 
if they are unable to retain the information long 
enough to allow them to make an informed choice, 
if they are unable to evaluate the information as 
part of the decision-making process, or if they are 
unable to communicate their decision. However, 
a person does not lack capacity if they require the 
information to be explained to them in a way that 
is appropriate to their ability to understand and 
interpret it, if they can only retain the information 
for a short period of time, if they lacked capacity at 
one time but no longer do so, or if they lack capacity 
for decisions on some matters but retain capacity to 
make this particular decision. 
The exact operation and impact of this new legislation 
is not yet clearly understood, but the position will 
become clearer over time and the consensus is that 
it will support better decision-making and consent 
processes. From the perspective of the person with 
dementia, the Act will enable them to appoint a co- 
decision maker to help them make informed consent 
decisions in a range of areas including whether to go 
on the dementia register, or what data can be held 
on the register (e.g. tiered consent). The Assisted 
Decision Making Agreement needs to be signed by 
both parties and two witnesses (one of which can be 
a family member) and registered with the Decision 
Support Service. Although this seems to be additional 
work, it is likely to be needed for a range of health-
care decisions required in day-to-day dementia care 
so it is not an additional step for the sole purpose of 
facilitating the collection of registry data.
Health Information and Patient Safety Bill 
(HIPS)
Legislative changes take a significant amount of time 
in Ireland and the long-awaited Health Information 
and Patient Safety Bill (HIPS) is a case in point. The 
proposed bill deals directly with issues related to 
patient registries (Department of Health, 2014a).  
It includes proposals on the definition of patient  
registries in Ireland, ethical approval processes,  
privacy impact statements, individual health  
identifiers, data matching, data sharing and  
regulations governing research other than clinical 
trials. However, the regulations contained within the 
bill are currently proposed as voluntarily guidelines 
for non-clinical-trial research whereas similar rules 
are mandatory in the EUDP. The most prominent 
area of conflict between the two pieces of legislation 
relates to consent. HIPS states that patient registries 
must operate with patient consent unless they are 
deemed exempt from needing this consent. There are 
currently situations where local ethics committees 
can waive the need for written consent under certain 
conditions (e.g. low-risk data collection or data 
collection that is in the national interest). HIPS 
proposes a change that would mean that this waiver 
can only be made by the Data Protection Commis-
sioner following a privacy impact assessment made 
in conjunction with HIQA (Department of Health, 
2014a). Concerns have already been raised that this is 
too restrictive and could inhibit research. Instead, a 
graduated system that has the Data Commissioner 
in an arbitration role has been suggested, but there 
is a need to ensure that whichever approach is  
adopted, it is EUDP compliant. It should be noted 
that the waiving of informed consent is a situation 
that currently exists for some of the patient registries 
that are operational in Ireland today and for many of 
the established international dementia registries. 
The other key aspect of the HIPS legislation is that 
it authorises the Minister for Health to introduce 
health identifiers for individuals and health providers. 
The format and operation of the identifiers are not 
included in the bill; they will be established under 
the Health Identifiers Act (House of the Oireachtas, 
2014). The aim is to allow for unique identification 
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of individuals and of health service providers for all 
health-related purposes including patient registries, 
thus facilitating interconnection and interdependence 
of policies and practice in health information and 
health research, reduced duplication and better data 
linkages (multiple cases of care). However, it assumes 
that a data sharing and legislative framework can be 
agreed and implemented (IHRF, 2016). Moreover, 
HIPS includes a provision whereby an individual can 
refuse to provide their individual identifier to health 
services and that any data matching on the basis 
of this or any other identifier needs consent from 
the patient (MRCG, 2012). These provisions seem 
contradictory to the objectives of introducing unique 
health identifiers and it is unclear how the potential 
waiving of consent will apply in this instance. 
2.4.3 Development and operation 
 of existing patient registries
The creation of patient registries in Ireland has been 
a relatively recent development and their numbers 
are	increasing;	three	developed	between	1966	and	
1991,	and	16	between	2001	and	2009.	The	MRCG	
and IPPOSI (2011) report analysed 47 existing patient 
registries in Ireland and found that: 
• The	primary	function	for	most	of	these	
registries	in	Ireland	(48%)	is	to	improve	patient	
safety and quality of care. Disease surveillance 
and	control	is	a	secondary	function,	while	
research is considered to be an important 
tertiary	function.	
• Approximately	40%	of	registries	had	all	of	their	
target	population	enrolled	on	the	register,	70%	
reached	coverage	levels	of	60%	and	30%	had	
a	coverage	rate	of	less	than	50%.	Assessments	
ranged	from	one	(60%	of	those	assessed)	to	
four	years	prior	to	publication.	
• Some	form	of	consent	was	used	by	73%	of	
those surveyed with just under half using 
written	consent.	Three	quarters	have	an	
‘opt	out’	system	of	some	kind;	55%	of	those	
registers without any form of consent also did 
not have an opt-out system).
• Case	definitions	were	used	by	58%,	clinical	
coding	systems	by	24%,	and	disease	
classification	systems	by	70%.	Half	of	all	
registries	use	data	dictionaries.
• Most registries had access to clinical and to 
technology support either directly through 
the registry or through available resources 
at	the	location	of	the	registry	(e.g.	university	
campus); one third of registries indicated that 
they	had	no	access	to	any	statistical	support.	
• A	total	of	21%	of	registries	reported	having	 
web-enabled access to data but paper-based 
data	transfer	is	active	in	71%	of	registries.	
• More than half of the registries carry out 
regular	data	validations,	70%	carry	out	data	
duplication	analyses	and	77%	perform	missing	
data analyses.
• Only	58%	of	registries	surveyed	specified	
the amount of annual funding they receive. 
Excluding the funding of one very large 
registry, the average annual funding was 
€231,450. 
• 68%	of	registries	received	start-up	funding	
from	the	state,	12%	from	commerce	and	
20%	from	charities;	72%	of	registries	have	
continued	state	funding,	4%	commerce,	12%	
charities,	but	12%	had	no	funding	when	asked.	
Three	registries	had	multiple	funding	sources.
• Staff	were	directly	employed	by	79%	of	the	
registries;	69%	of	those	reported	having	two	or	
less	staff	and	27%	between	three	and	ten	staff.	
The MRCG (2012) report also drew a number of  
conclusions about the operation of existing patient 
registries in Ireland. They also concluded that  
national policy and guidelines for patient registries 
are important to ensure standardisation and best  
practice and that these are urgently needed in Ireland.
• Fit-for-purpose registries that deliver tangible 
positive	improvements	in	healthcare	systems	
have	an	important	and	beneficial	role	in	our	
health services.
• Consent	based	registries	are	best	practice,	
but it is acceptable to waive consent in 
some circumstances to ensure that registry 
objectives	can	be	met;	for	example,	for	
large	population-based	registries	where	
data	collection	is	not	directly	linked	to	care	
provision.
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• Good internal governance and external 
oversight	is	essential	for	registry	success	 
and to building and maintaining public trust  
in the registry.
• Confidentiality,	privacy	and	security	must	 
be	guaranteed	in	accordance	with	legislative	
and	best-practice	requirements.
• The ability to link and share registry data 
with other registries and databases, and with 
other	data	providers	reduces	duplication	and	
maximises	the	potential	utility	of	the	registry.	
However, interoperability and the wider use 
of	data	increases	the	potential	for	misuse	of	
these	data	and	sanctions	will	be	required	both	
as a deterrent and to maintain public trust.
• Transparent and sustainable funding 
mechanisms	will	be	essential	to	the	successful	
and	ethical	operation	of	the	registry.
More	recently,	HIQA	(2016)	have	catalogued	109	
national data collections including administrative 
sources, censuses, national routine surveys and  
national patient registries. They have also developed 
guiding principles for national data collections (HIQA, 
2015) and they plan to translate these principles into 
standards that can be used to evaluate the quality  
of data within national data collections that fall 
within the remit of the HSE. In summary, HIQA’s 
recommendations for the operation of patient  
registries in Ireland (IPPOSI, 2015) are as follows: 
• A strategic framework needs to be developed 
for	the	oversight	of	national	data	collections.
• There is a need for standardising and 
improving	data	quality	in	data	collections.
• Information	use	should	be	optimised	rather	
than	information	being	fragmented	or	siloed.	
• Data	protection	compliance	and	frameworks	
for governance and data quality are needed. 
• Existing	health	information	should	be	
optimised	and	more	readily	available	 
to	patients	and	the	public.	
2.4.3.1 National Cancer Registry of Ireland 
 (NCRI)
The National Cancer Registry of Ireland (NCRI) is the 
largest patient registry in Ireland. It was established 
by	the	Minister	for	Health	in	1991	to	deliver	four	
statutory functions and with a national mandate to 
commence	data	collection	in	January	1994	(National	
Cancer Registry Ireland, 2015):
• To	identify,	collect,	classify,	record,	store	and	
analyse	information	relating	to	the	incidence	
and prevalence of cancer and related tumours 
in Ireland;
• To	collect,	classify,	record	and	store	information	
in	relation	to	each	newly	diagnosed	individual	
cancer	patient	and	in	relation	to	each	tumour	
which occurs;
• To publish an annual report based on the 
activities	of	the	Registry;
• To	furnish	advice,	information	and	assistance	
in	relation	to	any	aspect	of	such	service	to	the	
Minister.
The NCRI currently has 52 full-time and part-time 
staff. NCRI data are collected by trained Tumour  
Registration Officers (TROs) based in hospitals 
around the country, while the majority of the 
remaining staff are based at the Registry’s head-
quarters. Hospital pathology reports are provided 
to	NCRI	for	approximately	85%	of	all	new	cases	
(National Cancer Registry Ireland, 2016a). Most are 
registered manually by the TROs but data are also 
provided in electronic format for approximately 
33%	of	all	reports.	A	wide	range	of	information	is	
collected, including socio-demographic information, 
the type and location of the cancer, how advanced 
the cancer is, treatments received and if applicable 
the date and cause of death from death certificates. 
By December 2014, the NCRI database had  
approximately	500,000	registrations	and	over	38,000	
cancers were being registered annually; an increase 
from	19,000	in	1994	(National	Cancer	Registry	Ireland,	
2015). 
NCRI are exempt from needing patient consent to 
gather these data due to the nature of their statutory 
mandate. However, people do have the right to ‘opt- 
out’ of registering their information (National Cancer  
Registry Ireland, 2016a), although patients rarely 
exercise this right (NCRI, personal communication, 
2
May 2016). NCRI acknowledge their position of trust 
with healthcare professionals and the public alike 
and they observe the highest standards of data  
security, protection and confidentiality (National 
Cancer Registry Ireland, 2016b), including formal 
internal audits of registry functions (National Cancer 
Registry Ireland, 2015), the encryption and password 
protection of registry laptops and encoding of all 
data transmissions to and from the registry (National 
Cancer Registry Ireland, 2016b). NCRI has strict rules 
about who can have access to the data. Identifiable 
information is not released without the individual’s 
written consent with one exception; the person’s 
consultant can request information for the purposes 
of follow-up treatment. Published data are always 
anonymised. NCRI complies with international 
standards and criteria in recording of all major data 
items and has been consistent in its application of 
these since its inception.
NCRI operates under, and is funded by, the Depart-
ment of Health, but it is independent of it. It has a 
board comprising seven members who meet four 
times each year (National Cancer Registry Ireland, 
2016a). Board members come from professional 
backgrounds; National Cancer Control Programme, 
Northern Ireland Cancer Registry, Irish Cancer Society, 
HSE Public Health, Cork Cancer Research Centre, 
Department of Health and the Mater Misericordiae 
University Hospital. The Director of NCRI is  
responsible for the implementation of the Board’s 
policies and oversight of all registry functions.  
Performance indicators are used to evaluate the  
success of the registry in attaining its strategic  
objectives and to compare performance to the four 
other cancer registries of the United Kingdom  
(National Cancer Registry Ireland, 2016a). NCRI  
report that their data quality and case ascertainment 
levels are high; completeness of case ascertainment 
of all invasive cancers (excluding non-melanoma skin 
cancer)	is	estimated	to	be	97%,	although	there	is	
some heterogeneity between cancer sites (National 
Cancer Registry Ireland, 2012). NCRI publish detailed 
annual reports and related research findings on 
their	website.	To	date,	four	research	reports,	180	
scientific papers and 125 presentations demonstrate 
the value of patient registry data to the research 
community. In addition, NCRI data has contributed 
significantly to the recent review of the National 
Cancer Strategy (National Cancer Registry Ireland, 
2015). This review identified the need to make 
NCRI more relevant to service planning and clinical 
practice illustrating the need to continually evaluate 
registry performance to ensure that it continues to 
fulfil its goals. 
2.4.3.2 Cystic Fibrosis Registry of Ireland (CFRI)
The Cystic Fibrosis Registry of Ireland (CFRI) was 
established in 2001 by the Cystic Fibrosis Association 
of Ireland with funding from the Department of 
Health and Children and the HSE to keep the relevant 
medical records of all people with cystic fibrosis 
(CF).	It	became	an	independent	legal	entity	in	2008.	
It is now financed solely by the HSE (Cystic Fibrosis 
Registry of Ireland, 2016d). By the end of 2014 there 
were	1,183	people	registered,	representing	90.7%	
coverage of the known population (Cystic Fibrosis 
Registry of Ireland, 2016a). A very clear set of goals 
in four main areas have been established for the CFRI 
as reproduced with permission in Table 5 overleaf. 
The CFRI data sources include doctors, nurses, physio- 
therapists, dieticians and people with CF themselves 
(Cystic Fibrosis Registry of Ireland, 2016d). Every 
participating hospital that contributes patient data 
to CFRI must obtain ethical approval from their own 
research ethics committee. CFRI Clinical Research 
Associates take information directly from hospital 
medical charts and enter it into the CFRI database. 
It is envisioned that at some point in the future 
regionally-based staff will be trained to enter the 
required data. The CFRI collects a wide range of data 
including socio-demographics, diagnosis details and 
annual assessment details. Informed consent is  
required to collect data from all those registered with 
CFRI and each patient is assigned a unique identifier 
within the registry (Cystic Fibrosis Registry of Ireland, 
2016c). The CFRI database is encrypted and password 
protected on two levels, meaning a user must log on 
to the operating system first and then again onto the 
database. Access to data is restricted to CFRI staff 
and hospital consultants, who only have access to 
the personal data of their own patients. Identifiable 
information is never published in research or annual 
reports. The CFRI has also redesigned their IT infra-
structure in recent years to bring it in line with 
European infrastructure standards and to enable 
comparative studies with other European CF registries 
(CFRI, personal communication, April 2016). 
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Although located in University College Dublin, CFRI  
is administratively separate from the university. 
However, the academic setting provides benefits 
such as access to statistical support, potential funding 
opportunities and post-graduate researchers to carry 
out CFRI’s own scientific research agenda (CFRI,  
personal communication, April 2016). The CFRI is 
structured into four sub-committees and an Executive 
Council of eleven members. Each subcommittee 
nominates a member to the Executive Council and 
others are representatives of the consultants who 
treat CF as well as number of representatives from 
the Patient Association. This structure is designed to 
accommodate the multi-disciplinary teams who treat 
and interact with people with CF (Cystic Fibrosis 
Registry of Ireland, 2016d). The CFRI also currently 
employs three full-time staff, a doctor and research 
nurse. The third member of staff has been funded 
for one-year only by European grant funding (CFRI, 
personal communication, April 2016). Further details 
are available in the CFRI Annual Reports which are 
available on their website (Cystic Fibrosis Registry of 
Ireland, 2016d). CFRI data has contributed to several 
research studies (Farrell et al., 2007; Jackson et al.,  
2011; McKiernan, Molloy, Cryan, McElvaney, & 
Greene, 2014; Somerville, Jackson, Zhou, Fletcher,  
& Fitzpatrick, 2013) and they are currently piloting 
an innovative research project where they will create 
a patient portal to allow patients and their Consultants 
access to real-time information regarding their  
condition. They hypothesise that this could positively 
influence clinical outcomes (CFRI, personal  
communication, April 2016).
TABLE 5 
Main aims and objectives of the Cystic Fibrosis 
Registry of Ireland (2016b)*
1 Registry Process 
•     To	identify,	record,	analyse,	and	store	
information	relating	to	the	prevalence,	
incidence,	and	treatment	of	existing	and	newly	
diagnosed	people	with	Cystic	Fibrosis	(CF)	in	
the Republic of Ireland.
•     To	register	all	Persons	with	Cystic	Fibrosis	
(PWCF) whose usual residence is in the 
Republic of Ireland. 
•     To provide data on long term prognosis for 
CF	Patients	in	the	Republic	of	Ireland	and	to	
compare	this	information	with	international	
data. 
•     To compare CF management and treatment 
within	Ireland	and	with	best	international	
practice	standards.
•     To	ensure	that	all	information	is	complete,	
accurate,	timely	and	confidential;	in	order	to	
effectively	use	the	data	collected.
•     To develop and improve CF registry methodology.
2 Research
•     To promote and facilitate the use of clinical data 
in approved research projects.
•     To initiate research into the causes, distribution, 
treatment and outcome of PWCF, and to 
participate in similar research initiated by 
others; and to publish the findings.
•     To assist in the evaluation of novel treatments 
and screening programmes.
3 Planning and Management
•     To provide a Cystic Fibrosis information service 
for the Dept. of Health & Children, Health 
Boards, hospitals and clinicians.
4 Reporting 
•     To publish an annual report based on the 
activities of the Registry. The Annual Report will 
cover the incidence, prevalence and treatment 
of patients registered, at a sufficient level of 
morbidity and geographical detail to make it 
useful for planning and delivering services to 
PWCF.
•     The Annual Report will also contain financial 
statements regarding expenditure.
•     To furnish information and assistance in relation 
to any aspect of Cystic Fibrosis to the HSE, CF 
Ireland, other service providers, and PWCF.
•     To provide specially requested reports for 
clinicians, the HSE, and hospitals. To provide 
individual consultants with trends and updated 
information in respect of their patient population.
*Reproduced with permission from Source website.  
Copyright 2016 by The Cystic Fibrosis Registry of Ireland.
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2.4.3.3 Idiopathic Pulmonary Fibrosis Registry
(IPFR) 
The Irish Thoracic Society (ITS) recently established 
the Idiopathic Pulmonary Fibrosis Registry (IPFR)  
to capture data related to Idiopathic Pulmonary 
Fibrosis (IPF) and Sarcoidosis; two relatively rare  
interstitial lung diseases (ILD). The IPFR is an example 
of a group of smaller Irish patient registries, many 
of which relate to specific rare diseases and benefit 
from clear diagnostic procedure and treatment 
settings and highly motivated patient populations 
who see huge benefit in providing consent to collect 
their data in an attempt to further the knowledge 
and understanding of their condition (IPFR, personal 
communication, April 2016). ITS developed the IPFR 
to address three main objectives: 
• to	establish	prevalence	and	distribution	 
to	help	influence	policy	and	service	provision;
• to facilitate improved clinical management  
of the disease; 
• to facilitate research and the possible 
development of new therapies. 
Initial funding came from an unrestricted grant from 
a pharmaceutical company, although additional 
funding will be needed to sustain the registry  
following the initial set-up period. A separate grant 
from another pharmaceutical company funds a 
specialist nurse who visits each centre to collect and 
input data and to provide some additional support 
to the clinics. This specialist nurse is seen as a vital 
asset as it had been difficult to get ‘buy-in’ from 
clinicians initially due to concerns about available time 
and resources in the clinics to support registry data 
entry. The IPFR is governed by a board comprising 
of a CEO, an external expert who has a pharma 
background and good technology expertise and two 
consultants.
The IPFR chose to consult closely with the already 
well-established CFRI and they engaged the services 
of a well-respected software company with expertise 
in setting up patient registries (including the CFRI) 
which enabled them to co-locate their registry data 
on the CFRI server and benefit from the data security 
protocols already in place in the CFRI (IPFR, personal 
communication, April 2016). The IPFR expect to  
register 100 individuals with ILD within the first year. 
Initially, information will be collected from six 
specialist respiratory clinics in Ireland (Cork, Galway, 
Limerick, Mater, St. Vincent’s and Tallaght), rather  
than in every hospital in Ireland. Each specialist clinic 
has obtained ethical approval from their respective 
research ethics committees and collection of data 
has begun in four of the six clinics (IPFR, personal 
communication, April 2016). The clinics have pass-
word protected web based access to the IPFR data-
base. The data collected includes demographic  
information, how diagnosis was made and treatments 
with the aim of supporting the clinical management 
of registry patients. 
IPFR are using an ‘opt in’ process for consent. Each 
person is provided with information regarding the 
registry and what their information will be used for 
but they have right to decline registration (IPFR,  
personal communication, April 2016). Due to potential 
benefits of establishing prevalence of ILD and the 
strong relationship that IPFR has built with the Irish 
Lung Fibrosis Association, there has been great  
support from people with ILD and to date everybody 
has given consent for their data to be stored. The 
data at each centre will be identifiable to assist with 
clinical care management, but data held centrally by 
the registry will be pseudo-anonymised. The board 
is developing data access guidelines and they expect 
to have restrictions on the type of data that can be 
made available to interested parties outside the 
registry. Care is also being taken to ensure that only 
anonymised data will be made available to companies 
who provided registry funding. 
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SUMMARY
The review of the literature demonstrates that patient registry data are essential for  
informing public health policy, improving patient care, supporting health research and  
facilitating health technology assessment. 
Best practice guidelines have emerged in recent years that provide direction regarding  
registry purpose, data selection, collection and management, registry governance and  
registry quality.
Several international dementia registries are currently operational, but no one ideal model 
has as yet been established.  
•  The	Swedish	Dementia	Registry	(SveDem)	is	the	‘gold	standard’	and	most	
comprehensive	dementia	registry.	
•  The	Registry	of	Dementia	in	Girona	offers	a	simpler	model	that	could	be	used	as	a	
starting	point.	It	offers	the	potential	to	expand	the	scope	of	the	registry	over	time.
The successful operation of a patient registry is influenced by the environment in which  
it operates. Unfortunately, there is a lack of strategic direction in Ireland with regard to  
patient registries. However, patient registries should be cognisant of national legislation  
and international directives relevant to patient registries. In addition, patient registries 
should be aware of the implications of recent and proposed legislation such as: 
•  The	recent	European	Data	Protection	Reform	2016;
•  The Assisted Decision Making (Capacity) Act 2015;
•  The	long-awaited	Health	Information	and	Patient	Safety	Bill.
Although existing Irish patient registries vary considerably with regard to size, function,  
disease, funding, cost and governance, they demonstrate that a lot can be achieved within 
the current limitations of the Irish health system.
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This section presents the findings of the thematic 
analysis of the expert interviews and focus groups. 
This analysis revealed six themes: 
• Registry function
• Registry data
• Data collection
• Data management
• Registry governance
• Legislation. 
Three high level cross-cutting themes were also 
identified: (1) Benefits and risks, (2) Barriers and 
facilitators and (3) Dementia-specific challenges.   
Figure 2 presents a graphical representation of these 
themes.
Anonymised direct quotations provide context and 
serve as anchor examples for the themes and  
sub-themes identified. The type of expertise in each 
case is included. Categories of expertise and their 
associated codes are presented in Table 6. 
TABLE 6 
Categories of expertise with associated codes.
Clinical Expert    CE
Health	Informatics	Expert	 	 HI
Irish	Dementia	Working	Group	 	 IDWG
Legal Expert    LE
Policy Expert    PE
Registry Expert    RE
Research Expert   Res
Each of the six themes is presented below, with 
related sub-themes.
Barriers and Facilitators
Registry
Data
Demena-specific Challenges
Be
ne
fit
s a
nd
 R
isk
s
Registry
Funcon
Legislaon
Registry
Governance
Data
Management
Data
Collecon
FIGURE 2  General and cross-cutting themes identified in the analysis of expert opinion  
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3.1 Theme 1: 
 Registry function
 
“Patient	registries	are	very	valuable	 
repositories	of	clinical	information	 
that	can	be	used	first	and	foremost	 
to	support	patients	and	improve	patient	
care.	The	information	can	also	be	used	
for research purposes and to drive  
policy decisions. So, yes, they are  
extremely worthwhile.” [HI]
3.1.1 Provide Information
The majority of experts agree that dementia registries 
provide very useful information. The fact that the 
number of cases of dementia in Ireland is estimated 
and that we currently rely on data extrapolated from 
other jurisdictions is problematic for policy-makers 
and service providers as they cannot adequately plan 
for the specific needs of Irish people with dementia 
and those of their families and carers. The general 
view was that information from a national dementia 
registry in Ireland would be more accurate and more 
comprehensive. It would enhance knowledge,  
understanding and awareness of dementia and better 
inform public health policy as well as equitable  
distribution of health and social care resources to 
support dementia care. Better diagnostic tracking 
would assist clinicians in implementing a mutually  
agreed and standardised diagnostic process. Clinicians 
would also benefit from information regarding 
dementia treatments and supports so they could 
monitor the quality of care being provided.
 “The most important aspect of a registry is that  
it will provide a solid evidence-base on the  
population level burden of dementia. So we don’t 
have that in Ireland and we are very far from it.  
I think it’s one of the reasons that dementia isn’t 
attracting the type of funding that it really needs  
to in order to actually focus on the prevention 
aspect, but more importantly maybe, in the  
situation that we are in, is the diagnosis and care  
of dementia, it’s seriously under resourced and  
we do have a sense that there is this impending 
burden of dementia but we don’t have any  
quantification of that burden.” [PE]
People with dementia also generally agreed that 
more information would be helpful for a number  
of reasons including knowledge production and 
public awareness.
“The more information there is the more  
learning and more understanding, and I think  
also the more presence of awareness,  
acceptance.” [IDWG] 
That said, one expert questioned the need for a 
registry at all and felt that having really good age 
specific prevalence data on dementia would allow 
us to predict the likely numbers in certain areas. 
Other experts felt that this was a circular argument 
and questioned where this ‘really good’ data, taking 
into account local and national factors, would come 
from. A public health expert argued that examining 
dementia as an isolated condition was inappropriate, 
given high co-morbidity levels. 
“And I think the one thing to remember is that 
dementia is not a clinical problem per se, it has 
clinical manifestations but it is a population level 
burden and problem, and it’s a public health issue 
and concern, and I think it has to be pitched at  
that level because I think the emphasis on the  
clinical burden of patients, it almost makes them 
into this sole population in and of themselves of 
older people with very kind of distinct care needs, 
and yes they are, but they are also part of an  
overall population in Ireland.” [PE]
Number of cases of dementia 
A better understanding of the prevalence of dementia 
was seen as a critical objective for a dementia 
registry and information that would be beneficial to 
clinicians, policy-makers, researchers and to people 
with dementia. 
 “Then we know that there are quite a high  
proportion of people that never get a diagnosis 
of dementia or else a diagnosis very late in the 
disease... it would be very useful for providing 
information on that diagnostic gap”. [PE] 
“I mean, as a researcher, God, it would be gold. It 
would be just great to have a dementia register… 
my early public health background was very 
much trying to establish a need for services in a 
population and you do need to have some idea 
of the numbers we are dealing with. So it’s really 
valuable as a health-planning tool and also I think 
for proactive case management.” [PE] 
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People with dementia expressed concern that the 
number of cases of dementia around the country  
is not yet being adequately identified.
 “I hear of so many people who would say,  
‘But my parent isn’t sick.’ So there’s a group of 
people out there that actually aren’t even being  
recognised as having dementia. So when we talk 
of	48,000,	that’s	a	rubbish	number	really.”	[IDWG]	
Diagnosis
The majority of experts agree that there are difficulties 
diagnosing dementia and there is a lack of consensus 
on how best to do this among clinicians. A national 
dementia registry could address some of these  
diagnostic issues by providing information with 
which to improve diagnostic accuracy and by  
establishing standardised assessment and coding 
procedures. 
“I think part of the value of the registry also 
would be to actually try to improve the accuracy 
of the diagnosis… develop algorithms to try and 
understand pathways and also to develop services. 
So yes, it’s a challenge and it’s a problem but I 
think it’s also an opportunity.” [CE] 
“The data from it would be really good for looking 
at differences between different GP practices or 
different memory clinics or different areas within 
the country and saying, well look, they seem to 
be doing really well in terms of diagnosis, but we 
might need to do a lot more education around  
case finding or recognition and assessment of  
dementia or around diagnosis itself.” [PE] 
Day-to-Day living of people with dementia
In addition to difficulties diagnosing dementia, 
experts also recognise the complexity of the disease 
itself. Information on the day-to-day lives of those 
with dementia would enhance their knowledge and 
understanding and lead to better clinical care. 
“No one case of dementia is the same as the 
next... the social aspect of management on a day-
to-day level for people would be a very powerful 
set of data to collect… it may take a long time to 
actually get to a point where we can actually see 
some clear idea of what works for who and what 
circumstances”. [HI]
“Information about persons with dementia, can 
[help us] understand how the patient lives,  
whether it’s alone or with families and [provide] 
information of cost of dementia treatments”. [RE] 
Prevention 
Some experts also suggested that we do not have 
enough information about prevention of dementia 
in an Irish context. This could be a potential objective 
for a national dementia registry.
“So we were very reliant on international data on 
dementia prevention… we don’t have sufficient 
data in an Irish context. So I would certainly be  
an advocate for developing a data resource.” [PE]
3.1.2 Enhance Policy 
Most experts agreed that the integrated and  
co-ordinated nature of a national dementia registry 
would help inform dementia health and social policy 
and that it would provide an evidence-base to assist 
policy-makers in obtaining funding and in planning 
as well as providing dementia services. 
“If we are then looking at the aim of the strategy, 
[it] is to enable people with dementia to live well 
at home, but we need to have the information  
to be able to plan appropriately.” [PE]
 
“I think there’s a huge piece around population 
health and knowing who, where, when and why  
so that we can actually do planning for the future 
by looking at data. What we’re not great at, at  
the moment in health in Ireland is turning data  
into information and I think registries actually  
give us one of the keys to... something that can 
actually facilitate changes to be made to health 
care.” [HI]
However, there was also a general feeling that the 
cost of creating and maintaining a dementia registry 
might be prohibitive and that funds could be better 
used in paying for care services. 
“There is an impending burden... that’s a negative 
way to put it but I do think in terms of the health 
services itself that they [health service leaders]  
are struggling to know how to cope with it and  
I think they would very much welcome… an  
informed approach as to how to actually deal  
with dementia. I also think there is an awareness 
that we don’t have sufficient data to actually plan 
for service provision for dementia patients. So I 
do think there is an awareness there that some- 
thing needs to be done. I think the gap is in  
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finding something accessible and affordable that 
can actually be done to try and address it”. [PE]
An expert from an Irish patient registry argued that 
the analysis of registry data can identify ways in 
which to remove cost from within the health system 
and thus provide obvious economic benefits.
“Tests were being duplicated on a centre-by-
centre basis because there was no sharing of 
records… that’s adding extra cost into the whole 
healthcare system… Registries are often seen just 
as a research tool and we are trying to make it 
much more… we want it to be a situation that it  
is of use to the medical staff.” [RE]
Policy makers and people with dementia alike felt that 
the data from a dementia registry would enhance 
their ability to advocate for better dementia care.
“It’s going to give us… a little bit of power in  
pushing for services and pushing for policy  
changes. So I think it might help us as opposed  
to hinder us.” [IDWG]
“We can then use that information to lobby the 
Department of Health and kind of highlight the 
need for development of a registry. But the more 
information we have, the more evidence we have 
that having such a registry would benefit in the 
long-term, the benefits, I think that would be 
good.” [PE]
3.1.3 Improve Care
All experts agreed that having a national dementia 
registry would provide enormous potential to improve 
the quality of clinical care. This was seen as another 
core objective of any patient registry. One expert from 
a well-established Irish patient registry went so far as 
to argue that the ability of patient registries in Ireland 
is best-suited towards quality improvement. Although 
their experience suggests that this has not been an easy 
sell in Ireland (Personal communication, April 2016).
“We’ve found over the years that being a relatively 
small country and a relatively short-term registry 
that you don’t get a huge amount of epidemio-
logical value out of a registry like that because 
most of the questions could be answered by  
people from bigger countries with registries that 
have been around for much longer, so a lot of 
it then comes down to health services research 
which is to look at what the disease burden is, 
what sort of services that people avail of are, are 
there changes in disease burden over time, are 
there changes in the quality of outcomes, quality 
of life, that sort of thing?” [RE]
“It’s the way that the Swedish system uses it, as 
well as having the kind of clinical data, they also 
have quality indicators for the system, so they are 
able to track changes over time and the kind of 
service provision and clinical care and [look] at 
differences between different areas in the country 
and differences between memory clinics and GP 
practice, so they are able to look at the quality  
of the care.” [PE]
Formal dementia care 
It was generally acknowledged that public health 
services may be unable to adequately provide  
comprehensive services and supports for people 
with dementia. In order to improve the overall 
quality of clinical care while successfully managing 
the cost of providing this care, more information is 
needed about the types of treatments and supports 
that work best in different scenarios. 
“I do think it’s basically down to… seeing how you 
can impact the quality of service looking at the 
sort of treatments that people have, the sort of 
supports that they get, what their quality of life 
is, trying to investigate what factors affect that 
quality of life, what can be done to improve it  
and so on.” [RE] 
“If you were to look at someone … at the time of 
diagnosis and then you look at them two years 
on or four years on or six years on and then you 
look at … what measures have been taken to 
support this person... if you looked at their social 
care supports, their family support, their quality 
of life… if you could somehow establish quality 
indicators around inclusion in the community 
you could maybe establish whether particular 
interventions or a level of intervention was going 
to maybe delay the worsening of dementia and 
reduce possibly the reliance on the hospital  
services or entry into nursing homes because  
I guess we’ve got to find cheaper ways of helping 
people with these needs… [it] would be really  
important for us to be able to compare our de-
mentia data with those other countries and that 
in itself would be an impetus to improved ser-
vices if we were found to be sorely lacking.” [PE] 
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Informal caregiving
Policy experts openly acknowledged that adequate 
services may be unavailable for people with dementia 
and that it will become increasingly important that 
families and carers have sufficient support in place. 
Again, an understanding of the burden of care on 
family carers is essential to providing the requisite 
support.
“I think there’s so little known about the issues  
and the problems that people face in their  
homes… If you have a partner who has dementia 
and you know that partner, then to some extent 
you can see why somebody would want to  
continue to keep that person at home indefinitely. 
However, if it’s a child and the father and the 
mother then that person has a different family 
potentially of their own and trying to manage 
that in the home is really, really tough.” [HI] 
3.1.4 Support Research 
The majority of experts agree that a national  
dementia registry could facilitate research into  
dementia within an Irish context. Experts associated 
with existing registries confirmed that having a  
registry has led to increased research involvement. 
Assuming that the national dementia registry included 
consent to be contacted regarding research studies, 
it would have the additional benefit of easily enabling 
people with dementia and/or their family caregivers 
to participate in research if they wished. The people 
with dementia in this study certainly wished to be 
involved in research. Other advantages could accrue 
such as attracting clinical trials to Ireland and the 
potential access to new treatments for people with 
dementia and comparative data to other jurisdictions. 
“I have a strong leaning towards using it for the 
clinical research piece to be able to do and under-
stand who has got what illnesses and potentially 
through consent allowing us to have a cohort of 
people that we can actually contact to take part  
in clinical research”. [HI]
“We are seeking to improve services but we also 
have it as a research database because it allows  
us to understand the disease and we’ve  
contributed quite substantially to the literature, 
by virtue of being able to have a population-
based register with full ascertainment.” [RE]
 “We don’t know what’s actually going to happen 
in the future as a group, and how you’re going  
to be in the years to come. So I suppose I’m very  
keen on looking at alternatives to what the  
consultants are looking at, and I’d be very much 
up to engaging with any tests that need to be 
done. That’s one of the things obviously. If you’ve 
got an illness you want to try and treat it. So I’d 
like to be involved in that, when it comes to it.”  
[IDWG] 
“We see the potential of information collected for 
research purposes… around comparative analysis, 
looking at what’s happening in other countries.  
I think that’s important as well.” [HI]   
An international dementia registry expert outlined 
some of the research studies that they have been 
involved in to date. This description is very similar to 
the expectations of how dementia research could be 
supported in the words of an Irish dementia policy 
expert. 
“We have had various research studies. We  
partnered with a drug company and they were  
interested in looking at behavioural disturbances 
and nursing home placement. We used a sample  
of our registry… We have worked on different  
grant projects with hospitals in the area. And  
you know there is always new ideas and different 
things going on with research.” [RE] 
“I think it would be useful for delving down into 
specific issues, so if you were interested in  
medication prescriptions you can see, well, this  
is the percentage of people who are prescribed 
antipsychotics and do we need to do something 
about that? So you don’t have to set up a whole 
new piece of research just to find out the  
proportion of people who have been prescribed 
antipsychotics, you know from the real live data  
coming in from people.” [PE]
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3.2 Theme 2: 
 Registry data
3.2.1 Inclusion criteria and diagnosing 
 dementia
The discussion regarding whose data should be held 
on a national dementia registry was straight-forward. 
All experts agreed that the key inclusion criterion 
was having a formal diagnosis of dementia. The more 
interesting discussion centred on the diagnosis and 
coding of dementia and the added complexity of 
a dementia registry in comparison to a rare disease 
registry, for example.
Inclusion criteria
Most experts and people with dementia agreed that 
a formal diagnosis of dementia would be essential 
for inclusion on a dementia registry. In fact experts 
in the UK stressed that the entry point to the register 
must be a formal diagnosis of dementia, regardless 
of where that diagnosis comes from as the registry 
would be unmanageable otherwise. That said many 
worried that getting an accurate diagnosis is difficult 
given the complexity of diagnosing the condition 
and the hesitancy among GPs in particular at giving 
a definite diagnosis.
“It’s the accuracy of that [diagnosis] that’s key 
here. You could have somebody being labelled 
as having dementia when they may have MCI, or 
not getting into the registry because they’ve been 
diagnosed with MCI and they have in fact got 
dementia… I think if the diagnosis has been made 
in a memory clinic or other clinic… that’s probably 
okay. In my experience, very few GPs are making 
the diagnosis of dementia in their surgeries, they’ll 
put down cognitive impairment but they won’t 
necessarily put down dementia unless it’s been  
labelled so in the hospital by a specialist.” [CE]
There was evident need to have definite coding terms 
as expressed clearly by this policy expert. Yet, a person 
with dementia also clearly points out the inherent 
complexity of this with regard to dementia given the 
existing social stigma associated with the condition.
“The entry point should be a diagnosis of dementia 
or it becomes a register [of people with query  
dementia] which probably wouldn’t be much 
use so I think you need to define when the clock 
starts ticking and that’s when someone gets a 
diagnosis” [PE]
“So I know of and I’ve heard of and I’ve spoken to 
GPs who have said, ‘For older people, the family 
don’t want to call it ‘dementia’,’ so it’s not been 
entered. So that’s an area where we’re going to 
get not true and factual figures if that’s happening” 
[IDWG]. 
There was also a very clear direction that all forms 
of dementia should be included in the registry and 
that they should be sub-typed as accurately as  
possible. Similarly, there was an assumption that 
all sub-populations would be included. An expert 
regarding dementia and intellectual disability high-
lighted the specific difficulties with diagnosis in this 
population. 
“There may be other sub-groups in the other 
dementias. It could be quite a tree of categories.” 
[IDWG] 
“And the other big thing is the sub types. I mean,  
if you have a dementia register it might not tell  
you what the sub types diagnosis is and if you  
want to use that register for most instances you  
do want to know what kind of dementia they  
have. It’s still a huge problem” [Res]
 “There are very few specialist memory clinics for 
people with intellectual disabilities. The generic 
memory system and memory clinic system is  
literally at a loss and at odds and many people are 
either…there’s huge diagnostic overshadowing and 
under-shadowing. But there’s a massive lack of 
skill in relation to diagnosing this population.” [PE]
Dementia diagnosis
A significant concern was therefore the difficulty  
diagnosing dementia and the possibility of getting 
the diagnosis wrong. Many experts stressed that 
a dementia diagnosis is much more difficult than 
other diseases (e.g. cancer and cystic fibrosis) and 
accurately sub-typing dementia is even harder. 
There was an acknowledgement that many of these 
issues have been successfully dealt with by existing 
international dementia registries (the Swedish registry 
was the most often cited example) and that we must 
not reinvent the wheel in Ireland but learn from 
what has been done elsewhere. 
“My main concern would be how do you define 
dementia and how do you discover the people  
who are suffering from it? … You come across  
GPs who underdiagnose, you come across over- 
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diagnosis. And all of these so-called diagnostic 
tests have got quite a large margin of error. Again, 
it depends on what you call dementia... I think 
if you were to talk to GPs you’d find that there 
would be a wide divergence of opinion. The 
younger GPs tend to be more scientific and more 
numerate and to be more gone on things like the 
mini mental test score and so on. I think the older 
GPs are inclined to feel, well, there’s no point in 
going looking for trouble; trouble will find you in 
its own good time.” [RE]
People with dementia also expressed a concern 
about the accuracy of the diagnostic process and 
a lack of consistency among GPs and they felt that 
this could potentially lead to invalid data within the 
registry. Yet, if diagnostic processes are tracked and 
evaluated, this is one of the areas where a registry 
can be very beneficial as it allows clinicians to evaluate 
and improve diagnostic accuracy. Registry experts in 
Sweden and in the UK acknowledged that much of 
their day-to-day work revolves around addressing the 
issues with diagnosing and coding for dementia and 
collecting dementia-relevant data in primary care.
“It’s a cluster of symptoms that delivers a  
diagnosis. So obviously that’s not specific. It’s  
not precise. It’s a question of a valued judgment. 
One GP might say, ‘That’s the cluster,’ and  
another would say, ‘That’s not the cluster.’ So 
how tight is that focus?” [IDWG]
“So I would have to say I’ve heard some very 
strange tales of people who’ve been diagnosed. 
I’ve actually heard of a woman within four miles  
of me who was diagnosed and now they’re telling 
her she doesn’t have it.” [IDWG]
 “From what I understand from [GP], that doctors 
in Ireland, and I think that’s probably the case in 
other countries, aren’t always very good at coding 
for dementia, it’s not an easy thing to code for”.  
[PE]
There was a suggestion that the roll-out of the Single 
Assessment Tool (SAT) would be important in this 
context. It is a strategic priority for the HSE and it 
also results in an electronic record being established 
for everyone who is assessed. Although it will take  
some time to roll-out nationally (one expert suggested 
5+ years), it provides an opportunity to support  
improved diagnosis and recording. It also provides  
a data source in its own right and one that could 
easily be linked with and provide data to a national 
dementia registry. Experts advised against introducing 
new data collection systems for a dementia registry 
that would essentially duplicate information that will 
be available from another source. Although short-
comings of the system with regard to obtaining a 
specific dementia diagnosis were acknowledged.
“So while we probably still have the barrier of 
getting that definitive diagnosis, if you like, in 
the sense that this would be a way of diagnosing 
people with dementia but it would certainly flag 
those with diminished cognitive functioning. And 
while it wouldn’t be a standalone dementia  
register, it would probably be much more valuable 
in the sense that you’d have a really comprehensive 
picture of older people and where that cognitive 
ability sits among other issues that they might 
have.” [PE]
Coding systems
For a registry to be effective, there is also a need to 
identify proper coding systems and for these to be 
put in place across primary and secondary care so 
that there is consistent coding of dementia (and its 
subtypes). Coding systems should be carefully chosen 
and ideally the codes should also be consistent with 
(or be able to be mapped to) those in other countries 
so that comparative analysis can take place. Again 
experts mentioned that a lot of work has taken place 
in this area and that Ireland should learn from what 
has already been carried out.
“Well they’ve kind of grappled with that issue a 
little bit in the UK… one of the things they do is 
they have different kind of coding, so it might  
be if there’s still uncertainty around the diagnosis 
you’d have a particular code which might be 
query dementia, something like that… but when 
there’s a probable diagnosis and it’s very clear 
that this is Alzheimer’s disease or mixed dementia, 
whatever… depending on the code that’s picked 
up in different ways for reporting. So there are 
ways around it.“ [PE]
The roll-out of the National Dementia Strategy for 
Ireland includes the objective to improve the coding 
of dementia in primary care using ICD-10 and ICPC 
codes. A tool is currently being developed to help 
‘clean’ the codes that currently exist on patient 
records. A similar tool exists for atrial fibrillation but 
this will be the first of its kind within the gerontology 
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field (Clinician, personal communication, March 
2016). Improved coding in primary care will facilitate 
the development of more accurate practice records 
that can in turn feed into a national dementia registry, 
but given the current difficulties in this area and the 
fact that there are no current links between GP  
systems and any patient registries in Ireland (including 
the NCRI) it may be better to take data directly from 
patients until these changes are operational.
3.2.2 Required data elements
All experts agreed that the amount and type of data 
to be collected should be driven by the primary  
purpose of the registry and the primary consumers 
of registry data. Healthcare professionals may benefit 
from information regarding treatment protocols, 
care management and certain medications. This 
information could also be of use to people with  
dementia and their families, along with data regard-
ing diet and nutrition. So, the primary purpose of 
the registry needs to be established up front and 
this will dictate the minimum registry dataset; that 
is the collection of mandatory data items without 
which the registry cannot function effectively. 
 “You would need to set-up exactly what you 
think you want to look at first, and then you’d 
need to set-up what your core elements are that 
you want to include within the dataset, and then 
you need to set-up your structures by which 
you’re going to ascertain those. You have to be 
very careful with what you agree to put in the 
register and what you agree not to put in… So you 
have to decide what your criteria are, and if you 
don’t, if you’re woolly about your criteria, you’ll 
have a woolly register” [RE]
One health informatics expert warned against trying 
to be all things to all people.
 “I don’t see that the registry data or all of the 
elements that you’d collect in a registry would be 
the same as what you’d be collecting in a personal 
health record, so again it comes back to who are 
we collecting the registry for? If the registry is  
being established for patients, for families and  
carers who have dementia that would be a very  
different looking registry to one that’s being  
collected in line with the current registries that  
are being used today.” [HI]
Once the minimum dataset has been established, the 
broader range of registry goals, the availability of 
data sources and practical concerns such as funding, 
storage and time should drive the maximum dataset 
that will be collected. While it is possible that some 
of this secondary data will be mandatory, it is often 
the case that these data items are optional. In some 
registries these are considered to be added-value 
data and providers can decide themselves if they 
would like to provide this information. Typically, 
the benefit to the provider is that it enables them 
to review clinical care for their own patients over 
time and performance against pre-defined registry 
standards, the average provider and others in their 
local area or district.
Some experts argued for the inclusion of data items 
from outside formal health and social care services. 
For example, capturing all of those voluntary and  
informal sources of support for people with dementia 
and their families in order to fully understand and 
evaluate their contribution. While it is certainly 
possible to gather and store this type of data, care is 
needed to ensure that data sources are valid, that it 
contributes to the goals of the registry and provides 
benefits that outweigh the additional cost of data 
collection.
“There is very little collected at the moment 
about the role of the voluntary agencies in the 
services, so I think again that’s another piece that 
needs to be collected in a registry… These people 
play a huge part, and maintaining people at their  
existing outcomes is very important… There’s the 
other part which is more maybe downstream going 
back to the family, the carer, the role of the carer 
and certainly sort of non-medical interventions 
that may be found useful as well for people with 
dementia and I think they should be looked at 
as well in a registry if it’s going to be in line with 
the new models of the care from the eHealth 
perspective.” [HI]
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3.2.3 Patient consent
Some policy experts strongly argued that to be  
effective, a patient registry needs to have mandatory 
data collection and the NCRI was cited as an example 
of an Irish patient registry with a national mandate. 
Many experts were concerned that requiring opt-in 
or opt-out consent would seriously reduce the  
effectiveness of the registry and this is explored as a 
separate sub-theme below. There was also a general 
sense that new legislation could make it easier to 
collect registry data without needing consent and 
that we are at an opportune moment to influence 
the government and the Department of Health in 
this regard.
“The fact that there is [a law] gives a totally  
different legitimacy to the registry than if [the  
registry] did not have this law.” [RE]
 
“I think the usefulness of a registry would be  
seriously reduced if it was an opt-in or opt-out  
system. I don’t think you can have a valid system 
that produces robust data unless it has a  
mandate.” [PE]
Experts also felt that issues around consent can be 
blown out of proportion and that we need to be 
careful not to make more of it than is needed.  
Consent processes should fit with legislation but 
they should also be pragmatic and not too restrictive. 
“It’s easy to overplay it… you could probably sit 
three years considering and getting legal advice 
from anyone about it … if I was starting afresh… 
something relatively light touch and putting  
sensible things in there and if patients and carers 
agree to have their information on a register then 
that takes away all the bureaucratic nonsense 
that’s out there.” [PE]
Tiered consent
The general consensus was that people should be 
asked for their consent before having their data 
included in a patient registry. Most experts felt that 
people will consent as long as they know what the 
registry is all about and how the data will be used. 
Opinions were more divided among people with  
dementia. Some felt that the need for comprehensive 
and accurate data far outweighed any risk involved 
in gathering this type of data and that participation 
should be mandatory, while some had no issue with  
mandatory provision of anonymised ‘statistical’ data 
but would like consent to be required for other types 
of data. A few people were nervous about the 
implications of being on a dementia registry and 
wanted optional consent processes to be put in 
place for all types of data. 
“I think the state has a right to say, ‘We need  
to know. We’re not saying we’re giving this  
information out... but we need to know how 
many people.’ So I certainly wouldn’t have a 
difficulty with that. I don’t know if anybody else 
would.” [IDWG]
 “I mean the information in itself, we could have 
no complaint, I imagine, in my statistic as a male 
at a certain age having an onset diagnosis at a 
given time. That is of no consequence to me that 
anybody can have that information because they 
don’t know it’s me. So as long as it’s anonymised 
that’s the key thing. I do think the individual  
attribution of, ‘This set of statistics relates to this 
person … lives in … There’s his phone number. 
There’s his email.’ That’s a completely different 
situation. Anonymised data, to my mind, I can’t 
see any reason to object or be anxious.” [IDWG]
“I think anonymising the information is one 
phase. If there’s any move outside of that phase, 
for any reason, then I think the individual needs 
to be in charge.” [IDWG] 
“There are some real difficulties that somebody 
might say it’s an infringement on our rights. The 
thing about it is I think you can sign-in or you can 
sign out, and you don’t have to. Nobody has to do 
it.” [IDWG]
This supports the idea of having a tiered consent 
policy (i.e. consent flags for different elements of 
data collection and/or data use). A number of the 
experts advocated for this approach as different types 
of registry data will fulfil different registry functions. 
Both 2-tier (anonymised, non-anonymised) and 3-tier 
consent models (anonymised, identifiable for health 
purposes and clinical care, identifiable for research) 
were suggested. Irish health informatics experts 
highlighted the fact that the Individual Health  
Identifiers (IHI) already have a two-tier consent flag 
built in; one for clinical care and one for research.
 “It shouldn’t be a register that says ‘you can  
access my information or you can start using me 
in research’. It should be more about… ‘I am happy 
to be contacted to have a conversation about  
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being a part of research’. So that we take away 
some of that ‘consent for consent sake’ which 
has tied a lot of countries up in knots as they try 
to work out how do I now use this information to 
contact the person.” [HI]
“I think most people who would agree to this 
are doing it because they understand that this is 
really important in terms of service development, 
quality of care and also potentially for research. 
So as long as it’s managed, operated and over-
seen correctly with respect to data protection 
and confidentiality, I think there shouldn’t be 
any great risks. If you go to step 2 in terms of 
contacting them to see if they will participate 
in a research study, they still would have to give 
informed consent for any additional involvement 
in a research study or clinical trial.” [CE] 
Some experts suggested creating an online web 
page that would allow the person with dementia 
to change their levels of consent at different times. 
This proposal would need further investigation, 
however, as it would need to be able to manage 
situations where data had already been released 
under the previous consent options. 
“If it was developed it would be some kind of 
online system, so you could have consent to be 
on the dementia register for clinical purposes,  
for the national registry and then for the research 
things. So you can opt in and out of different  
aspects of it... You’d have to consent for each  
level. I think it would be also important that 
people can ask for them to be taken off that  
registry at any time.” [RE]
Opt-in or Opt-out consent?
The consensus in one of the focus groups with 
people with dementia was very much that people 
should have the option to opt-out of non-anonymised 
information but that basic statistical information 
should still be gathered even if consent is refused. 
This supports the Model of Consent in England 
where the patient can go to the GP and say that they 
don’t want any personal data leaving the practice. 
This only applies to identifiable data and patients 
can’t object where data has been anonymised.  
Only	5%	of	people	currently	opt-out	(UK	Health	
Informatics Expert, personal communication, May 
2016). One person with dementia and one policy 
expert were also concerned that seeking any form  
of consent would deter people from seeking a  
diagnosis.
“If you get a piece of paper that’s signed, that 
says, ‘I’m not happy to do that,’ you still have a 
number. So if you have 50 of these forms saying, 
‘I don’t want to be involved with it,’ you know 
there are another 50 people, by default, who have 
actually got dementia of some kind.” [IDWG] 
“I suppose, on balance, I would think the opt-out 
route is probably the most open and practical 
approach. That’s what I would feel, but it is a 
judgment call really. I think the nation would  
have a right to insist, if it felt it was necessary,  
to properly guide policy.” [IDWG] 
“So I think that’s a challenge in and of itself in 
terms of the actual consent from patients them-
selves and their willingness to actually report it. 
So you don’t want a registry to act as a deterrent 
for people to get a diagnosis.” [PE] 
Written consent is also preferred, although telephone 
consent has been used in some circumstances in  
Ireland, with specific agreement from the data  
protection commissioner. Some international  
registries also consider online consent (via a patient 
portal) to be equivalent to written consent.
Capacity to provide consent
Some experts were very worried about the  
competence and capacity of those with dementia 
to be able to provide consent. Yet, many others felt 
that this has already been dealt with in the research 
arena and that people with dementia shouldn’t be 
further stigmatised by assuming that they would  
be unable to provide informed consent. It was 
acknowledged that those making the request would 
need to be skilled in communicating with people with 
dementia so that they can present the information 
about the registry in a way that is easily understood.
“I think in a situation where the person doesn’t 
have the capacity to consent but does not object 
to participating in research, we should allow next 
of kin to be able to consent or give permission on 
their behalf. This is what we do in clinical research 
all the time.” [CE]
 “Unless somebody is extremely impaired it’s  
often the case that they are competent to consent 
to their inclusion of very basic data onto a register. 
So I think there are theoretical concerns but in  
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reality I think that those ethical concerns are more 
theoretical than reality.” [RE]
“People with dementia are no different to anyone 
else, they have the same rights as everybody else 
and that is that if any information on them is to be 
kept or retained or put on a register, they have to 
give full and free consent for that. So the question 
is how do you get consent for somebody who has 
dementia to go on a register? I think for anyone 
you’d have to explain what the register is for, what 
the information is going to be used for, who is 
going to have access to it, is it going to be public, 
all of that, and that applies equally to people with 
dementia. The difference is going to be that you 
may need to explain it in a different way because 
the person with dementia may need things 
explained more in terms of storytelling or using 
analogies in a different way and more simply  
explained than other people. So you need that 
skill, first of all.” [LE]
“I feel we are in danger of stigmatising dementia 
yet again by simply saying nobody has capacity… 
in the UK there’s a presumption people have  
capacity unless it’s sort of proven otherwise, and 
I think that’s a good way of dealing with it... 
because the kind of benefits of doing this really 
outweigh any potential problems that, there 
might be occasional cases where someone, their 
information goes up and they haven’t really given 
the… they don’t really have capacity to make that 
decision.” [Res]
Experts also felt that it was difficult to understand, 
as yet, exactly how the new Assisted Decision Making 
(Capacity) Act (2015) would influence informed  
consent. The consensus was that although the  
legislation has been well articulated, the decision 
support office has yet to be set up and it will take 
time to see how this Act translates into practice.
 “In the new decision making capacity legislation, 
when it comes into force, will have a range of 
decision support mechanisms and it is possible 
that the person with dementia may have signed 
an advanced healthcare directive, for example, in 
which they say ‘I give consent in advance for my 
name to be put on a register and used for research 
purposes,’ or whatever. So, that may get them onto 
the register or they have appointed somebody 
who is a designated healthcare representative 
to make all healthcare decisions for them now… 
Equally well, if they don’t have an advanced health 
care directive and they are in a hierarchy, they may 
have appointed a power of attorney with health 
care decisions… if the EPA is registered, [they] 
may have authority to give consent.” [LE]
The timing of the consent request
Many were concerned about how to identify the 
right moment to request consent especially if the 
intention is to do this at diagnosis. Registry experts 
stressed that there were often delays in obtaining 
consent and not to underestimate the impact this 
has on data collection. 
 “It’s a very difficult conversation and then you  
get into the difficulties around who is the person  
in the family who can admit or agree to that.” [HI]
“So I think if you go in and you have the diagnosis 
and it’s like, ‘Hey, here, now just sign this and 
you’re going on the register,’ I think I’d see that  
as not fair.” [IDWG]
“We find that doctors and nurses, having broken 
bad news to somebody, are not particularly keen 
on then asking them to sign a consent form to 
have their data handed over to a third party… 
For	instance	in	Germany	in	the	1990s	two	of	the	
registries were forced by their legal federal health 
authorities to seek consent and their registrations 
went	down	to	about	10%.	They	reported	back	this	
wasn’t because patients were refusing consent but 
the doctors and nurses just wouldn’t ask for it  
because they felt it just wasn’t the right time.” [RE]
One suggestion was that anonymous coding for all 
people diagnosed with dementia should be made 
on GP and secondary care systems. This includes 
coding those that ultimately decline consent and this 
would facilitate the collection of basic anonymised 
prevalence data. Another was that consent for 
personal data use should be included in advance 
healthcare directives so that you could consent now 
for your data to be used at some point in the future 
if needed. 
“I think the other issue then for me is about the 
ethics of advance use of data collected today with 
new technologies, like biotechnology in the future 
and trying to find what way we are going to get 
that consent… They were talking the other day 
about dynamic consent which means that the  
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consent now to use the data in a dynamic way in the 
future as new knowledge comes through and we 
can sort of see things from a different advantage 
point. I don’t think it’s black and white.” [HI] 
People with dementia and legal experts also raised 
the point that additional consent should be sought 
for new uses of the information. Given the fact that 
dementia is a progressive disease, this can introduce 
complexities where someone who had previously had 
capacity, no longer does. Although the same process 
for gathering consent in the absence of capacity (e.g. 
assisted decision support) can be followed here.
“If something new comes up then it’s brought  
to people again” [IDWG]
“The only difference is that you might be able to 
go back to somebody else at a later stage to say, 
‘We are now using this information for this reason,’ 
but you might not be able to go back to the  
person with dementia because they may have lost 
full capacity at that stage. So I would think that 
when the person with dementia gives consent, 
the consent is only valid if they know very clearly 
what it’s being used for and that use can’t change 
later on.” [LE] 
3.2.4 Anonymised and identifiable 
 data
In discussions about the use of anonymised and 
non-anonymised data, expert opinion varied, but all 
agreed that it really depended on the type of data 
that was going to be collected and the functions 
these data were to fulfil in the registry. Two different 
approaches are generally taken: 
• where non-anonymised data are held at source 
(i.e.	identifiable	in	data	provision	centres	such	
as	a	specific	primary	care	provider,	hospital	
clinic, or memory clinic), but anonymised 
centrally	and	for	all	reporting.	
• where non-anonymised data are held both  
at source and in the core registry, but data  
is	still	anonymised	for	reporting	and	data	
access	unless	specific	consent	exists	to	allow	
the transfer of some subset of available  
non-anonymised data. 
The first approach makes data management and 
data access rules simpler for the registry, but it limits 
its function to reporting high level prevalence data 
and makes clinical care and research goals more  
difficult. Option two facilitates a broader range of 
uses albeit with more complex data management 
and access rules. Taking this position is a little easier 
for rare disease registries where the registry is often 
co-located in one of the main diagnostic or treatment 
centres, but it can and has been achieved for larger 
registries. Often, only a core group of registry staff 
have access to the key that identifies the person as 
that is needed to manage data matching and data 
issues. So, while the data are identifiable within 
the registry, data are pseudo-anonymised for most 
uses. Anonymised data are then made available to 
consumers of registry data including those using the 
data for research purposes.
“The information centre has a lot of information 
on dementia that’s generally not held at the level 
of a person that you can identify.” [PE]
“There’s no identifiable information on an  
individual in the registry, but if you have to go 
back and contact the person for a particular  
reason, that information would be available and 
you would have permission to do so.” [CE]
“Our research group has access to the codified 
data, but not to the individualised datasets 
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through which people can be identified. So they’re 
de-identified … it’s not [pseudo-anonymised] 
because we can track it back, because we have  
to track it back… So the person who has the  
codes is the data manager. So the person who has 
the codes can identify the patient’s name through  
paper files… but you can’t do it on the register.” 
[RE]
 “Obviously it’s important that personal details 
aren’t released to researchers, there’s a balance 
there in terms of what can be released to ensure 
that there is quality research enabled and then 
also to protect the identity and security of the 
actual patients themselves.” [PE]
Some countries have taken the additional caution  
of locating the registry within the health service 
such that any gaps in anonymisation are essentially 
managed by having identifiable data remain within 
the health service. While this may work for a co-
ordinated health service such as the NHS in the UK, 
it would not provide additional protection in  
a fragmented service such as that in Ireland. There 
is also the valid question about maintaining the 
independence of the registry which seems to be the 
best-practice approach favoured by most experts 
(refer to Theme 5: Registry governance).
3.2.5 Accuracy and comprehensiveness 
 of the data
The accuracy of the data in a registry was felt to be 
of paramount importance if the registry was going 
to be of any value. One registry expert argued that 
ensuring data accuracy and completeness was one 
of the biggest challenges for any patient registry.
“People get worried about things like data  
protection and ethics… but they’re not the big 
problems in the registers. The big problems are 
the biases, the unknown biases or the poorly 
thought out registers with the biases that people 
should have known but didn’t, and they’re much 
more serious because they lead to erroneous 
conclusions which are dangerous.” [RE] 
Despite this challenge, public health experts clearly 
advocated for a population-based registry as they 
saw data accuracy as one of its greatest benefits. 
They argued for the widest range of data collection 
of any expert group so perhaps unsurprisingly they 
were also the most sceptical about the registry’s 
ability to easily collect and ensure the accuracy of 
these data. This is where it may be easier for bigger 
countries to implement these kinds of registries, 
as highlighted earlier in section 3.1.3 by one of our 
registry experts. 
 “The most accurate registers are population-
based… they give us the most accurate 
information. Nobody’s too old, nobody’s too sick. 
Nobody’s too poor to go on a register. So that’s 
the best type of register to have, but for dementia 
that’s difficult because your ascertainment is  
going to be very difficult because dementia is 
fairly common, there isn’t a single place that 
somebody with dementia goes.” [RE]
 “So background characteristics of patients would 
be incredibly important for us to try and establish 
any type of epidemiological evidence base on risk 
factors so that we could try to develop strategies 
for prevention... so things like socioeconomic  
status, lifestyle risk factor behaviours, such as 
smoking, alcohol consumption, exercise, obesity 
levels, those types of things, but also the more 
basic patient characteristics such as socioeconomic 
status, age, sex, those types of things and also it 
would have to take into account the other factors 
that are kind of emerging as really important in 
terms of developing risk which would be around 
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early childhood trauma and mental health issues 
over the life course educational status.” [PE] 
There is, however, more to public health than 
prevention although there is some overlap between 
data required for prevention and that needed for 
clinical care.
Experts expressed the view that the best data 
are generally available in primary care but those 
involved in existing registries also commented that 
this was the hardest data to get and that a lot of 
work is needed in order to ensure comprehensive 
data collection.
“In terms of health information, the data  
collected by GPs in primary care is one of the 
richest sources of clinical information, collected 
directly at the point of care.” [HI]
“A digital solution has been in GP practice for ten 
years or more in both the NHS and in Ireland and 
therefore the robustness of the data, the length 
of the data and the learning that’s been slowly 
undertaken across that dataset is huge compared 
to hospital datasets where it’s very siloed.” [HI]
“It	took	us	I	would	say,	five	years	to	cross	the	60%	
threshold. And really you need to have at least 
60%	of	the	total	population	covered	in	order	to	
be really statistically relevant and now we are 
running	at	about	92%.	We’ll	never	hit	the	100%	
because there’s always the lag time between  
diagnosis and then getting the actual consent 
form signed.” [RE]
Experts also saw a link between standardisation of 
data and the accuracy and credibility of the registry, 
but those experienced with patient registries in  
Ireland highlighted the difficulties in achieving this.
“So trying to standardise that across the country 
I could see could be a major problem. Getting 
credibility of your data in the clinical community 
even for us is quite an uphill task… Because 
clinicians keep seeing patients over and over 
again, they tend to considerably overestimate 
the disease burden. So if you come along and say 
in this hospital 20 patients were diagnosed with 
dementia last year, they’ll say, ‘That’s ridiculous, 
that’s stupid. I see 20 every week in my clinic,’ 
and you have to say, ‘Yes, but they’re the same  
20 people’. So if your credibility is undermined  
by sloppy methodology in the beginning or by 
technical limitations or errors or whatever, it’s 
very, very difficult to retain it. It really took us I’d 
say 10 years before people were willing to accept 
our figures without arguing with them.” [RE]
In fact, the general consensus was that registry data 
will never be entirely comprehensive and many 
experts argued that you should never expect it to  
be given the local factors that can influence the data 
collection process. This was not considered to be 
problematic as health economic models are built  
to deal with incomplete data, although that is not  
a sufficient reason to be complacent about data  
collection. It would be essential to keep a close 
watch on data comprehensiveness rates and registry 
data cannot be expected to be immediately relied 
upon. 
“You can’t really rely on a register for the first few 
years because it’s going to have all sorts of biases 
in it.” [RE]
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3.3 Theme 3: 
 Data collection
3.3.1 Data sources
Conflicting opinions emerged about the size of the 
task faced when setting up a registry. For some,  
particularly those with a public health and epidemio- 
logy background, the challenge is daunting. For  
others, often those who have experience with 
existing registries, it is possible and manageable 
once you are clear about what you want to do and 
pragmatic about what can be achieved. That said, 
a consensus emerged in that all experts found it 
hard to see a situation in the near term where data 
collection would be seamless and all acknowledged 
that some manual intervention would be likely. 
Multiple data sources
Registries in the UK have an advantage where they 
can operate centrally to a large extent as they have 
the ability to see everything from referral letters 
to discharge letters online, but the process is more 
complex in Ireland.
“… so it means you don’t have to have people 
trailing round from hospital to hospital but it still 
means that you have to have a significant number 
of staff sitting in front of computer screens reading 
letters and going through medical records and 
trying to make sense of it and code it and all that. 
So it does cut down on work a bit.” [RE] 
Policy and registry experts all spoke of the difficulties 
that were likely to be encountered collecting  
dementia-related data in Ireland and they felt that 
the challenge of obtaining comprehensive data should 
not be underestimated. There is no one natural 
source of data related to dementia as diagnosis 
happens in multiple settings. Although primary care 
data are seen as the ‘gold standard’, most formal 
diagnoses occur in secondary care. All registries,  
including international dementia registries, find  
primary care data the most difficult to manage and 
that which gives rise to the most data gaps. However, 
sourcing data from secondary care alone is also 
problematic as this will not give comprehensive 
coverage. As such, registries need to collect data 
from multiple settings and develop a process that 
accurately matches data across these settings. 
“We’re not very good really at collecting information 
in primary care settings. In the hospital context 
as people come through the door its part of the 
process. We need to look [at] sustaining that kind 
of data piece within primary care settings and I 
presume that’s where you would want people 
with dementia.“ [HI] 
“[The National Dementia Strategy contains]  
actions about recording in primary care and acute 
care. If you started work on that you might have 
the basis to build a register on at a later stage. 
That’s just a thought because to my knowledge 
there is very poor recording of dementia diagnoses 
in any of those sources, it’s very much hit and 
miss apparently and if dementia has not been 
diagnosed in primary care then you know it often 
doesn’t get put in the notes in the hospital.” [PE]
On the positive side, using multiple sources of 
information and cross-referencing the data for each 
patient does negate the potential bias of collecting 
data from a single data source.
“You can’t have a register drawing from just one 
dataset. It’s going to be biased…If you ascertain 
dementia through old-age psychiatry, for example, 
that would be a far different cohort from  
geriatricians, which would be a different cohort 
from neurologists, because each would be  
drawing from a slightly different segment of the 
population. If you draw from GPs, the diagnostic 
criteria for dementia are not very clear. So, 
dementia is quite a difficult one because it’s a 
heterogeneous condition.” [RE] 
Many existing registries, such as the Swedish and 
US dementia registries have experience gathering 
data from multiple sources and demonstrate that 
it is achievable. That said, these registries typically 
have a legislative mandate that supports their data 
collection requests and they are also more advanced 
with regard to electronic records and unique patient 
identifiers.
“We pull from hospitalisation data, inpatient  
hospitalisation, Medicaid data, emergency room 
visits, long-term care evaluations... We have a 
State Health plan here that a lot of people belong 
too	so	we	can	search	that	for	those	ICD-9	codes.	
And there’s also community mental health facilities 
and we have one private practice that is giving us 
information and we are hoping to expand to get 
more private practices to provide their information 
as well… We try also to include free clinics... In the 
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sense of the providers furnishing us the data, it’s 
voluntary. However the fact that there is this law 
gives a totally different legitimacy to the registry 
than if we did not have this law.” [RE]
“If [data collection] is a challenge in Sweden 
where they have very good records and systems, 
it’s going to be an incredible challenge for us here 
in Ireland... We don’t have a joined-up system 
here, we don’t have electronic records systems 
and there’s difficulty in communicating from one 
hospital to another. There are going to be lots of 
practical issues in terms of accessing records but 
also in terms of data protection.” [CE]
Yet, having a legislative mandate doesn’t protect 
registries from the complexities of the Irish system. 
For example, the NCRI are still seen by the HSE as 
being ‘outside the wall’ and essentially ‘not their 
problem’, so they don’t see the need to actively 
collaborate with them, nor do they see the need to 
have any direct role in terms of funding the registry, 
including contributing to the cost of data collection. 
Furthermore, having a national mandate would 
imply that all cancer-related data are captured by 
the NCRI and passed to the National Cancer Control 
Programme, but this is not the case as the registry 
does not include data from the private hospitals.  
Essentially	they	are	missing	the	30%	of	cancer	 
patients that are not seen by the HSE. Experts  
concurred that it would be important that a dementia 
registry would be set up in such a way that data would 
be collected on a national basis and not just for the 
HSE. Given the lack of investment in dementia care 
in Ireland and the increasing privatisation of home 
care, it must be assumed that this will be a growth 
sector for private healthcare providers and any new 
dementia registry needs to be future-proofed to  
account for this.
Electronic health records (EHR) and electronic 
data entry
Irish registry experts describe data collection as 
a huge challenge when you don’t have electronic 
health records (EHR) or any type of electronic data 
interface or data exchange with data providers.  
Registry staff are often required to go to data providers 
and to go through patient records and manually 
transcribe the data into electronic registry systems 
(personal communication, May 2016). There are 
obvious time and cost implications of this approach 
but experts agree that it is possible to get what you 
need in order to operate a patient registry success-
fully. Some experts feel that we are close to the 
adoption of EHR in the future, but despite clearly 
enthusiastic supporters, there was a general view 
that their rollout would realistically be in the order 
of 6-10 years given the significant issues with regard 
to legacy records, the necessity to run paper and 
electronic records in parallel for a period of time 
and data capture from paper to electronic records. 
One expert also recalled previously unsuccessful 
attempts to introduce EHRs in the mental health 
system. However, all agreed that all new registries 
must be designed with an eye to the future and the 
automatic uploading of required information from 
EHRs should be catered for. It should be noted that 
EHRs will not automatically result in all of their data 
transferring to a patient registry and appropriate 
consent and data collection processes will still be 
required. EHRs will just simplify the data collection 
process and reduce the time and cost involved.
“So we have some of the building blocks in place 
to really move towards what eHealth Ireland the 
strategy describes, having completed eReferrals, 
having put in place the individual health  
identifiers, having invested reasonably heavily  
in infrastructure over the last 12 months. We  
are setting ourselves up, as long as investment 
continues, to really deliver what we described  
we would by 2021 at the latest”. [HI] 
Many of the countries who have access to electronic 
data records have also built online data entry portals 
so that secondary data not present in the EHRs can 
be easily added.
“One of the other things, looking at other jurisdic-
tions who are doing this now though is to get it 
out there and open it up so that you can actually 
have a portal to the citizen that says put yourself 
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on this register and you consent to taking part  
in research or being part of population health 
studies and that has been very useful and very 
powerful certainly in the NHS in the dementia 
area in the past 12 months.” [HI]
Data matching and unique health identifiers
Experts felt that the practice and use of patient  
registries was probably best established in the  
Scandinavian countries where unique health identifiers 
are a prerequisite. Policy experts in particular saw 
the need for some form of IHI in Ireland to facilitate 
the accurate matching of patient data from different 
sources. Certainly the introduction of the Chi-number 
in Scotland (similar to the proposed health identifier 
in Ireland) facilitates data matching and helps avoid 
double-counting. Similarly, the NHS number enables 
patient data from a range of different centres to be 
linked and it is an important benefit for registries in 
the UK (Newton & Garner, 2002). It should be noted 
that if the registry holds the key to identifying 
patient data using the NHS number, that this is 
deemed to be identifiable data in legal terms. One 
expert expressed particular concern at the idea of 
attempting to set up a patient registry before IHIs 
were in place, although this view was not shared by 
the other experts interviewed.
“I just see a unique identifier is a prerequisite,  
so that would be another requirement here,  
because otherwise you can’t have people going  
to different GPs and, again, you know, the  
accuracy then of a kind of national register there 
becomes harder to manage if you don’t have 
unique identifiers.” [PE]
Registry experts highlighted the fact that while IHIs 
are ideal, existing patient registries are managing to 
effectively match data from different sources today 
and that ‘good enough’ workarounds (e.g. match 
on name and date of birth) can be used to link data 
with	high	accuracy	(e.g.	95-98%).	These	can	be	put	
in place with appropriate controls and consent.  
Although a minority view was that data linking could 
threaten privacy, most felt that taking this approach 
is better than doing nothing and having no data 
with which to support clinical care and health policy 
planning. 
“So a universal patient identifier makes life easier. 
It doesn’t completely avoid some of the  
difficulties that I mentioned, but it does make  
cross-referencing a bit less tedious”. [RE]
Recent progress has been made with the creation of 
IHIs in Ireland, although this progress has been slow 
and no clear roll-out plans are as yet available. Most 
experts expressed their frustration at the delays 
and suggested that there are more obstacles to be 
overcome before they will be fully in place.
“Well the unique health identifier has very much, 
I guess, progressed to a point where they are now 
looking at and have set up the infrastructure in 
the ICT department, albeit at an embryonic stage 
in terms of rollout... It is now established on a 
database and we have a unique… number set that 
is used…The health identifier will be in. It’s not  
a matter of if as much as when it will be in.”  
[HI]
“It [UHI] seems to have receded into the distance 
a small bit again. Nobody seems to know exactly 
what… some additional legal concerns now have 
been raised by the attorney general. Now what 
these could be, nobody has any idea, but it’s 
headed up for another little bit and I think there’s 
some consultation going on and usually consultation 
going on means that things are going to be put 
off for a long time.” [RE]
But the importance of having some kind of unique 
identifier on registry data records is important as 
it is what establishes the connectivity out to other 
databases.
“It’s the connectivity out to other databases and 
taking the impact on privacy and getting that 
right that’s actually the next challenge. So we’ve 
actually created the individual health identifier 
for every patient in Ireland, put that into a single 
place that we can reference out from. It’s the 
next stage is connecting those spokes to the hub 
basically.” [HI]
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3.3.2 Process of data collection
Registry data collection is not a once-off activity (i.e. 
at diagnosis); improving clinical care or supporting 
public health policy requires a registry process that 
supports longitudinal data collection. Unfortunately, 
Ireland does not have a health data infrastructure 
that easily supports this type of data collection. Many 
Irish patient registries have been set up as secondary 
data entry processes, which results in duplication of 
effort and an additional financial burden in terms  
of data collection and administration. Experts felt 
that it would be more beneficial for registries to be  
positioned at point of care, wherever that may be. 
As far as possible, data should be extracted from  
existing data sources where they are available. 
These data can then be transferred electronically to 
the registry in whatever format is required. Within 
the registry, data can be aggregated and combined 
with additional data from other sources as needed.
“I would say the most important thing and maybe 
the biggest obstacle is getting access to various 
data sources and then having continuity of the 
data. So what has been wonderful about our reg-
istry is that we’ve had these data sources for  
a very long period of time and we’re able to  
compare data over the years… I think that would 
be a very important thing to look at for Ireland.” 
[RE]
 “I think you’d have to get the data in from  
clinicians’ clinics, but also from primary care. So 
anybody who actually has a diagnosis or where 
a diagnosis has been made; e.g. memory clinics, 
geriatric clinics, other specialist clinics… But as 
the dementia strategy gathers momentum, there 
should be more opportunities for the diagnosis to 
be made in primary care or to be confirmed over 
time in primary care, so it should link it back into 
primary care as well.” [CE]
“What it is does [automatic data collection  
process] is draw out the information from the 
electronic medical record and so you need to 
decide how often that happens. It could be on 
a monthly basis or a daily basis or whatever is 
needed, and when updated it will bring all the 
new cases in and it kind of uploads the records  
of existing cases.” [Res]
Although experts agreed that automatic data  
collection processes should be the long-term goal, 
in the short term they felt that at least some manual 
intervention was inevitable. In particular, the need 
to collect data for an individual from a range of  
different sources requires the registry to be able to 
link and match data across these sources. IHIs will 
eventually make this easier but in the meantime 
resources are required to do this work or to resolve 
discrepancies that cannot be taken care of auto-
matically. While experts felt that waiting for IHI and 
eHealth to be implemented in Ireland was impractical 
and would result in nothing moving forward with 
regard to registry creation, they recognised that now 
was an opportune time to engage with the eHealth 
debate in terms of looking at the data collection 
requirement for national datasets. 
“To drive efficiencies and to have a more  
harmonised and integrated system, as much as 
possible we should be trying to make better use 
of our existing data sources. So, the ability to 
link and match registries with other sources of 
information is very important. This will also help 
to reduce duplication and fragmentation which 
currently exists.” [HI]
The need to link and match data must be built into 
funding and resourcing plans. In addition, it requires 
at least some identifiable data to be available in 
the core registry itself so that this matching process 
can occur. The availability of an IHI may remove the 
need for any identifiable data although there is an 
argument that says that the IHI itself becomes the 
key identifying piece of data. Registries should  
create a separate unique health identifier that  
cannot automatically be matched to the IHI.
Buy-in from data providers
Registry experts stressed the need for buy-in from 
the health professionals who would be providing the 
data, so it is important for these health professionals 
to see the benefits of providing these data.
“So I guess you would have to convince and… 
have on your side the medical professional that 
actually provides the diagnosis, you know the 
role players here… it’s key for the success of the 
registry.” [RE]
Registry experts were generally upbeat about the 
ability to collect the data.
“We had a few holdouts and from time to time… 
individual hospitals have withdrawn for short 
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periods of time…. On one occasion they wrote 
to us and said that they couldn’t supply [us] 
with the information because they didn’t have 
the manpower to do this, and again we went 
and worked out a solution… These have all been 
transient problems, we’ve always managed to get 
over them really I suppose by saying, ‘Well this 
is it, this is here. Everybody else in the world is 
cooperating with us, what’s your problem?’  So… 
there was no way that I was going to go round 
and try to get explicit consent from every doctor 
in the country. I’d be there for the next 200 years 
trying to manage that, you know.” [RE]
But, collecting registry data is an onerous process 
and one which is likely to add to already burdened 
clinics. 
“I think the worry is that while most of the 
registries are independently funded and they 
collect the data independent of any clinical care 
process… clinical people are battle weary, and 
we certainly don’t want any data registries being 
developed with… additional workload for data 
entry”. [HI]
“…now that they’ve started to input data I think 
people realise how onerous a task it is and busy 
clinical settings and busy clinics. I think that’s 
one of the comments that has come back quite 
strongly.” [RE]
Some experts suggested that incentives would be 
required and commented not only on the fact that 
monetary incentives were introduced in the UK, 
but also the fact that the need to provide data for 
patient registries has been built into their work-
load and into their contracts. A recent federal law 
in the US provides a type of tax benefit for those 
who provide data to a health registry. This has been 
described as helpful and some private practices now 
seek out the registry and look to join. Many felt that 
some form of incentivisation or acknowledgement 
of the additional workload required to provide  
registry data would be needed in Ireland, while  
others regard the system as being too complicated 
to introduce these effectively.
“ What would be really important for that type of 
an approach is that the GPs have protected time 
to actually invest in that initiative… that there 
is training so they are very much on board with 
what is happening, but also that they actually 
have time allocated to investing in this [initiative], 
because what will happen is that you will find 
that the feasibility study won’t yield the type  
of effectiveness that it should because it’s not 
getting the investment from the key actors that  
it should”. [PE]
 “In Ireland there are incentives for GPs for some 
of the, I’d say, diabetes, I think, and asthma, so 
that dementia will be included on that menu. I 
think if that happened then I think the introduction 
of a registry, it would be easier. I think it would be 
easier to get the GPs on board.” [PE]
 “I think there has to be some incentive to be 
able to get data out of different organisations... 
whether it’s around payment for data, whether 
it’s around clinical time, and additional processes 
to additional systems. There’s different ways that 
incentives can be put in place but it’s not some-
thing that’s probably going to be done just  
for free just because it’s a good thing to do  
unfortunately.” [HI]
There was also a general view from experts, and 
not just those in primary care, that the workload 
of GPs has increased a lot in recent years and they 
are being asked to do a lot more documentation 
and provide a lot more information so it would be 
important to look for synergies with how GPs are 
coding dementia-related data in their own practices 
and develop automatic data transfer processes to 
reduce the workload for individual GPs. There was 
also a feeling that the timing was opportune as work 
is underway as part of the rollout of the National 
Dementia Strategy for Ireland regarding the  
collection and coding of dementia data in primary 
care. 
“I know certainly in terms of GP burden you don’t 
want to end up that this is a very burdensome 
process because obviously GPs don’t have the 
time to dedicate towards that.” [PE]
48
3 A NATIONAL DEMENTIA REGISTRY FOR IRELAND  A Feasibility StudyThematic	Analysis	of	Expert	Opinion
Skilled registry staff
In some registries the clinician makes the diagnosis 
and informs a technician who then takes the  
information required for the registry from the medical 
charts. In many cases they enter this information  
directly into a registry data collection system. In 
other cases a member of the registry staff inputs 
the data. Registry experts stressed the importance 
of having skilled staff involved in the data collection 
process and suggested three different approaches:
• front-line health professionals for each data 
provider; 
• data managers or research nurses located  
at each data provider; 
• separate personnel for data entry. 
Having staff located within a data provider’s  
organisation alleviates issues regarding access to 
patient charts but raises many more issues related 
to capacity to take on these additional tasks. As a 
result, hiring separate staff is often preferred. The 
advantage of looking for people with medical or 
nursing backgrounds is that they are easy to train 
but difficult to get and to retain. Alternatively, clerical 
staff can be recruited. They are much easier to get 
and typically easier to retain than nurses but a longer 
training period is required. Dedicated training  
resources will also be needed that cover a broad 
range of areas from anatomy to pharmacology.  
This in turn raises the need for adequate funding to 
support data collection.
“There’s a lot of interpretation when you are 
capturing it as well… It’s the skill levels. I’m just 
blessed that we have a very dedicated team  
who work at a very low salary level.” [RE]
“And the critical thing which we have to  
emphasise to everybody all the time is that text  
is text and text has to be coded by somebody into 
some meaningful format before you can actually 
use it to register a disease.” [RE]
In addition to data entry tasks, registry staff also  
provide their support and expertise to those input-
ting the data in provider sites, are involved in decision 
making and documentation of particular data sets, and 
have the ability to tweak data collection processes 
when problems emerge.
3.4 Theme 4: 
 Data management
3.4.1 Access
There was consensus across policy, legal and registry 
experts that the registry data, first and foremost, 
should be available to those responsible for providing 
health care (e.g. the Department of Health and the 
HSE). It was also recognised that there would be many 
other stakeholders looking for access to registry 
data. There was clear agreement that the guiding 
principle for data access should be that consumers 
of registry data should only have access to the data 
specific to their needs; this is particularly relevant 
for identifiable data. A clear data access plan should 
be developed when the registry is being planned 
and this sits well with the idea of a tiered approach 
to patient consent. 
 “You’ve got to think about things like access  
controls to that information – should there be  
a hierarchy of access based on the sensitivity  
of the information concerned? Who has the right 
to amend the data at any point in time? Who 
will that data be shared with? And, ultimately, 
how long should that data be retained before it’s 
either deleted completely or what’s referred to as 
anonymising the data.” [LE]
Some existing patient registries in Ireland have  
developed their online systems so that data providers 
can see their own information. This can be useful 
in terms of looking at performance over time and 
for improving cross-provider clinical care. It also 
gives the potential for data providers to compare 
their performance to the average and to other data 
providers. As no centralised ethics approval process 
exists in Ireland, each centre does need to apply to 
their own ethics board before access can be granted. 
Although time consuming, it has not been prohibitive 
to date, but the introduction of a National Ethics 
Committee would be advantageous here. 
“We have now developed a system whereby 
each individual hospital can log into the system 
but they will only see their own patients. If the 
patient and the two hospitals have agreed on 
shared care … then at least both [care centres] 
can see [this shared] patient data.” [RE]
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This expert went on to elaborate on the economic 
benefits of this approach as it can remove cost from 
the healthcare system. As noted earlier in section 
3.1.2 by one of our registry experts, duplicating tests 
in different settings could be avoided if relevant data 
was stored and shared across all those providing 
patient care. 
In many cases, at least some registry staff have access 
to personal identifiers as they are needed to resolve 
duplication and data matching issues. Where registry 
staff don’t have this option, data issues are necessarily 
harder to resolve. Given the absence of IHIs to date, 
experts suggested that Irish registries need to give 
serious consideration to storing some form of  
identifiable data within the registry and including 
adequate data protection and data access policies for 
some sub-set of registry staff to have access to the 
key that links these identifiers to specific patients.
“Within the registry we ourselves are registered 
data administrators with the Data Protection 
Commissioner, so our patients have given  
permission for the staff within the registry to  
see the patient identifiers. In certain European 
countries the registry doesn’t even see that and 
that creates problems with regard to a duplica-
tion… have I got this person before because now  
I can’t identify them.” [RE] 
Many experts felt that safeguards were needed 
against unacceptable or unethical use of registry data; 
for example, US patient registries are becoming  
an ‘economic target’ with patients treated as  
commodities where information gets collected  
primarily for clinical trials and industry purposes.
“… the risks that some will get the information 
from pharmaceutical companies or people like 
that might get the information and use it for their 
own benefit… be very clear in terms of how the 
data is going to be used and for what purpose.” 
[PE]
People with dementia were concerned about some 
of the ways in which registry data could be used and 
were worried about the potential impact for them. 
For some it was a generalised anxiety while others 
saw implications for their employment, finances, 
insurance and driving. This was particularly the case 
for younger people with dementia and a number of 
experts expressed similar concerns. Each was aware 
of instances where individuals were not disclosing 
their diagnosis for fear of the ramifications of doing 
so. 
 “We need to be covering our tail ends as opposed 
to just doing this to get it done and then realising, 
‘Oh my God, we’ve opened up a vulnerable part 
of society where they can be....whatever. I don’t 
know what the ‘whatever’ is, but….” [IDWG]
“So I think that that is a huge fear for people 
working… I’d love to say we were further along in 
the country with it, with dementia being treated 
like any other disability, but unfortunately as we 
all know around the table, that’s not the case. So 
it’s a difficult one, because if you are employed... 
They’ll find ways of giving you the nudge out the 
door. So it’s an issue.” [IDWG]
“I don’t think it’s black and white. It’s not  
insignificant and then you also have the health 
insurance piece, the driving piece, the ability to 
work and be employable, getting a mortgage, all 
of those social elements come to play as well.” 
[HI]
“I think it’s more about the fact that if I’m  
diagnosed in the very early stages… there are 
some important implications like they question 
me on my ability to drive, legal decisions and 
so on… I think it’s more to do with the potential 
negative consequences that go with a diagnosis.” 
[PE]
Experts also highlighted the importance of having 
adequate security processes in place to safeguard all 
registry data regardless of the medium in which it is 
held. Avoiding unauthorised access to the registry 
data is key. There are also a range of legal implications 
that need to be considered if data access is given, 
even when it is appropriate, to organisations outside 
the EU as this creates problems with safe harbour. 
These concerns are significantly reduced when 
purely anonymised data are shared. 
“There are controls that have to be applied 
depending on the medium to make sure that is 
safeguarded… But what you want to avoid is a 
data breach.” [LE]
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3.4.2 Privacy
Although potential risks to privacy and confidentiality 
were discussed by all experts, they also acknowledged 
that once the registry has proper procedures and 
guidelines in place, there should be no real cause for 
concern. 
“Well I guess the danger is that if the system isn’t 
robust and doesn’t work well that there will be 
problems with data protection and confidentiality. 
That’s if the system is not robust and isn’t set up 
correctly and monitored. So I think as long as it’s 
managed, operated and overseen correctly, from 
the data protection and confidentiality point of 
view, I think there shouldn’t be any great risks.” 
[CE] 
Data protection
Experts agreed that a person’s right to privacy and 
confidentiality must be assured. They also highlighted 
the fact that data breaches can and do happen and 
that the ramifications vary depending on the type 
of data that was accessed and the response to the 
breach itself. 
“The most important thing is that we have to 
respect a patient’s right to privacy and  
confidentiality, so whoever maintains the register 
must ensure that there are no data breaches … 
Information will have to be very strictly controlled 
and under no circumstances should names or  
addresses or any identifiers be released to any-
one outside of the business unit that is looking 
after that information.” [LE]
Some people with dementia were particularly worried 
about privacy because of breaches reported in the 
media and due to potential negative outcomes of 
being on a dementia registry. 
“That’s something you would want to think of, the 
ramifications, is it going to impact? If somebody 
loses this hard-drive or steals the computer, we’ve 
all heard those tales of files getting out there, so 
I think that’s something people fundamentally 
should be given time to ponder on.” [IDWG]
 
“Couldn’t people get access to it? Will I forever 
be labelled ‘she’s no good she’s on the dementia 
register’, and I think people would have to be very 
assured of confidentiality and the use of a register 
beforehand and that could be quite difficult to  
explain to somebody who is in the earlier or 
middle phases of dementia, especially when the 
whole illness itself makes it difficult to under-
stand that you have an illness in the first place.” 
[IDWG] 
Two elements need to be considered when thinking 
about data protection. The first relates to advance 
controls that are put in place by having adequate 
data security and risk management to prevent data 
breaches, or if one does occur, to lessen the impact. 
Secondly, there are other procedures and controls 
that can be put in place that are followed if a data 
breach does occur, depending on the nature of the 
breach and the nature of the data. This directs who 
needs to be informed. The type of controls depend 
on a range of factors including the data that is going 
to be stored, how it will be stored, amended,  
accessed and shared, how long data will be retained 
and how data will be removed from the registry. 
A data protection framework has been in place in 
Ireland for some time, so establishing appropriate 
privacy and security procedures would not be a  
huge undertaking for a new registry as long as it is 
considered up front in the planning stages. A number 
of experts also referred to the fact that these  
challenges are not new and that they have already 
been addressed in other areas. For example, guide-
lines have already been developed for GP practices 
around patient information and how to share this 
data within a practice. The key for a new registry is 
not to reinvent the wheel but to build on what is 
already there.
“It doesn’t have to be overly complicated, it just 
means taking some time out at the start of the 
project to consider what we are going to collect, 
why we are collecting it and how we communicate 
the reasons and the nature of the studies… to the 
data subjects in advance, prior to actually receiving 
their information, and then considering once we 
have the information in our possession, what 
controls we are going to apply to ensure that it’s 
safeguarded and processed in a manner compliant 
to legislation, and ultimately how long we are 
going to use that information for and maybe how 
we’ll dispose of it at the end.“ [LE]
One registry expert raised the need to ensure that 
privacy rights extend beyond death. This is one area 
where existing policies and guidelines may need to 
be enhanced.
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Privacy impact assessments (PIA)
HIQA and experts from existing patient registries in 
Ireland recommended undertaking PIA when planning 
the data needs of a new registry. A PIA requires a 
data controller to carry out an assessment prior to 
the collection of any personal information (including 
new categories of information for existing registries) 
to understand what the implications of collecting 
these data are for the data controller and for the  
individuals who provide the data. The PIA should 
also demonstrate compliance with the enhanced 
data protection regulations (Data Protection  
Commissioner, personal communication, May 2016). 
In essence, it formalises the work already being 
done by data controllers in existing registries. Indeed, 
if HIQA take over the quality evaluation of patient 
registries, it is likely PIAs will become mandatory, at 
least for HSE registries. 
“If you are going to go to the department with a 
proposal, they would want you to adhere to the 
HIQA principles, they would want you to do a 
privacy impact statement because these are the 
sort of things that HIQA would insist on. So you 
wouldn’t have much of a day-to-day relationship 
with HIQA but you will be expected to conform to 
their standards.” [RE]
3.4.3 Technical requirements
Having a robust IT system was considered beneficial 
from a cost perspective and also for the ease with 
which it supports data management and facilitates 
data sharing. Some aspects that need to be  
considered are: 
• data	collection	(how	often,	when	and	push	 
or pull data transfer) 
• data storage
• security
• implementing	access	rules	(including	 
password management) 
• data	transfer	(including	encryption).	
Experts with existing patient registries also highlighted 
the importance of web-based access, not only for 
data entry and data reporting, but also in terms of 
improving security by allowing varying levels of  
access to one copy of the registry data.
“At the moment the system is not very good, it’s 
quite an old system, and each one of the people 
who enters the data has a copy of the database 
on their laptop because it’s not a web access, 
it’s a fixed database, so we have 21 copies of the 
data at any one time, which is not great from 
a security point of view but it’s encrypted and 
double-password protected and so on. But we 
are moving now to, at the end of this year, to a 
web-based one where there will only be a single 
copy of it.” [RE]
There was a clear recommendation to use an  
established technical partner in terms of providing 
technical support for any new registry. Many existing 
registries use the OpenApp company and they were 
considered to have significant expertise both in 
establishing and running registries in Ireland and 
elsewhere in the EU. Many of the policies, procedures 
and systems needed to manage data security, for 
example, have already been dealt with by this  
organisation as part of their work with some of the 
larger patient registries in Ireland.
“They’ve [OpenApp] got great expertise in this 
area... They also won the tender for the European 
[registry]. So they are very kind of embedded in 
this area... there’s a lot of expertise within that 
group… But I think also the fact that the [Irish 
registry] that we were consulting with them,  
and that a lot of the systems had already been  
established as part of the larger registry.” [RE]
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This same company has been involved in a major 
redesign of the CFRI technology infrastructure over 
the last two years and CFRI has now been brought in 
line with European infrastructure recommendations. 
This in turn allows for cross-Europe collaboration 
between registries (CFRI, personal communication, 
April 2016). Other Irish and international registries 
are keen to incorporate the CFRI model and IT  
infrastructure and the CFRI group currently host 
some smaller registries on their servers; for example 
IPFR and some test developments for the Irish Skin 
Foundation Registries. This enables smaller registries 
to benefit from a more substantial infrastructure than 
they are likely to be able to develop on their own.
“…that the people who are operating within the 
registries are at least thinking about it and going 
about it that sort of way of, you know, sharing 
core competencies.” [RE]
Despite long-term cost savings, significant funding 
is needed at the outset to develop an appropriate 
technology base. For example, the CFRI acquired 
lottery funding and contributions from the Pharma 
industry, but this still wasn’t sufficient. They were 
fortunate that the European CF Registry were also 
looking at updating their technology and by getting 
onto the steering group for that project, and through 
a lot of hard work, they were able to benefit from the 
fact that the EU paid for the core of the technology 
and the CFRI could benefit from this (CFRI, personal 
communication, April 2016). It is also possible to 
co-locate the registry within a high-performance 
computing centre, most likely in a university, and 
this has additional benefits such as established 
data protection policies and structures within the 
university, access to expert data managers in these 
centres, specialist statistical analysis experience, 
natural research partners and collaborators for 
funding applications. If following this approach, it is 
recommended that the registry remain independent 
of the hosting institution. 
Finally, some health informatics experts felt that 
we are at a point in Ireland where we need to think 
about our broader health information infrastructure. 
Although this is commendable, it is likely that it will 
take considerable time to debate, agree and  
implement any policy or guidelines in this area. 
“I think you really need to have a way of linking it 
in with broader health information infrastructure 
that exists within the country… You know so there 
is a legislative infrastructure and then there’s a 
kind of health standards infrastructure that sits 
alongside and also as part of that so I think they 
all need to be kind of thought of in the context  
of you know the feasibility around any new  
registries.” [HI] 
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3.5 Theme 5: 
 Registry governance
3.5.1 Governance structures
Experts agreed that formalised governance arrange-
ments should be established from the earliest  
planning stages as these ensure the creation of a 
registry that is fit-for-purpose. They set the standards 
for registry data collection thus ensuring the quality 
of the registry data. Assigning overall responsibility 
and accountability within this governance structure 
is crucial, as is ensuring that registry personnel map 
onto the specific domains and competencies required 
to support the effective running of the registry. An 
existing Irish patient registry described how they have 
a board that includes representatives from the registry
itself, an external expert with a broad scientific, 
pharmacological and technological background, and 
two lead consultants from data provision centres. 
Health informatics experts agreed and added that 
a named individual, such as the CEO, needs to have 
overall responsibility and accountability while a 
management committee would be responsible for 
the day-to-day operation of the registry.
 “You need a relatively small board and I think 
you need people who are actually going to turn 
up to board meetings and contribute rather than 
people who are just going to come and sit there… 
You need a good dynamic chair, somebody who 
is going to push things along, who is going to 
support your CEO. I think that’s a great asset as 
well because they have the authority on behalf of 
the board to say things which a CEO or a director 
might feel that they didn’t have, you know?” [RE]
However, the registry must avoid creating an  
unwieldy and bureaucratic governance structure. 
One international expert suggested that people 
with dementia and their carers should not only 
be involved in the registry governance but should 
lead it. This expert was particularly concerned that 
those with expertise in areas such as ethics and data 
protection could put onerous processes in place that 
would act as barriers to getting the registry up and 
running whereas those whose data is actually being 
captured and stored would be more pragmatic with 
regard to how this could be managed.
“You would spend more money governing it than 
you would you know actually doing it… But if it 
was kind of light touch, led by patients and carers 
I’m sure you would get much more out of it.” [PE]
There was a general feeling that we have made 
some positive strides towards good governance of 
existing registries in Ireland. While this may have 
been very ad-hoc in the past and managed by specific 
patient organisations or universities, registries such 
as CFRI are seen as leaders in the field and people 
who have been through the process with a lot of 
learning that they can share. It is also very beneficial 
to have a broader scientific (or expert) advisory 
board that meets at least once a year. They can  
review policies and procedures, operations and 
quality evaluations and provide comments and 
guidance as required, but they should also have a 
strategic planning focus addressing the long-term 
sustainability of the registry.
“I think that was very, very helpful. We built up 
contacts with [another registry] at a very, very 
early stage and certainly for the first ten years 
that was hugely helpful to have somebody else 
to exchange ideas and problems with and all that 
sort of thing. Although they operate in a different 
way, at the same time it certainly was a great 
resource for us.” [RE]
It should also be noted that the organisation that 
sets up the registry also becomes the ‘data controller’ 
from the perspective of data protection legislation in 
Ireland. Experts highlight the importance, therefore, 
of clearly identifying the director or owner of the 
registry as they will be responsible for ensuring 
registry compliance.
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3.5.2 Registry ownership and 
 independence
Having an independent registry was considered 
paramount. Most Irish experts expected that the 
registry would be completely independent of HIQA. 
While some felt that HIQA would have a remit in terms 
of monitoring governance and quality assurance, this 
wasn’t obvious to all; many argued that this function 
should be met by a quality assurance group with 
appropriate scientific and specific registry expertise. 
One expert also highlighted the importance of  
ensuring that registry governance was protected 
from political agendas, while experts in health  
informatics cautioned that the registry should not  
be unduly influenced by one particular organisation 
or type of data collection.
“Now, ours is a professional board which I would 
very, very strongly urge, because some bodies 
have really what you might call a political board 
where you have former TDs and people like that 
and many state agencies have boards which are 
quasi-political and really they are no use. You 
need a technical board. You need a board that 
you can actually go to for advice and steer and  
all that sort of thing.” [RE]
 “Who will own and be responsible for the  
database? If it’s the Alzheimer’s Society of Ireland 
versus a health policy group I think there might 
be very different data collected.” [HI]
In fact, only one expert expressed a reservation with 
regard to independent registries but this was more 
in relation to the duplication of effort needed for data 
collection than the autonomy of the registry itself 
(as discussed in section 3.1.2 above; [HI]).
Expert opinion was less consistent regarding own-
ership of the registry although all agreed that a 
clear and independent owner was required. Some 
questioned the ability of patient organisations to 
successfully run national registers in the longer 
term. They also felt that establishing the registry in 
the Department of Health would just result in more 
of the same data already available. Others argued 
that the registry organisation must have the ability 
and the competence to run the registry.
“If it’s going to be national… I think you’d have to 
have one body responsible for it.” [PE]
“It certainly would be brave, I think, from the 
Alzheimer’s Society’s perspective to take owner-
ship of a registry like this and to try and push it 
forward. I think putting it automatically into the 
Department of Health we’ll probably get more  
of the same in terms of the data that you are  
collecting… there’s nothing wrong with that,  
because that’s very powerful data, but I don’t 
think, looking at the models of care that are  
coming and the lack of funding that we have 
available for long-term care… I think it’s worth-
while looking at it from a different angle.” [HI]
Some experts felt that it was important to ensure 
that the registry would be embedded in a structure 
that links directly with policy and research. However, 
others felt that the overall ownership of the registry 
should sit with people who have a vested interest  
in the dementia agenda (e.g. practice and/or policy) 
rather than just a research focus. The exception to 
this would be if the registry was used to support 
clinical trials and particular research projects, in 
which case the data specific to this use would need 
to be managed by an appropriate clinical or research 
team. 
“I’m not sure about a standalone company or  
an organisation managing this. For a dementia 
registry, you’d like it to be an organisation that 
has either an academic research or clinical  
connection.” [CE]
 “The tangible links that you can make from a  
registry so that the data can be used by research 
and that that research is part of a loop to feed 
back into policy making and service delivery  
planning.” [PE]
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3.5.1 Registry quality
The formality of the quality assurance process differs 
across the range of national and international  
registries explored in this study. Some registries  
self-evaluate and this process is typically guided  
by their executive committees and advisory boards, 
while others operate within a framework that  
requires periodic external registry evaluations.  
Regardless of which process is currently in place  
in a given registry, all experts suggest that formal 
evaluation processes are required. Experts also felt 
that it would be really important for us to be able  
to compare our data with that of other countries 
and that this would facilitate improved dementia 
care.
“The fact that we looked at a lot of international 
experience and we looked for international 
standards and international coding and operating 
procedures… meant that from day one our data 
was internationally comparable and it also gave 
us a certain amount of clout locally, when people 
came up with alternative suggestions, then we 
were able to say, ‘Well that’s a great suggestion, 
but it actually doesn’t conform to international 
practice and this is what the international practice 
is.’” [RE]
In Ireland, HIQA currently have a remit under the 
Health Act (Department of Health, 2007) for the HSE 
and services funded by the HSE. This includes  
monitoring standards for national data collections, 
setting standards for health information and  
developing guidance in this area and identifying 
deficiencies in the national health information 
landscape. HIQA achieve this primarily through the 
setting of recommendations which are submitted to 
the Minister for Health. Based on the current draft 
of the HIPS (Department of Health, 2014a), HIQA is 
expected to have a stronger role across the broader 
health information landscape as the Minister for 
Health would have provision under this legislation to 
prescribe specific health information resources and 
bring them into the scope of HIQA monitoring. HIQA 
would then set the standards for those prescribed 
resources and broaden their remit beyond the HSE 
including monitoring compliance against standards 
and reporting to the Minister (HIQA, personal  
communication, April 2016). Irish experts generally 
recognise that HIQA’s role is continually expanding 
and that it could encompass this kind of compliance 
monitoring but they question if HIQA has the  
competencies and capacity to provide true quality  
assurance for patient registries. They suggest that  
perhaps HIQA could be one link in a more comprehen- 
sive and registry-specific quality assurance process.
“There is a kind of a push to… harden up the 
approach… [to] apply standards as opposed to 
here’s some guidelines you might think of applying 
in any context… There’s an issue about capacity 
and how they [HIQA] would deliver on that.” [HI]
“So you would have an operations and a steering 
group. Now, you could have expert input on that 
steering group from quality assurance people like 
HIQA… but you would probably have to have your 
own quality assurance people on the operations 
side as well.” [CE]
3.5.1 Costs, funding and sustainability
Experts agreed that getting access to funding can be 
challenging. They also stressed that in addition to 
securing initial funding, it is important to be able to 
guarantee the sustainability of a dementia registry 
into the future. 
 “Registers are expensive. There’s no other way 
around it. You can’t run a register without  
spending money.” [RE]
“I think a challenge has been in terms of some 
smaller clinical registries which are set up on a 
more ad-hoc basis. In terms of the sustainability… 
funding, support and sustainability... would  
probably be the three biggest risks”. [HI] 
Registry experts spoke of the difficulty of obtaining 
funding for the initial set-up and the day-to-day run-
ning of patient registries and the constant challenge 
to grow patient registries in the current environment.
“Five years ago I went to my board and I sort 
of said we are going to have to close down the 
registry. We just can’t keep going… We applied for 
an HRB grant about a year ago, we got to the final 
adjudication phase and we didn’t cross the actual 
line, and one of our challenges is because we are 
not seen as a research establishment, so we are 
not academic... if you had a centralised registry 
foundation then straight away you can align  
yourself with the academics but you still can  
be independent. [RE]
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“Funding registers is difficult because the health 
services are not really interested in registers… 
they don’t see them as valuable, though I disagree, 
with respect to delivery of service, and research 
agencies and funding agencies for research won’t 
fund registers because they’re not outputs of 
themselves. So funding registers falls between 
two stools”. [RE] 
 “The way the law is written it does not exactly 
determine where the financing for the registry 
comes from, which is a problem, however until 
up to this moment there’s been a gentleman’s 
agreement let say where the state cover part of 
the funding for the registry so it’s helpful in that 
sense.” [RE] 
So, registries are not currently perceived by funding 
agencies as being of as much value as research out-
put, nor are health services particularly interested 
as they also often don’t see their value. One of the 
difficulties raised by Irish experts is the lack of clarity 
around where the responsibility for national registries 
lies in Ireland. There is currently a distinction between 
care provision (remit of the HSE) and national health 
policy (remit of DOH) but there seems to be an  
ambiguity between the two organisations in terms of 
who actually manages the funds for service delivery. 
This may be changing, but for the moment the  
responsibility still resides with the health service.  
Yet many experts, including those within the Irish 
health service, felt that the DOH should take a 
leading role. Overall, there was little agreement 
regarding who should be responsible for a national 
dementia registry in Ireland. The consensus that did 
emerge was that it would be best for this registry 
to be independent and that a champion would be 
needed in order for it to progress.
“And I do honestly believe that you need that 
national mandate for that and that national  
mandate comes from the Department of Health 
and it has to be supported by the HSE, but I do 
believe that it has to be led by the Department of 
Health and fully supported at that level.” [PE]
“I would say that the Department of Health not 
the HSE because there’s lots of places outside of 
the HSE. So it is more Department of Health.”  
[PE]
If the registry was not to have a national mandate 
with appropriate funding streams in place, there 
was a clear view that it should be linked to either an 
academic institution or to have research as one of 
its primary objectives in order to be able to access 
existing funding sources. Indeed, this is one of the 
reasons why using a registry to attract clinical trials 
is seen as beneficial. 
“When something like a dementia registry has to 
be developed from a source of funding that isn’t 
coming directly from government it’s very difficult 
to get the mandate that you need to actually  
enforce it. So I think it’s really important that it 
does actually come directly from government 
funding”. [PE]
“One way to support a registry like this would be 
as a research activity. There may be opportunities 
in terms of linking with cohort studies, ongoing 
clinical trials or other types of research and  
ultimately you might be able to fund it that way. 
But the problem here is that’s all so project  
specific and once the project is over, you might 
not be able to continue to fund it”. [CE]
Irish experts echoed the call for appropriate funding 
mechanisms and suggested that a National Dementia 
Registry could be funded through a combination of
Public-Private-Partnerships (PPP). These can comprise 
of some combination of public and private enterprise, 
government and academia (universities and university 
hospitals), health services, professional and patient 
associations and public payers. Other potential 
sources of funding were identified as the social care 
budget, the budget for older people and primary 
care. The argument being that if you were to look 
at the costs involved in supporting someone with 
dementia from diagnosis through home care (social 
needs, quality of life supports), formal care, acute 
care and palliative care, it is apparent that cheaper 
ways are needed to support people with these needs. 
“You’ve got to have a balance between evidence 
generation and having money for underlying  
provision and it’s a difficult one… But I suppose 
the Dementia Strategy down the line is going to 
have to look at a version 2, and if we had better 
evidence base we could decide on what the policy 
priorities should be [and that they would be 
based on] peoples’ lived experience.” [PE]
Yet, given the costs associated with establishing and 
running a patient registry, some experts questioned 
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the priority of funding national registries at a time 
when the health service is struggling for resources 
at every corner. Some experts seemed fearful of the 
gaps we might find if we went looking too closely at 
dementia care needs in Ireland. In some ways there 
was almost an argument against finding out about  
a demand that we already know we cannot meet.
“So we know the level of community-based  
supports is quite poor and then the pressure even 
on long-term care resource, Fair Deal and so on, is 
also immense … we know we are not in a position 
to provide enough support at the moment… If it’s 
under primary care we know that there are lots 
of calls on that funding already… memory clinics 
will probably be based in secondary care and we 
know again the demands in that sector can’t be 
met either and increasing waiting lists for fairly 
standard and basic procedures… So should we 
divert that scarce resource towards something 
like a dementia register, probably not right now, 
you know, as a balance of the benefits that would 
flow from it.” [PE] 
3.5.5 National strategic planning 
 regarding patient registries
In addition to considering the governance of a registry 
itself, a number of Irish experts identified the need  
for a national strategic approach to the creation and  
sustainability of registries, which supports the findings 
of the MRCG and IPPOSI (2011) report. There was a 
suggestion that this should be part of the remit of 
the Assistant Secretary General with responsibility 
for research, development and health analytics in 
the Department of Health. They have responsibility 
for developing strategy and policies regarding national 
health information. They are also in a good position 
to be able to look at the viability, sustainability and 
funding of national registries, the need for and  
efficiencies related to the gathering of national health 
information, and how it can best support policy. 
“I think there is a gap there in terms of oversight 
and governance of all of our national health  
information sources at a national level so …  
I think there is a move in that direction. I think 
people are identifying that there is this need  
for integration and oversight that’s missing at  
the moment” [HI]
Experts concur that national standards should 
specifically address robust governance arrangements. 
They also spoke about the need for a centralised 
resource to advise on issues of classification, coding 
and diagnostic standards. This does not need to be 
a permanent registry resource, although it can be. 
One registry has a pathologist and a haematologist 
on retainer for one session a week, for example,  
and they find this a great resource. 
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3.6 Theme 6: 
 Legislation
3.6.1 Data protection legislation
Privacy and data protection were key concerns within 
the data management theme discussed in section 
3.4.2 above. The legal data protection requirements 
are driven by the data that is being collected. If it is 
just the fact that a person has dementia, with some 
anonymised demographic characteristics, then this is 
of little impact, but if enhanced personal information 
is collected such as medical history, socioeconomic 
background, level of education and treatment plan, 
the more useful the data but the more data protection 
controls are required. That said, most experts felt that 
data protection legislation should not be seen as a 
barrier to collecting data, rather a framework that  
supports the confidentiality and privacy of the individual 
and facilitates data collection and sharing in a secure 
way. We should also learn from the various guidelines 
that have already been established in this area. 
Some experts mentioned the recent (May 2016) 
amendment to EU data protection legislation and 
recognised that some work would be required 
before we could be certain of the data protection 
needs for different types of registries in Ireland and 
the processes related to mandatory data collection 
and consent exemptions under this new legislation. 
“But data protection should not be seen as a  
barrier to obtaining this information. It’s a worth- 
while goal and it will ensure that the way you treat 
the information is proper and correct… Ultimately, 
it is very beneficial to the organisation and to the 
patients themselves. So while this may seem like 
unnecessary red tape, the whole idea is to safe-
guard the rights and privacy rights of the people 
who are giving their information, but it also safe-
guards your own reputation, because if you are 
seen to be haphazard in the way you manage the 
information, your reputation will be damaged.” [LE]
Privacy Impact Assessments (PIAs) are also being  
introduced as part of this legislation. This means that 
data protection can no longer be bolted on to the end 
of a data collection process. It needs to be completed 
in advance. Current expert opinion suggests that this 
will not be very complicated, but that it will mean 
planning in advance to ensure that the registry complies 
with the eight basic data protection principles; the 
most important being consent from the data subject. 
In	addition,	the	Article	29	Working	Group	has	been	
set up by the EU to interpret the eight principles and 
provide guidance to member states on how to put 
them into practice. Experts believe that this group 
will also provide guidance on how to obtain consent 
which would be beneficial to vulnerable populations 
such as those with dementia. This guidance would 
be welcomed by non-legal experts.
“What happens to other registries is that they do 
get tied up let’s say in the different understandings 
of what the data protection act means, and I 
think there needs to be an information for health 
type policy or piece of legislation around who can 
access what information, what information can be 
collected and the pieces around that.” [HI]
3.6.2 Other relevant Irish legislation
Experts only spoke about two other specific pieces 
of Irish legislation when asked to consider the legal 
requirements relevant to creating a national  
dementia registry: 
• The	forthcoming	Health	Information	and	
Patient	Safety	Bill	(HIPS)	and	the	related	
legislation	regarding	individual	health	
identifiers.	The	likely	impact	of	this	legislation	
has	been	discussed	under	the	Data	Collection	
theme	above.	There	was	definite	frustration	
at	the	length	of	time	this	legislation	was	
taking to come into force and a sense that the 
Department of Health was using the impending 
nature	of	this	legislation	to	avoid	answering	
specific	questions	regarding	patient	registries,	
data	collection	and	consent	exemptions.	
• The Assisted Decision Making (Capacity) Act 
2015.	This	has	been	discussed	in	relation	to	
obtaining consent in the Registry Data theme 
above.	People	with	dementia	felt	that	the	
Act was working to protect their rights and 
all experts welcomed the idea of having an 
elected person to support decision making, 
including	those	related	to	patient	registries.
“I suppose that act will provide a legal structure 
for us, which is very good that we have that 
structure and that for people to help us with our 
decisions, we can make our own decisions but 
also there’s a provision in there, as in the bill now, 
that we have somebody that will help us with our 
decisions.” [IDWG]
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3.7 Cross-cutting theme 1: 
 Benefits and risks
Overall the majority of experts agreed that dementia 
registries are worthwhile and have numerous benefits.
These predominately relate to the range of different 
objectives that a dementia registry would have and 
they have been described in the Registry Function 
theme above. The consensus is that it is vital to  
collect better dementia-related data and that it 
will be difficult to progress policy or to improve the 
quality of clinical care without this information. In 
particular, the collection of longitudinal dementia 
data can support improved diagnostic accuracy and 
better sub-typing of dementia. Additionally, the 
establishment of a national dementia registry would 
bring Ireland in line with international best-practice.
“Oh absolutely, there’s no doubt. I mean… I would 
be surprised if anybody would say there isn’t a 
benefit in collecting this information because as 
it is we say that we have approximately 50,000 
people with dementia but we actually really don’t 
know how many people we have in Ireland with 
dementia”. [PE] 
The majority of experts agreed that there are 
numerous risks to establishing a dementia registry, 
but these risks can be mitigated. Experts felt that 
the biggest challenge would be securing appropriate 
funding to ensure the sustainability of the registry. 
A number of concerns were also raised regarding 
privacy, confidentiality, data protection and data 
access. There was a sense that a degree of stigma 
is still associated with dementia and that this could 
prevent people with dementia providing consent 
for their data to be included in the registry and that 
there would be a higher risk for these individuals 
if these data fell into the wrong or inappropriate 
hands. Ensuring the ethical use of dementia registry 
data was therefore an important objective for all. 
Finally, those experts who had hands-on experience 
with patient registries cautioned that there was a 
real risk of not having a clear understanding of the 
aims and objectives of the registry. Without this, it 
will be difficult to design and implement a registry
that is fit-for-purpose and create appropriate data 
collection and data management processes. There 
would also be a very real danger of trying to attempt 
to do too much too quickly. Some experts felt that 
there was an over-emphasis on collecting registry 
data that meets the medical model of the disease 
and that it would be more beneficial to collect  
additional psychosocial data to ensure that a bio-
psychosocial model is facilitated by registry data 
collection.
“I think we just need to take the blinkers off. I 
mean, when people think of registries they just 
think of clinical trials, they think of treatment  
protocols… It’s a whole medical model... So we 
need to look at maybe further afield to see what 
other countries are doing and see how we can 
learn from those if there are more, I guess, socially 
orientated registries collected which include 
health and social care elements.” [HI]
Finally, health care organisations in Ireland were also 
seen as fundamentally not patient-centred and used 
to putting their own interests ahead of those of 
the patient. This was seen as a significant threat to 
achieving buy-in from data providers and the health 
service as whole.
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3.8 Cross-cutting theme 2: 
 Barriers and facilitators
Experts identified a number of barriers and facilitators 
to establishing a national dementia registry for Ireland, 
but interestingly there was a lack of consensus across 
the group; what were considered barriers for some, 
were facilitators for others. Registry experts argued 
that the main barrier was a lack of strategic policy 
and of a sustainable funding mechanism for patient 
registries. This view was shared by policy experts.
“I think the biggest challenge is money... the 
second biggest challenge is confidentiality and 
consent and trying to ensure that those don’t 
interfere	with	your	ability	to	register	100%...	this	
is something you have to be very, very careful 
about, that once you set it up, that you are  
looking	for	100%	capture”.	[RE]
The inherent difficulties and time-consuming nature 
of data collection, including the variety of locations 
in which a dementia diagnosis is made and the 
current poor state of eHealth and EHRs in Ireland, 
were also widely seen as detrimental to the creation 
of patient registries. Yet, while some felt that the 
unsuccessful implementation to date of IHIs was 
further proof of this, other experts felt that the fact 
that IHIs were in the pipeline could facilitate the 
data collection needs of a dementia registry. Similarly, 
some experts argued that the lengthy timeline that 
was likely to be needed for the national rollout of the 
SAT would be a barrier to the creation of a dementia
registry, but others saw SATs as reducing the amount 
of new data collection that could be needed and 
providing an additional opportunity to convert to 
EHRs for those that were assessed in this way. Further
barriers that were identified were the difficulties 
diagnosing and accurately coding dementia, a lack 
of clarity regarding the consent model to be used, 
a lack of a centralised ethical approval process and 
generally the length of time it takes to implement 
any policy or legislative changes in Ireland.
While many experts saw nothing but barriers  
associated with gathering dementia data from 
primary care providers, others felt that primary care 
was the best place to go for these data and that the 
forthcoming work to improve GP coding as part of 
the rollout of the National Dementia Strategy would 
facilitate the collection of these data. Many experts 
also felt that the recent Assisted Decision Making 
(Capacity) Act 2015 and the flexibility afforded by 
the latest EU Data Protection Directive create an  
environment more conducive to creating patient 
registries. There was a recognition that we can learn 
from dementia registry expertise in other jurisdictions. 
More importantly, we have significant patient registry 
expertise in Ireland not least with the CFRI and the 
OpenApp organisation that supports many of our 
registries. Finally, the positivity that people with  
dementia felt towards the idea of a dementia registry, 
particularly regarding the inclusion of anonymised 
data that could support policy and advocacy, is a 
clear facilitator to the creation of a registry albeit 
that there will be potential risks that the registry will 
need to mitigate. It would seem to be an opportune 
time to examine the feasibility of a national dementia 
registry given the current direction of Government 
strategy and the increasing focus on dementia. That 
said many experts were unsure if anyone would be 
willing to pay for it. 
“I think in general the health service’s leadership 
would welcome an informed approach as to how 
to actually deal with dementia. I also think there 
is an awareness that we don’t have sufficient data 
to actually plan for service provision for dementia 
patients.” [HI]
“There isn’t any national data register and that  
is something that was highlighted in the strategy, 
that there was a need for… if we are looking at 
kind of international best practice we do need  
a registry.” [PE]
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It was clear that there is still a stigma associated 
with the diagnosis of dementia and to some extent, 
there is a stigma associated with the idea of ‘being 
on a register’. Some experts worried that either or 
both of these would prevent people with dementia 
from seeking a diagnosis. In the former case there 
could be a concern about the ramifications of being 
placed on a dementia register with regard to who will 
see the data and the likely impact on an individual’s 
welfare, employment and insurance, for example. 
In the latter case, the very idea of being placed on 
a register could prevent people from seeking advice 
if concerned about potential cognitive impairment. 
Furthermore, the stigma and fear associated with 
dementia makes the receipt of a diagnosis a very 
difficult time for individuals and their families. This 
deters clinicians from making informed consent 
requests at this time and people with dementia 
expressed the concern that they might not be in the 
best place to make an informed decision at that time.
3
3.9 Cross-cutting theme 3: 
 Dementia-specific 
 challenges
There were a number of areas that were seen as 
particularly challenging with regard to the creation 
of a dementia registry above and beyond those likely 
to be encountered if creating a registry for other 
diseases. Dementia is a cluster of symptoms that can 
be hard to diagnose and open to subjectivity bias. It 
is not as easy to diagnose as a disease with a specific 
test or within a specific clinic which is the case for 
many of the rare disease registries that are currently 
in operation in Ireland. People with a diagnosis of 
dementia also typically have a range of co-morbid 
conditions and there is an argument against tracking 
dementia without also monitoring these as clinical 
care and dementia policy are impacted by the  
combination of these items and not just dementia 
alone. The degenerative nature of dementia provides
a further challenge with regard to capacity to provide 
informed consent, although there was recognition
that this challenge has been addressed in the research 
arena. The recent Assisted Decision Making (Capacity) 
Act 2015 will provide more support and direction in 
this area. 
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SUMMARY
The analysis of the expert interviews and focus groups revealed six themes with related  
sub-themes: 
1. Registry function
•  Provide	information
•  Enhance policy
•  Improve care
•  Support research
2. Registry data
•  Inclusion criteria and diagnosing 
dementia
•  Required data elements
•  Patient	consent
•  Anonymised	and	identifiable	data
•  Accuracy and comprehensiveness
3. Data collection
•  Data sources
•  Process	of	data	collection
4. Data management
•  Access
•  Privacy
•  Technical requirements
5. Registry governance
•  Governance structures
•  Registry ownership and 
independence
•  Registry quality
•  Costs, funding and sustainability
•  National	strategic	planning	regarding	
patient	registries
6. Legislation
•  Data	protection	legislation
•  Other	relevant	Irish	legislation
 
Three high-level cross-cutting themes were also identified:
•  Benefits and risks	–	The	majority	of	experts	agreed	that	dementia	registries	are	
beneficial.	Although	there	are	associated	risks,	these	can	be	mitigated.
•  Barriers and facilitators	–	The	main	barriers	to	developing	a	national	dementia	
registry	were	identified	as	a	lack	of	strategic	policy	and	of	suitable	funding	
mechanisms,	and	the	complexity	of	data	collection.	However,	recent	legislation	
changes,	the	availability	of	registry	expertise	in	Ireland	and	the	acknowledged	 
lack	of	dementia	data	were	considered	to	be	facilitators.
•  Dementia-specific challenges	–	the	complexity	of	a	dementia	diagnosis,	the	
degenerative	nature	of	dementia,	and	the	stigma	that	is	still	associated	with	the	
diagnosis	in	Ireland,	are	challenges	that	a	national	dementia	registry	will	need	 
to overcome. 
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4.1 Learning from experience
4.1.1 Lessons learned from existing 
 patient registries
It is clear from the discussions with registry experts 
in Ireland and in other jurisdictions that there are 
a number of key lessons that can be learned from 
their experiences. Many of these lessons are common 
to all types of patient registries and some to dementia 
registries or to Irish patient registries in particular 
(see Figure 3).
Those lessons that are common across all patient 
registries are:
• Clear aims and objectives are needed for the 
registry to be successful. The most important 
starting	point	for	any	registry	is	asking	‘What	 
is it that you want to know?’, ‘What is the value 
of	knowing	this	information?’	and	‘Where	do	
you want to get the data from?’ Experts also 
cautioned	against	trying	to	over-extend	and	
recommended	an	initial	focus	on	meeting	the	
primary	objectives	of	the	registry.
• Legislative support	is	considered	a	beneficial	
facilitator	when	setting	up	and	maintaining	
a registry. Registry experts reported that 
it	gives	legitimacy	to	the	registry	and	that	
it is advantageous with regard to securing 
funding, the sustainability of the registry 
and to accessing data sources and obtaining 
buy-in	from	data	providers.	While	legislative	
support can be advantageous it is important 
that the registry remains independent and is 
not	subject	to	any	undue	political	influence	or	
pressure directly from the health service itself.
• Stable funding is crucial for the longevity 
of a registry. It should be noted that while 
legislative	support	may	facilitate	funding,	
some	existing	registries	have	found	that	it	
does	not	guarantee	funding.	In	particular,	
budget	deficits	can	lead	to	cuts	in	funding.	All	
experts advised that the challenge of securing 
stable and sustainable funding should not be 
underestimated.	
Internaonal Demena Registries Irish Paent Registries
Demena Diagnosis
Privacy and Confidenality
Opportune Timing
Mulple Ethical Approvals
Data Sharing
Clear Aims and Objecves
Legislave Support
Stable Funding
Strong Relaonships
Registry Locaon
Paent Consent
Paent Recruitment
Data Collecon Complexity
Comprehensiveness of Data
Clear Outcome Measures
Governance
Quality
FIGURE 3  Lessons learned from international dementia registries and Irish patient registries.
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• Strong relationships are needed with health-
care professionals in order to capture accurate 
and	comprehensive	data,	although	getting	their	
buy-in	can	be	difficult	due	to	time	pressures,	
difficulties	diagnosing	dementia	and	the	
potential	implications	for	the	person	with	
dementia.	In	particular,	SveDem	learned	that	
in	order	to	ensure	adequate	representation	
of data the involvement of primary care 
general	practitioners	was	crucial	(Religa	et	al.,	
2015).	Building	supportive	relationships	with	
other	patient	registries	additionally	benefits	
a	new	patient	registry.	Wider	stakeholder	
(state, university, third sector and voluntary 
organisations,	patient	advocacy	groups,	
informal	caregivers	and	people	with	dementia)	
commitment and involvement is also crucial to 
the	success	of	a	registry.	A	close	relationship	
with	advocacy	organisations	is	particularly	
advisable	to	ensure	that	the	information	
provided	by	the	registry	positively	impacts	on	
patient	care,	and	‘passionate	drivers’	need	to	
be	identified	within	the	stakeholder	group.
• Registry location also needs careful 
consideration.	Locating	it	within	existing	
structures	can	support	security	and	continuity	
although again it is important that the 
independence of the registry is maintained. 
Location	within	a	university	can	facilitate	
access	to	additional	funding	streams,	to	
analytical	expertise	and	it	facilitates	the	
research	objectives	of	the	registry.
• Patient consent needs to be carefully 
considered.	The	NCRI’s	exemption	from	
the need to obtain consent has been very 
beneficial,	but	this	has	only	been	possible	
due	to	their	legislative	mandate.	Existing	
Irish	patient	registries	have	found	that	there	
can be a considerable delay in obtaining 
informed consent (e.g. up to six months) 
as	diagnosis	is	an	especially	sensitive	time	
for	patients	and	it	can	be	expected	that	this	
will be the case for people newly diagnosed 
with	dementia.	The	difficulties	of	obtaining	
consent	from	this	vulnerable	population	
must	also	be	considered.	Many	international	
dementia	registries	have	not	had	to	address	
this challenge as their mandate allows them 
to collect data without obtaining consent, but 
our experts felt that this challenge has been 
addressed in research context and a similar 
process could be adopted.
• Patient recruitment	is	essential	to	the	success	
of any registry and explicit goals and strategies 
must be set during the planning of the registry 
and	continually	monitored	and	adjusted	as	
needed	during	its	operation.
• Data collection is a complex process. Skilled 
staff	are	required	in	order	to	interpret	medical	
records accurately and registries should 
not	assume	that	frontline	clinical	staff	have	
sufficient	availability	to	be	able	to	complete	
this	task	without	adequate	incentives	to	do	
so.	All	existing	dementia	registries	highlighted	
data	collection	challenges	that	they	still	face.	
For example, SveDem acknowledge that 
primary	care	data	collection	requires	further	
improvement (Religa et al., 2015). SCADR are 
working	hard	to	increase	dementia	coverage	
from private health care providers (SCADR, 
personal	communication,	May	2016)	and	
ReDeGi highlight the importance of agreeing 
a	minimum	dataset	for	all	patients	from	all	
providers	(Garre-Olmo	et	al.,	2009).	UK	experts	
commented on the fact that they really have 
no	good	data	for	routine	epidemiology	at	the	
moment and that while linked data (across 
conditions,	co-morbidities,	clinicians)	would	
be ideal, especially for vulnerable older 
people, they have been working on this for 10 
years	and	they	are	still	not	there	yet.	So,	they	
advise that you have to start with something 
that	is	‘good	enough’	and	figure	out	how	to	
continually	improve	it	as	you	go	along.
• Data will never be truly comprehensive and 
registry experts recognise that there will 
always	be	an	unknown	portion	of	incident	
cases due to individuals not coming into 
contact with medical services and where 
diagnostic	processes	have	not	yet	begun.	
Other challenges are the number of ‘missed’ 
patients	who	are	diagnosed	but	not	reported	
and the lack of integrated data across public 
and private health care providers. This is a 
particular	issue	in	the	Irish	health	system.
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• Clear unambiguous and tangible outcome 
measures are required that facilitate accurate 
interpretation	of	registry	findings	and	enable	
the	registry	to	meet	its	objectives.
• Registry governance must be formalised 
but not unwieldy. Board members should 
comprise	of	representatives	from	the	registry	
and external experts including someone with 
previous	registry	expertise.	The	selection	
of the right Chairperson is also vital. This 
should be someone who is strong, dynamic, 
enthusiastic	and	highly	committed	to	achieving	
the aims of the registry. 
• Quality evaluations are vital in order to ensure 
that all required data are entered and valid 
(e.g.	the	consistency	of	dementia	diagnoses)	
and that it meets the purpose for which it was 
collected.	There	was	a	clear	recommendation	
that	the	results	of	these	evaluations	should	be	
published. 
Only one area emerged that was specific to the 
creation and operation of dementia registries – 
standardisation of dementia diagnoses. Dementia 
registries are challenged by the subjectivity of a 
dementia diagnosis. It has been demonstrated that 
diagnosis is complex and differences are often seen 
between medical specialities (geriatrics, psychiatry 
and neurology); even when mutually agreed  
diagnostic criteria exist, clinicians may still differ 
in how the criteria are applied (Garre-Olmo et al., 
2009;	Johannsen	et	al.,	2011).	Standardisation	of	 
dementia diagnoses is needed to protect the credibility 
of the data, along with an emphasis on training  
physicians and other clinical personnel in achieving 
and coding accurate dementia diagnoses. 
Lessons learned from patient registries in Ireland 
are:
• Privacy and Confidentiality needs to be 
assured for those registered and all Irish 
experts underlined the importance of having 
strict policies in place to protect individuals. 
Many	experts	highlighted	confidentiality	as	
being one of the key challenges faced when 
setting	up	a	registry,	in	addition	to	funding	and	
patient	consent.
• Opportune timing can be instrumental in the 
setting	up	of	a	new	registry.	For	example,	the	
NCRI	was	established	at	a	time	where	local	
pressure, a central government need for cancer- 
related	data,	cross-border	collaboration	and	
the establishment of cancer registries in other 
European countries came together. It can also 
be	helpful	if	opportunities	are	available	with	
other smaller countries/regions to pool 
resources, energy and momentum in order 
to make progress (e.g. Republic of Ireland, 
Northern Ireland and Scotland or other EU 
countries).
• Multiple ethical approvals are currently 
needed	from	the	plethora	of	ethics	committees 
relevant	to	different	sectors	of	the	health	
system in Ireland. All experts commented on 
the	time-consuming	nature	of	this	approach	
and	highly	recommend	the	creation	of	a	
centralised process.
• Legal difficulties arise with regard to sharing 
data	across	different	health	institutions	in	
Ireland	as	each	is	a	separate	legal	entity.	It	
was felt that this is something that needs to 
be	dealt	with	as	a	matter	of	urgency	and	that	
primary	legislation	will	be	needed;	governance	
or	regulatory	directives	will	not	be	sufficient	to	
establish	a	firm	legal	basis	for	data	collection,	
research and data sharing with regard to 
patient	registry	data.
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4.1.2 Characteristics of successful 
 registries
Registry success was succinctly defined as “careful 
planning + active upkeep” by the Milken Institute 
(2016). It is possible to determine the characteristics 
of successful patient registries by combining the 
findings from the rapid literature review and the 
existing patient registry guidelines (Australian  
Commission on Safety and Quality in Health Care, 
2008;	EyeNet	Sweden,	2005;	Gliklich	&	Dreyer,	2014;	
Milken Institute, 2016; Newton & Garner, 2002) with 
expert opinion and lessons learned in the creation 
and ongoing operation of existing patient registries. 
These characteristics are:
• Clear,	focused	and	agreed	aims	and	objectives.
• Tangible	benefits	from	the	outset.
• Stable funding.
• A registry designed with respect to its primary 
purpose.
• Clearly	defined	inclusion	and	exclusion	criteria	
for	registry	participation.
• Clearly	defined	data	sources.
• Clearly	identified	and	agreed	minimum	data	
set.
• Minimal	data	collection	–	concise	and	relevant	
information	is	gathered	and	duplication	is	
avoided.
• Data	collection	methods	that	match	the	
specific	needs	and	objectives	of	the	registry.
• Data	collection	methods	that	are	adaptable	 
to	local	variation	in	how	care	is	provided.
• Data providers are reimbursed for work 
required to provide data to the registry  
(e.g.	GP	practice	software	suppliers	in	the	
UK	are	reimbursed	for	the	cost	of	extracting	
minimal data from their systems).
• Data and reports that are useful to front-line 
clinical	staff.
• Web-access to registry reports (and in many 
cases data entry).
• Clear and transparent plans for governance 
with	explicit	roles	and	responsibilities	for	all	
stakeholders.
• Patients	expect	to	and	are	treated	as	partners.
• Clear ownership of the registry (data and 
functions).
• Clear and visible leadership.
• The	establishment	of	a	multidisciplinary	
registry team – all disciplines involved in 
providing	care	to	the	target	patient	group	 
are involved.
• A dedicated registry administrator with 
guaranteed funding. 
• Formal	procedures	relating	to	consent,	privacy	
and	confidentiality	and	data	protection	
adherence that are established at the outset.
• Formal procedures for data analysis, 
publication	and	data	sharing	–	plans	for	
managing	potential	conflicts	of	interest	are	
advisable.
• Formal	quality	control	and	registry	evaluation	
procedures.
• Flexibility	to	adapt	to	changing	conditions.
• Registry	functions	include	raising	awareness	 
of the value of and the need for the registry.
• Educational	support	is	provided	for	all	those	
interacting	with	the	registry.
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4.1.3 Characteristics of poorly 
 performing registries
It is also easy to identify the characteristics of poorly 
performing registries, namely:
• Lack of funding.
• Lack	of	strategic	policy	direction	and	support	
for the registry.
• Registries that were driven by one person who 
subsequently	retired	or	lost	interest.
• Unclear	or	conflicting	aims,	objectives	and	
outcome measures.
• Trying to do too much too quickly.
• Inability to mobilise registry data to inform 
clinical	practice	and	public	health	policy.
• Overly	inflated	ambitions	of	how	much	data	
could be collected.
• Lack	of	recognition	of	the	time	required	to	
collect data. 
• Incomplete data.
• Out of date data.
• Inaccurate and poor quality data.
• Understaffed	registries.
• Too	high	a	data	collection	burden	on	front-line	
health professionals.
• Inability	to	attract	participants.
• Poor stakeholder buy-in and/or lack of 
clarity regarding stakeholder roles and 
responsibilities.
• Disparate and non-standard data sources, or 
too	many	small	databases,	that	are	too	difficult	
to bring together.
• Inadequate technical infrastructure (e.g. MS 
Excel spreadsheets, MS Access databases) that 
cannot adequately support governance and 
data security needs.
One concern regarding the suggested Patient  
Registries Framework in the MRCG and IPPOSI (2011) 
report, and presented in section 2.4.1 above,  
is that although not its intention, it may seem to  
support a move towards establishing less complex 
and less costly patient databases in individual 
clinical settings with the assumption that these 
databases can be brought together at some future 
point to form a national patient registry. As has 
been demonstrated with other diseases and in other 
jurisdictions, this is not as simple as it seems and it 
has often been unsuccessful. The most successful 
registries instead commence with a design that is 
suitable and scalable to a national level even if the 
first implementations are less ambitious.
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4.2 The road to a National 
 Dementia Registry for 
 Ireland
This report brings together extensive evidence and 
analysis on the feasibility of establishing a National 
Dementia Registry for Ireland. It is clear that there are 
a number of key questions that need to be answered 
and key decisions that need to be made in order to 
develop a comprehensive proposal for a national 
dementia registry and these are discussed in this 
section. We also recommend actions that can be 
taken to advocate for a suitable policy and legislative 
environment conducive to the effective operation of 
any registry.
4.2.1 Getting started
The first questions that need to be addressed relate 
to establishing clear leadership to drive this debate 
forward, identifying all those interested parties that 
need to be involved in the discussion and decision-
making with regard to its establishment, and  
identifying funding to support the creation of  
a comprehensive registry proposal. 
Question 1: Who will take the lead in furthering the 
discussion regarding the feasibility of the National 
Dementia Registry of Ireland?
One individual (or one organisation) should have 
overall responsibility for driving these discussions 
forward, but they will not be able to do this alone.  
It is also important that this individual is someone 
who is enthusiastic about and committed to the 
aims and objectives that the national dementia 
registry is setting out to achieve.
Question 2: Who are the stakeholders that need to 
be involved in these discussions?
Relevant stakeholders need to be identified from all 
interested parties including those from government, 
health and social care services, patient organisations, 
people with dementia and their families, academia 
and industry. An expert group should then be 
established to guide the future development of the 
registry and to ensure that the proposed registry has 
a sound financial, clinical and scientific basis. The 
expert group will determine the primary aims of the 
registry and the initial data content and data  
collection processes. It will be very important that 
the expert group includes the voice of the person 
with dementia and that of their family carers. 
Question 3: Is creating a national dementia registry 
the right thing to do (a) at all and (b) now? 
A fundamental question that needs to be addressed 
is the value of creating a national dementia registry 
for Ireland. The need for a dementia registry needs 
to be formally debated and suggestions that our  
dementia data needs could be provided in another 
way need to be considered. Being able to answer 
these questions will be important in terms of arguing 
the need for a dementia registry and countering 
challenges to this position and to concerns that this 
is not the right time to consider establishing this 
registry given budgetary constraints and the current 
state of the Irish health and social care system. For 
example, the most proximal goal of a dementia  
registry for people with dementia is the improvement 
of patient care. Objectives such as public health and 
research, while still important, are typically more 
distal. So in this case if findings based on registry 
data can enable more parsimonious and equitable 
care for people with dementia, the idea of funding 
this registry from existing money within the health-
care system needs to be discussed with this in mind.
Question 4: What funding is needed to support 
proposal development?
It will be necessary to secure funding for the develop- 
ment of a comprehensive registry proposal. The 
expert group will need to estimate the likely costs 
involved in this work, identify potential funding 
sources and secure the appropriate funding to 
progress to proposal development. It is difficult 
to determine where this funding can be sourced 
from. Government support will undoubtedly be 
required either directly to make funding available 
for the development of this proposal (e.g. through 
the National Dementia Strategy Office) or indirectly 
through the setting of research funding priorities 
with the HRB.
Associated issues: 
lack of funding for patient registries.
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4.2.2 Determining the scope and 
 design of the Registry
It is clear that a National Dementia Registry for 
Ireland should be designed with respect to the 
main function that it is being created to support. 
This primary objective will drive the registry model 
selected, the data that are required and all of the 
processes and procedures necessary to develop 
and operate the registry effectively, efficiently and 
ultimately successfully. 
Question 5: What are the primary aims and  
objectives of an Irish national dementia registry? 
A case can be made for establishing a dementia 
registry to provide better dementia-related data in 
Ireland to enhance policy, to improve patient care 
and to support research. Trying to address all of 
these objectives at the outset will be challenging. 
The costs and benefits of addressing each needs to 
be examined and a roadmap developed such that 
a focused set of objectives are initially delivered 
but that the registry is designed to enable further 
growth over time. 
Question 6: What outcome measures should be 
included in the registry? 
Policy and clinical requirements need to be translated 
into measurable items and outcomes that can be 
included in the registry database.
Question 7: What is the scope and who are the 
target population of the registry? 
The inclusion and exclusion criteria regarding whose 
data will be captured and stored in the database 
will need to be established such that they facilitate 
unbiased data collection. Best-practice suggests that 
a formal diagnosis of dementia should be required, 
but issues such as inconsistencies in the assessment 
and coding of dementia need to be addressed as 
part of this process. Advances are being made to 
standardise and improve coding of dementia in GP 
practices as part of the rollout of the National  
Dementia Strategy and it would be opportune to 
capitalise on this work with regard to being able  
to use these data to populate a national dementia 
registry. 
Associated issues: 
lack of standardisation of dementia diagnoses,  
inconsistent coding of dementia and lack of  
adequate coding of dementia in primary care.
Question 8: What data will be collected?
The primary purpose of the registry will drive the 
data that needs to be collected. A minimum dataset 
will be required without which the registry cannot 
operate effectively. This minimum dataset should 
be mandatory for all data providers. Additional data 
items can then be mandatory or optional depending 
on their centrality to the primary aims and objectives 
of the registry, their general availability and the cost 
of their collection. Standardised data definitions will 
be required for all data items under consideration 
for the registry. These definitions must be clearly 
described in a well maintained data dictionary. Data  
sharing, data security and data confidentiality 
processes will be required in order to maximise 
the value of linking data from different sources and 
across different national and international registries.
Associated issues: 
lack of standardised definitions for dementia-related 
data and the need to create and maintain a dementia 
data dictionary.
Question 9: Where will these data be sourced?
Dementia is not diagnosed in one place in Ireland 
and it would seem inevitable that data will need 
to be collected from primary and secondary data 
sources. This in turn requires the ability to match 
data from these sources for a given patient. It is 
unlikely that IHIs will be rolled out nationally in 
the near term, but it has been demonstrated that 
data matching is possible without the availability of 
unique patient identifiers although they do simplify 
the process greatly.
Associated issues: 
method of determining unbiased case definition 
(inclusion and exclusion criteria); lack of standardisa-
tion of dementia diagnoses, inconsistent coding of 
dementia and lack of adequate coding of dementia 
in primary care; lack of readily available unique 
patient identifiers, lack of clarity regarding the 
operation of unique health identifiers and the final 
content and timing of the HIPS bill; the need to hold 
at least some identifiable data in the registry to 
facilitate data matching and the need for consent  
to collect and hold these data.
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Question 10: What consent process is required to 
gain access to these data?
Given the increasing importance of privacy impact 
assessments in Ireland, a PIA should be carried out 
on the proposed dataset for a national dementia 
registry. The results of this PIA will drive data  
protection and security requirements and it will also 
inform the debate regarding the most appropriate 
consent mechanisms for the registry. 
It will need to be established at the outset if a 
national dementia registry will have a legislative 
mandate to collect data (anonymised or otherwise). 
If this were unavailable or if it did not cover all  
required data items, appropriate consent mechanisms 
will need to be put in place. It will be important to 
achieve the right balance between privacy and the 
common good and to have a data protection process 
that is rigorous, robust and fair, but also facilitates 
the data collection and sharing needed to improve 
health policy and research in Ireland. A tiered consent 
process would seem the most pragmatic approach 
at this time.
Associated issues: 
lack of strategic national policy regarding patient 
registries including the lack of clarity around patient 
consent; lack of clarity regarding the Irish legislation 
that will ratify the recent EU Data Protection Directive.
Question 11: How will the data be collected and 
stored?
Data collection procedures and the associated staffing 
requirements will need to be investigated. The lack 
of electronic records will be problematic and although
the MRCG and IPPOSI (2011) are calling for the 
mandatory introduction of EHRs for certain disease 
categories, this is unlikely to occur in the near term. 
It is more likely that registry data will need to be 
captured by front-line staff, by registry staff located 
with front-line data providers, or by registry staff 
secondary to front-line dementia care. The ramifica-
tions of each of these options in terms of time, cost 
and likely incentives need to be evaluated. Options 
such as web entry, automatic data transfer where 
electronic records exist (e.g. GP practices) and the 
technical infrastructure needed to support data  
collection and storage need to be considered.  
Ultimately, a standardised implementation process 
will be required for all data providers to ensure 
consistency and reduce bias in the data collection 
process.
Associated issues: 
lack of clarity regarding the operation of unique 
health identifiers and the final content and timing 
of the HIPS bill; poor electronic recording of patient 
data, lack of an agreed policy with regard to EHRs 
in Ireland and the lengthy timeframe that will be 
required even if EHRs became recommended policy. 
Question 12: How will registry data be analysed 
and results disseminated?
The outcome measures established for the registry 
will determine the data analysis and reporting needs 
of the registry. In most cases the registry is responsible 
for carrying out this work but it often has support 
from academia or specialist statistical centres. There 
is some overlap here with the governance of the 
registry and strategic partnerships are likely to be 
required. In addition, arrangements need to be 
established to determine how outputs from the 
analysis of registry data will be disseminated. Secure 
data access procedures will be required to ensure 
that data protection legislation is adhered to. It may 
also be possible that the registry’s strategic partner 
would be willing to house the dementia registry 
database within their I.T. infrastructure, therefore 
reaping the benefits of existing security protocols. 
Associated issues: 
lack of a legislative basis for data sharing across Irish 
health and social care institutions; need for strategic 
partnerships to provide the registry with the expertise 
needed to perform the necessary statistical analyses, 
data protection and data security.
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Question 13: What is the most appropriate and 
practical design for the registry?
It will be important to select the most appropriate 
and practical design for the registry with an eye to 
future growth potential. As already indicated in  
Section 2.3, no one ideal model for a dementia  
registry has as yet been established. It has been  
argued that design should be based on the objective 
of the proposed registry (González, 2015). The 
answers to the preceding questions will therefore 
be needed in order to select the most appropriate 
model for an Irish dementia registry. 
The MRCG and IPPOSI (2011) argue that while patient 
registries remain the gold standard, patient data-
bases have the potential to develop into registries 
as resources and time permit. Previous dementia 
registries that have tried to bring disparate patient 
databases together have found this very difficult and 
they typically have been unsuccessful. Re-consent 
processes are also needed where data are used for 
a purpose other than that for which it was originally 
collected. While a comprehensive model similar  
to that used in Sweden might be preferred, it is  
possible to adopt a phased approach to building  
a registry but the initial design of the registry must  
be pragmatic, sensitive to the challenges of the Irish 
health system and future-proofed to facilitate this 
growth. Typically the first phase of development 
is used to decide what data needs to be collected, 
who will collect it and how it will be collected. It 
includes a pilot implementation of these processes 
to determine the suitability of the data collection 
methods based on patient recruitment rates, data 
quality evaluations and feedback from the clinicians 
and patients providing the data. Subsequent phases 
involve national implementation of the core registry 
functions followed by expansion to include new data 
sources, secondary registry objectives and other 
potential updates required to adapt to a changing 
health care environment. It is vital that a strategic 
plan for a phased implementation exists from the 
outset. In many cases where this was expected to 
evolve from the first pilot, registries have failed to 
achieve their full set of objectives and have ceased 
to operate. 
Pilot studies are very common in the Irish health 
system but few are implemented nationally. There is 
a significant danger that excessive pilot studies have 
now limited the buy-in needed from data providers 
to make a success of future studies. That said, Irish 
patient registries such as the CFRI and the IPFR have
been successful with phased implementations and 
their models could be applied to setting up a national 
dementia registry in Ireland. The IPFR benefits from 
being kept on CFRI’s server. In addition to the technical 
benefits, the close relationship with a pre-existing 
registry also affords IPFR the opportunity to benefit 
from CFRI’s experience and expertise. This removes 
the need for a newly established registry like IPFR to 
‘reinvent the wheel’ regarding the basic principles of 
operating a registry. The National Dementia Registry 
of Ireland should consider establishing close links 
with the CFRI and with the ‘gold-standard’ Swedish 
dementia registry when investigating the most  
appropriate and pragmatic model for an Irish registry. 
Consultation with a software company with expert 
knowledge of patient registries and the healthcare 
environment in Ireland would also be recommended. 
Associated issues: 
development of disparate sets of patient data and 
unstandardised data collection processes that cannot 
subsequently be amalgamated into a single working 
registry; potential need to re-consent for data uses 
not considered in the original consent process.
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4.2.3 Ensuring the sustainability of the 
 registry
Looking at the feasibility of a national dementia  
registry is just the first step and part of the work 
of the registry group will be to determine how to 
sustain the registry in the longer term.
Question 14: What are the potential long-term 
sources of funding for a national dementia  
registry?
While Question 4 above considered the relatively 
small amount of funding required to prepare a  
detailed proposal regarding the development of a 
national dementia registry for Ireland, significantly 
more funding will be required to develop and sustain 
the registry itself. Potential funding sources will need 
to be identified for the creation and the ongoing 
operation of the registry. It is not current practice 
for research funding to cover the establishment of 
patient registries, so existing funding structures will 
have to change to facilitate this need or a new  
national funding structure for registries will need  
to be established. It is not currently clear where this 
new funding is likely to come from and a range of 
options including government funding, PPPs and 
support from other stakeholder groups must be 
considered. 
Associated issues: 
lack of national strategic direction with regard to 
patient registries; lack of availability of national 
funding sources for patient registries; uncertainty 
regarding the likely costs of such a venture.
Question 15: What are the costs involved in initially 
developing the registry and what are the potential 
ongoing operational costs?
Experts in international dementia registries, Irish 
patient registries and the technical development 
and design of patient registries will need to be 
consulted in order to estimate the costs involved in 
creating and running a dementia registry in Ireland. 
A number of manual steps are likely to be required 
and therefore need to be included in the costs, at 
least in the short-term. It is likely that some of this 
cost can be reduced in the longer term if IHIs and 
EHRs become common place in the Irish healthcare 
system, but the lack of certainty regarding these 
proposals means that they should not be considered 
as a given when first developing the registry.
Associated issues: 
consent requirements (and the potential for a 
national mandate to support the registry); registry 
scope and design; reporting and evaluation needs of 
the registry; potential to co-locate the registry with 
other existing patient registries and/or academic 
institutions that may provide shared value regarding 
technical infrastructure, data management, data 
validation support, statistical and analytical support 
and prior experience with similar datasets.
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4.2.4 Delivering a quality dementia   
 registry
The remaining questions relate to the governance 
and evaluation of the registry. 
Question 16: Who will own the National Dementia 
Registry of Ireland?
A clear owner needs to be established for the 
National Dementia Registry of Ireland. All expert 
opinion recommends that the registry should be 
established as an independent entity. If this is not 
possible, giving responsibility to an existing HSE 
directorate or to an existing agency such as HIQA is 
suggested (MRCG & IPPOSI, 2011). The implications 
of the lack of independence in this instance needs 
careful consideration. While locating a registry 
within the Department of Health or the HSE might 
be additionally attractive from a funding and a data 
protection perspective, it presents real challenges  
in terms of the comprehensiveness of the data  
collected (e.g. omission of data from private  
providers), having the expertise to operate a registry 
successfully and ensuring that all objectives are met. 
It has also been demonstrated that this does not 
guarantee sustainable funding when budget cuts are 
being made.
Associated issues: 
Lack of strategic policy with regard to the responsibility 
for patient registries in Ireland; potential conflict 
between funding providers and the goal of an  
independent registry.
Question 17: How will the National Dementia  
Registry of Ireland be governed?
Registry management and governance teams should 
be selected on the basis of their expertise and  
experience. The Swedish Dementia Registry and the 
CFRI have comprehensive governance structures 
that can be used as exemplars. They recommend 
setting up a steering group to ensure the registry  
is run according to its aims and objectives and  
patients’ rights are respected. This group should  
also govern the use of registry data including all  
data access requests for research projects. 
Question 18: How can the quality of the registry be 
assured and maintained?
Quality is not something that can be inspected into 
a registry at the end of the process and it therefore 
needs to be considered at the outset. Developing 
standardised data definitions and dementia codes, 
comprehensive and transparent data inclusion and 
data collection processes, reviewing all potential 
sources of bias and undertaking the appropriate 
practical steps to address these biases will be  
essential to ensure the quality of registry data. It 
will also ensure that biases inherent in the data are 
quantified and suggest how these systematic errors 
could impact on the use of registry data. Additionally, 
external periodic evaluation of the registry is  
recommended. 
Associated issues: 
lack of a national patient registry strategy and clarity 
of HIQA’s role with regard to patient registries that 
encompass all healthcare providers (i.e. not just 
those within the HSE), and concern regarding HIQAs 
competence and expertise to comprehensively 
evaluate patient registries.
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4.2.5 Advocating for strategic policy   
 and legislation to support patient 
 registries 
There are a number of actions that will be required 
to support the successful development of patient 
registries in Ireland and this is an opportune time  
to advocate for patient registry needs. In terms  
of strategic policy, the registry team should be  
advocating for:
• A	national	strategic	policy	with	regard	to	
patient	registries.
• Clear	long-term	funding	streams	for	patient	
registries.
• The	inclusion	of	dementia	as	a	priority	disease	
category.
• Categorisation	of	dementia	as	a	chronic	illness	
and	review	of	dementia	care	as	part	of	the	
upcoming	renegotiation	of	GP	contracts.
• Standardisation	of	dementia	coding	within	
primary care and across primary and 
secondary care.
With regard to legislation, the registry team should 
engage with the Departments of Health and Justice 
to advance and positively influence the following 
legislation: 
• Irish	implementation	of	the	EU	Data	 
Protection	Directive	2016.
• Nationwide	implementation	of	IHIs.
• Clarification	of	the	content	and	timeline	 
for the outstanding HIPS bill.
• Data sharing across Irish health and social  
care providers.
To achieve this, it will be essential for the registry 
team to increase awareness of the value of patient 
registries and the specific benefits of having a  
National Dementia Registry for Ireland.
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SUMMARY
This report brings together extensive evidence and analysis on the feasibility of establishing  
a National Dementia Registry for Ireland. It presents the lessons that can be learnt from  
international dementia registries and from existing patient registries in Ireland. The  
characteristics of successful patient registries demonstrate good practice. Those of poorly 
performing registries illustrate common pitfalls to be avoided.
It is also clear that a number of key questions need to be answered and key decisions need 
to be made in order to develop a comprehensive proposal for a national dementia registry. 
These are:
•  Who will take the lead in furthering the discussion regarding the feasibility of the 
National	Dementia	Registry	of	Ireland?
•  Who are the stakeholders that need to be involved in these discussions?
•  Is	creating	a	national	dementia	registry	the	right	thing	to	do	(a)	at	all	and	(b)	now?
•  What funding is needed to support proposal development?
•  What	are	the	primary	aims	and	objectives	of	an	Irish	national	dementia	registry?
•  What outcome measures should be included in the registry?
•  What	is	the	scope	and	who	are	the	target	population	of	the	registry?
•  What data will be collected?
•  Where will these data be sourced?
•  What consent process is required to gain access to these data?
•  How will data be collected and stored?
•  How will registry data be analysed and results disseminated?
•  What	is	the	most	appropriate	and	practical	design	for	the	registry?
•  What	are	the	potential	long-term	sources	of	funding	for	a	national	dementia	registry?
•  What	are	the	costs	involved	in	initially	developing	the	registry	and	what	are	the	 
potential	ongoing	operational	costs?
•  Who	will	own	the	National	Dementia	Registry	of	Ireland?
•  How	will	the	National	Dementia	Registry	of	Ireland	be	governed?
•  How can the quality of the registry be assured and maintained?
In addition, the registry team must advocate for a suitable policy and legislative environment 
conducive to the operation of any patient registry in Ireland.
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5 Conclusion
There are many challenges facing health and social 
care systems in Ireland but these can be met with 
proper planning underpinned by comprehensive and 
accurate data. There is general agreement in the 
literature that patient registries have a role to play 
in national public health strategies and that they can 
facilitate improvements in policy and patient care 
as well as supporting related research endeavours. 
Successful registries aim to capture data from the 
patient’s point of entry into the health system and 
across all interactions that they have with health and 
social care services once in. They also demonstrate a 
clear need for collaboration and data sharing to take 
place across health and social care services including 
public, private and voluntary providers. The creation 
of relatively effective and efficient patient registries 
in Ireland, such as the Cystic Fibrosis Registry of  
Ireland, demonstrates that a lot can be achieved 
within the limitations of the current Irish health 
system. 
With regard to dementia, there is undoubtedly a 
need for more accurate and comprehensive data in 
Ireland and the development of a national dementia 
registry would certainly address this need.  
International evidence and expert opinion suggests 
that the construction and population of a dementia 
registry is feasible, but that the costs of such a  
solution cannot be underestimated. Initial develop-
ment will be complex due to: 
• a lack of funding mechanisms to support 
patient	registries;	
• a	lack	of	awareness	of	the	value	of	investing	 
in these registries; 
• difficulties	and	inconsistencies	in	making	 
a	dementia	diagnosis;	
• the lack of standardised coding structures  
and	data	definitions	related	to	dementia;	
• the	fragmented	nature	of	dementia	care	in	
Ireland and poor data recording structures 
in hospitals and within the broader health 
service. 
Although a number of concerns will also need to be 
examined regarding privacy, confidentiality and data 
protection, robust legislation and guidelines exist to 
assist with this process, and many of these issues 
have already been addressed in other jurisdictions 
and in a research context. 
The findings of this study suggest that the benefits 
of developing a national dementia registry make the 
required investment worthwhile as long as the  
registry has clear and focused aims and objectives, 
solid data management and data collection processes, 
produces credible results and is demonstrably fit- 
for-purpose. The funding for such a registry needs  
to be discussed in light of these key objectives (i.e.  
a definitive understanding of what the registry is for) 
as they will guide the identification of appropriate 
funding sources and the prioritisation of the  
dementia registry in comparison to other potential 
calls on this money. Clear leadership will be required 
to win the ‘hearts and minds’ of the stakeholders 
that will be involved and the people with dementia 
who will provide their data to the registry. Ireland 
can and should learn from the development of  
dementia registries in other jurisdictions and the  
development of other patient registries in Ireland. 
Ideally a national strategic policy on patient registries, 
adequate funding mechanisms, data sharing  
legislation and a robust eHealth system that includes 
unique health identifiers would be pre-requisites  
to the development of the registry, but one of the  
biggest challenges in Ireland is the length of time 
policy development and legislative and regulatory 
changes take and the long-awaited Health  
Information and Patient Safety Bill (HIPS) is a case  
in point. Were we to wait for each of these pre- 
requisites to arrive, it is likely that the National  
Dementia Registry would never be developed. 
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Appendix:  
Acronyms and abbreviations 
ACT Adult Changes in Thought (programme)
AD Alzheimer’s Disease
ADRD Alzheimer’s disease and related disorders 
ASI The Alzheimer’s Society of Ireland
BDRS Blessed Dementia Rating Scale
BMI Body Mass Index
CDCR Camberwell Dementia Case Registry 
CDR Clinical Dementia Rating Scale
CE Clinical Expert
CEO Chief Executive Officer
CERAD Consortium to Establish a Registry for Alzheimer’s Disease
CF Cystic Fibrosis
CFRI Cystic Fibrosis Registry of Ireland
CRIS Clinical Record Interactive Search (system)
CT Computerised Tomography
DCDR Danish Clinical Dementia Registry
DCU Dublin City University
DoH Department of Health
DPO Data Protection Office
DSM-IV-TR Diagnostic and Statistical Manual of Mental Disorders-Version 4-Text Revision
EHR Electronic Health Record
EPR Electronic Patient Record
EU European Union
EUDP European Union Data Protection Regulation 2016
FAQ Functional Activities Questionnaire
GARDR Georgia Alzheimer’s and Related Disorders Registry 
GDPH Georgia Department of Public Health
GP General Practitioner
HI Health Informatics Expert
HIPAA Health Insurance Portability and Accountability Act
HIPS Health Information and Patient Safety Bill
HIQA Health Information and Quality Authority
HRB Health Research Board
HSE Health Service Executive
ICD9 International Classification of Diseases Ninth Edition
ICD10 International Classification of Diseases Tenth Edition
ICPC International Classification of Primary Care
IDWG Irish Dementia Working Group
IHI Individual Health Identifiers
IHRF Irish Health Research Forum
ILD Interstitial Lung Disease
IPF Idiopathic Pulmonary Fibrosis
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Appendix:	Acronyms	and	abbreviations
IPFR Idiopathic Pulmonary Fibrosis Registry
IPPOSI Irish Platform for Patients’ Organisations, Science and Industry
IT Information Technology
ITS Irish Thoracic Registry
LE Legal Expert
MCI Mild Cognitive Impairment
MMSE Mini Mental State Examination 
MRCG Medical Research Charities Group
MRI Magnetic Resonance Imaging
NCRI National Cancer Registry of Ireland
NHS National Health Service (UK)
NIA National Institute on Aging
NYSDR New York State Alzheimer’s Disease and other Dementias Registry
PE Policy Expert
PIA Privacy Impact Assessment
PPP Public-Private-Partnerships
PwD Person with Dementia
RE Registry Expert
ReDeCAr Centralised Registry of Cases with Cognitive Impairment in Argentina
ReCeDemCu Cuban National Dementia Registry
ReDeGi Registry of Dementia in Girona
Res Research Expert
RKKP Danish Clinical Registries 
RSG The Health Region of Girona
SALAR Swedish Association of Local Authorities and Regions
SAT Single Assessment Tool
SCADR South Carolina Alzheimer’s Disease Registry
SveDem Swedish Dementia Registry
TRO Tumour Registration Officer
UCLA University of California in Los Angeles
USC University of South Carolina
WADPR Washington Alzheimer’s Disease Patient Registry
WVADR West Virginia Alzheimer’s Disease Registry 
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For further informaon contact: 
The Alzheimer Society of Ireland
Temple Road
Blackrock
Co Dublin
Phone: +353 (0) 1 2073800
Web: www.alzheimer.ie
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